This	O
can	O
translate	O
into	O
global	O
effects	O
on	O
cellular	O
health	O
and	O
differentiation	O
state	O
.	O

Recently	O
,	O
several	O
reports	O
have	O
identified	O
crucial	O
roles	O
for	O
miRNAs	O
in	O
controlling	O
the	O
production	O
,	O
differentiation	O
,	O
and	O
health	O
of	O
myelinating	O
cells	O
of	O
the	O
mammalian	O
nervous	O
system	O
.	O

As	O
single	O
miRNAs	O
are	O
often	O
predicted	O
to	O
target	O
up	O
to	O
hundreds	O
of	O
individual	O
transcripts	O
,	O
miRNAs	O
are	O
able	O
to	O
broadly	O
affect	O
the	O
overall	O
protein	O
expression	O
state	O
of	O
the	O
cell	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
how	O
individual	O
miRNAs	O
regulate	O
these	O
various	O
processes	O
,	O
and	O
also	O
how	O
miRNA	O
production	O
in	O
general	O
is	O
required	O
for	O
several	O
stages	O
of	O
myelin	O
generation	O
and	O
maintenance	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
class	O
of	O
small	O
(	O
approx	O
.	O
22	O
nt	O
)	O
noncoding	O
RNAs	O
that	O
are	O
capable	O
of	O
post	O
-	O
transcriptionally	O
silencing	O
mRNAs	O
that	O
contain	O
sequences	O
complementary	O
to	O
the	O
miRNAs	O
'	O
7-	O
to	O
8-bp	O
'	O
seed	O
'	O
sequence	O
.	O

MicroRNAs	O
in	O
oligodendrocyte	O
and	O
Schwann	O
cell	O
differentiation	O
.	O

Identification	O
of	O
blood	O
microRNAs	O
associated	O
to	O
Parkinso≈Ñs	O
disease	O
.	O

While	O
miR-1	O
,	O
miR-22	O
*	O
and	O
miR-29	O
expression	O
levels	O
allowed	O
to	O
distinguish	O
non	O
-	O
treated	O
PD	O
from	O
healthy	O
subjects	O
,	O
miR-16	O
-	O
2	O
*	O
,	O
miR-26a2	O
*	O
and	O
miR30a	O
differentiated	O
treated	O
from	O
untreated	O
patients	O
.	O

They	O
form	O
two	O
groups	O
according	O
to	O
their	O
expression	O
profile	O
in	O
control	O
,	O
non	O
-	O
treated	O
,	O
early	O
-	O
onset	O
and	O
treated	O
Parkinson	O
's	O
disease	O
subjects	O
.	O

A	O
set	O
of	O
six	O
differentially	O
expressed	O
microRNAs	O
were	O
identified	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
blood	O
samples	O
can	O
be	O
used	O
as	O
a	O
source	O
of	O
miRNA	O
identification	O
associated	O
to	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

This	O
study	O
is	O
innovative	O
in	O
contributing	O
to	O
the	O
development	O
of	O
effective	O
PD	O
biomarkers	O
.	O

Our	O
data	O
suggests	O
that	O
down	O
-	O
regulation	O
of	O
miRNA-128	O
may	O
contribute	O
to	O
glioma	O
and	O
GBM	O
,	O
in	O
part	O
,	O
by	O
coordinately	O
up	O
-	O
regulating	O
ARP5	B
(	O
ANGPTL6	B
)	O
,	O
Bmi-1	B
and	O
E2F-3a	O
,	O
resulting	O
in	O
the	O
proliferation	O
of	O
undifferentiated	O
GBM	O
cells	O
.	O

Addition	O
of	O
exogenous	O
miRNA-128	O
to	O
CRL-1690	O
and	O
CRL-2610	O
GBM	O
cell	O
lines	O
(	O
a	O
)	O
restored	O
'	O
homeostatic	O
'	O
ARP5	B
(	O
ANGPTL6	B
)	O
,	O
Bmi-1	B
and	O
E2F-3a	O
expression	O
,	O
and	O
(	O
b	O
)	O
significantly	O
decreased	O
the	O
proliferation	O
of	O
CRL-1690	O
and	O
CRL-2610	O
cell	O
lines	O
.	O

Three	O
bioinformatics	O
-	O
verified	O
miRNA-128	O
targets	O
,	O
angiopoietin	B
-	I
related	I
growth	I
factor	I
protein	I
5	I
(	O
ARP5	B
;	O
ANGPTL6	B
)	O
,	O
a	O
transcription	O
suppressor	O
that	O
promotes	O
stem	O
cell	O
renewal	O
and	O
inhibits	O
the	O
expression	O
of	O
known	O
tumor	O
suppressor	O
genes	O
involved	O
in	O
senescence	O
and	O
differentiation	O
,	O
Bmi-1	B
,	O
and	O
a	O
transcription	O
factor	O
critical	O
for	O
the	O
control	O
of	O
cell	O
-	O
cycle	O
progression	O
,	O
E2F-3a	O
,	O
were	O
found	O
to	O
be	O
up	O
-	O
regulated	O
.	O

The	O
down	O
-	O
regulation	O
of	O
miRNA-128	O
was	O
found	O
to	O
inversely	O
correlate	O
with	O
WHO	O
tumor	O
grade	O
.	O

High	O
density	O
micro	O
-	O
RNA	O
(	O
miRNA	O
)	O
arrays	O
,	O
fluorescent	O
-	O
reporter	O
miRNA	O
assay	O
and	O
Northern	O
miRNA	O
dot	O
-	O
blot	O
analysis	O
show	O
that	O
a	O
brain	O
-	O
enriched	O
miRNA-128	O
is	O
significantly	O
down	O
-	O
regulated	O
in	O
glioblastoma	O
multiforme	O
(	O
GBM	O
)	O
and	O
in	O
GBM	O
cell	O
lines	O
when	O
compared	O
to	O
age	O
-	O
matched	O
controls	O
.	O

Micro	O
-	O
RNA-128	O
(	O
miRNA-128	O
)	O
down	O
-	O
regulation	O
in	O
glioblastoma	O
targets	O
ARP5	B
(	O
ANGPTL6	B
)	O
,	O
Bmi-1	B
and	O
E2F-3a	O
,	O
key	O
regulators	O
of	O
brain	O
cell	O
proliferation	O
.	O

This	O
reveals	O
a	O
previously	O
unrecognized	O
signaling	O
cascade	O
involved	O
in	O
meningioma	O
tumor	O
development	O
and	O
highlights	O
a	O
novel	O
molecular	O
interaction	O
between	O
miR-200a	O
and	O
Wnt	O
signaling	O
,	O
thereby	O
providing	O
insights	O
into	O
novel	O
therapies	O
for	O
meningiomas	O
.	O

A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
downregulation	O
of	O
miR-200a	O
and	O
the	O
upregulation	O
of	O
beta	B
-	I
catenin	I
in	O
human	O
meningioma	O
samples	O
.	O

Thus	O
,	O
miR-200a	O
appears	O
to	O
act	O
as	O
a	O
multifunctional	O
tumor	O
suppressor	O
miRNA	O
in	O
meningiomas	O
through	O
effects	O
on	O
the	O
E	B
-	I
cadherin	I
and	O
Wnt	O
/	O
beta	B
-	I
catenin	I
signaling	O
pathways	O
.	O

miR-200a	O
was	O
found	O
to	O
directly	O
target	O
beta	B
-	I
catenin	I
mRNA	O
,	O
thereby	O
inhibiting	O
its	O
translation	O
and	O
blocking	O
Wnt	O
/	O
beta	B
-	I
catenin	I
signaling	O
,	O
which	O
is	O
frequently	O
involved	O
in	O
cancer	O
.	O

Downregulation	O
of	O
miR-200a	O
in	O
meningiomas	O
and	O
arachnoidal	O
cells	O
resulted	O
in	O
increased	O
expression	O
of	O
beta	B
-	I
catenin	I
and	O
cyclin	B
D1	I
involved	O
in	O
cell	O
proliferation	O
.	O

Upregulation	O
of	O
miR-200a	O
decreased	O
the	O
expression	O
of	O
transcription	O
factors	O
ZEB1	B
and	O
SIP1	O
,	O
with	O
consequent	O
increased	O
expression	O
of	O
E	B
-	I
cadherin	I
,	O
an	O
adhesion	O
protein	O
associated	O
with	O
cell	O
differentiation	O
.	O

Elevated	O
levels	O
of	O
miR-200a	O
inhibited	O
meningioma	O
cell	O
growth	O
in	O
culture	O
and	O
in	O
a	O
tumor	O
model	O
in	O
vivo	O
.	O

Meningiomas	O
,	O
one	O
of	O
the	O
most	O
common	O
human	O
brain	O
tumors	O
,	O
are	O
derived	O
from	O
arachnoidal	O
cells	O
associated	O
with	O
brain	O
meninges	O
,	O
are	O
usually	O
benign	O
,	O
and	O
are	O
frequently	O
associated	O
with	O
neurofibromatosis	O
type	O
2	O
.	O
Here	O
,	O
we	O
define	O
a	O
typical	O
human	O
meningioma	O
microRNA	O
(	O
miRNA	O
)	O
profile	O
and	O
characterize	O
the	O
effects	O
of	O
one	O
downregulated	O
miRNA	O
,	O
miR-200a	O
,	O
on	O
tumor	O
growth	O
.	O

Downregulated	O
microRNA-200a	O
in	O
meningiomas	O
promotes	O
tumor	O
growth	O
by	O
reducing	O
E	B
-	I
cadherin	I
and	O
activating	O
the	O
Wnt	O
/	O
beta	B
-	I
catenin	I
signaling	O
pathway	O
.	O

In	O
neurodegenerative	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
brain	O
miRNA	O
profiles	O
are	O
altered	O
;	O
thus	O
miRNA	O
dysfunction	O
could	O
be	O
both	O
a	O
cause	O
and	O
a	O
consequence	O
of	O
disease	O
.	O

These	O
small	O
non	O
-	O
coding	O
RNA	O
regulators	O
are	O
highly	O
enriched	O
in	O
brain	O
where	O
they	O
play	O
key	O
roles	O
in	O
neuronal	O
development	O
,	O
plasticity	O
and	O
disease	O
.	O

Normal	O
brain	O
development	O
and	O
function	O
depends	O
on	O
microRNA	O
(	O
miRNA	O
)	O
networks	O
to	O
fine	O
tune	O
the	O
balance	O
between	O
the	O
transcriptome	O
and	O
proteome	O
of	O
the	O
cell	O
.	O

Neuronal	O
microRNA	O
deregulation	O
in	O
response	O
to	O
Alzheimer	O
's	O
disease	O
amyloid	B
-	I
beta	I
.	O

Bioinformatic	O
analysis	O
predicts	O
that	O
the	O
deregulated	O
miRNAs	O
are	O
likely	O
to	O
affect	O
target	O
genes	O
present	O
in	O
prominent	O
neuronal	O
pathways	O
known	O
to	O
be	O
disrupted	O
in	O
AD	O
.	O
Remarkably	O
,	O
we	O
also	O
found	O
that	O
the	O
miRNA	O
deregulation	O
in	O
hippocampal	O
cultures	O
was	O
paralleled	O
in	O
vivo	O
by	O
a	O
deregulation	O
in	O
the	O
hippocampus	O
of	O
Abeta42-depositing	B
APP23	O
mice	O
,	O
at	O
the	O
onset	O
of	O
Abeta	B
plaque	O
formation	O
.	O

Time	O
-	O
course	O
assays	O
of	O
neuronal	O
Abeta	B
treatments	O
show	O
that	O
Abeta	B
is	O
in	O
fact	O
a	O
powerful	O
regulator	O
of	O
miRNA	O
levels	O
as	O
the	O
response	O
of	O
certain	O
mature	O
miRNAs	O
is	O
extremely	O
rapid	O
.	O

We	O
used	O
sensitive	O
TaqMan	O
low	O
density	O
miRNA	O
arrays	O
(	O
TLDA	O
)	O
on	O
murine	O
primary	O
hippocampal	O
cultures	O
to	O
show	O
that	O
about	O
half	O
of	O
all	O
miRNAs	O
tested	O
were	O
down	O
-	O
regulated	O
in	O
response	O
to	O
Abeta	B
peptides	O
.	O

Our	O
study	O
dissects	O
the	O
complexity	O
of	O
human	O
AD	O
pathology	O
,	O
and	O
addresses	O
the	O
hypothesis	O
that	O
amyloid	B
-	I
beta	I
(	O
Abeta	B
)	O
itself	O
,	O
a	O
known	O
causative	O
factor	O
of	O
AD	O
,	O
causes	O
neuronal	O
miRNA	O
deregulation	O
,	O
which	O
could	O
contribute	O
to	O
the	O
pathomechanisms	O
of	O
AD	O
.	O

In	O
addition	O
,	O
the	O
miRNA	O
deregulation	O
in	O
hippocampal	O
cultures	O
and	O
APP23	O
hippocampus	O
overlaps	O
with	O
those	O
obtained	O
in	O
human	O
AD	O
studies	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
neuronal	O
miRNA	O
deregulation	O
in	O
response	O
to	O
an	O
insult	O
by	O
Abeta	B
may	O
be	O
an	O
important	O
factor	O
contributing	O
to	O
the	O
cascade	O
of	O
events	O
leading	O
to	O
AD	O
.	O

Isolation	O
and	O
characterization	O
of	O
a	O
novel	O
pituitary	B
tumor	I
apoptosis	I
gene	I
.	O

We	O
report	O
the	O
isolation	O
of	O
a	O
novel	O
differentially	O
methylated	O
chromosome	O
22	O
CpG	O
island	O
-	O
associated	O
gene	O
(	O
C22orf3	B
)	O
.	O

To	O
determine	O
mechanisms	O
for	O
pituitary	O
neoplasia	O
we	O
used	O
methylation	O
-	O
sensitive	O
arbitrarily	O
primed	O
-	O
PCR	O
to	O
isolate	O
novel	O
genes	O
that	O
are	O
differentially	O
methylated	O
relative	O
to	O
normal	O
pituitary	O
.	O

Sodium	O
bisulfite	O
sequencing	O
of	O
individual	O
adenomas	O
showed	O
that	O
6	O
of	O
30	O
(	O
20	O
%	O
)	O
that	O
failed	O
to	O
express	O
pituitary	B
tumor	I
apoptosis	I
gene	I
(	O
PTAG	B
)	O
were	O
methylated	O
;	O
however	O
,	O
genetic	O
change	O
as	O
determined	O
by	O
loss	O
of	O
heterozygosity	O
and	O
sequence	O
analysis	O
was	O
not	O
apparent	O
in	O
the	O
remaining	O
tumors	O
that	O
failed	O
to	O
express	O
this	O
gene	O
.	O

Sodium	O
bisulfite	O
sequencing	O
of	O
pooled	O
tumor	O
cohorts	O
,	O
used	O
in	O
the	O
isolation	O
of	O
this	O
gene	O
,	O
showed	O
that	O
only	O
a	O
proportion	O
of	O
the	O
adenomas	O
within	O
the	O
pools	O
were	O
methylated	O
;	O
however	O
,	O
expression	O
analysis	O
by	O
quantitative	O
RT	O
-	O
PCR	O
of	O
individual	O
adenoma	O
irrespective	O
of	O
subtype	O
showed	O
the	O
majority	O
(	O
30	O
of	O
38	O
;	O
79	O
%	O
)	O
failed	O
to	O
express	O
this	O
gene	O
relative	O
to	O
normal	O
pituitary	O
.	O

Enforced	O
expression	O
of	O
C22orf3	B
in	O
AtT20	O
cells	O
had	O
no	O
measurable	O
effects	O
on	O
cell	O
proliferation	O
or	O
viability	O
;	O
however	O
,	O
in	O
response	O
to	O
bromocriptine	O
challenge	O
(	O
10	O
-	O
40	O
microm	O
)	O
cells	O
expressing	O
this	O
gene	O
showed	O
a	O
significantly	O
augmented	O
apoptotic	O
response	O
as	O
determined	O
by	O
both	O
acridine	O
orange	O
staining	O
and	O
TUNEL	O
labeling	O
.	O

In	O
those	O
cases	O
where	O
the	O
CpG	O
island	O
of	O
these	O
genes	O
was	O
methylated	O
it	O
was	O
invariably	O
associated	O
with	O
loss	O
of	O
transcript	O
expression	O
.	O

In	O
addition	O
,	O
in	O
time	O
course	O
experiments	O
,	O
direct	O
measurement	O
of	O
active	O
caspases	O
by	O
fluorochrome	O
-	O
labeled	O
inhibition	O
of	O
caspases	O
,	O
showed	O
an	O
augmented	O
increase	O
(	O
approximately	O
2.4	O
fold	O
)	O
in	O
active	O
caspases	O
in	O
response	O
to	O
bromocriptine	O
challenge	O
in	O
cells	O
expressing	O
C22orf3	B
relative	O
to	O
those	O
harboring	O
an	O
empty	O
vector	O
control	O
.	O

The	O
apoptotic	O
response	O
to	O
bromocriptine	O
challenge	O
was	O
inhibited	O
in	O
coincubation	O
experiments	O
with	O
the	O
general	O
caspase	O
inhibitor	O
z	O
-	O
VAD	O
-	O
fmk	O
.	O

The	O
pituitary	O
tumor	O
derivation	O
and	O
its	O
role	O
in	O
apoptosis	O
of	O
this	O
gene	O
led	O
us	O
to	O
assign	O
the	O
acronym	O
PTAG	B
to	O
this	O
gene	O
and	O
its	O
protein	O
product	O
.	O

The	O
ability	O
of	O
cells	O
,	O
showing	O
reduced	O
expression	O
of	O
PTAG	B
,	O
to	O
evade	O
or	O
show	O
a	O
blunted	O
apoptotic	O
response	O
may	O
underlie	O
oncogenic	O
transformation	O
in	O
both	O
the	O
pituitary	O
and	O
other	O
tumor	O
types	O
.	O

It	O
has	O
been	O
recently	O
demonstrated	O
that	O
herpesviruses	O
encode	O
miRNAs	O
to	O
control	O
the	O
post	O
-	O
transcriptional	O
regulation	O
of	O
expression	O
from	O
their	O
own	O
genomes	O
and	O
possibly	O
that	O
of	O
their	O
host	O
,	O
thus	O
adding	O
an	O
additional	O
layer	O
of	O
complexity	O
to	O
the	O
physiological	O
cross	O
-	O
talk	O
between	O
host	O
and	O
pathogen	O
.	O

MicroRNAs	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
approximately	O
22	O
nt	O
long	O
that	O
modulate	O
gene	O
expression	O
in	O
animals	O
and	O
plants	O
.	O

Co	O
-	O
expression	O
of	O
host	O
and	O
viral	O
microRNAs	O
in	O
porcine	O
dendritic	O
cells	O
infected	O
by	O
the	O
pseudorabies	O
virus	O
.	O

Almost	O
95	O
%	O
of	O
reads	O
mapped	O
to	O
the	O
draft	O
pig	O
genome	O
sequence	O
and	O
pig	O
miRNAs	O
previously	O
annotated	O
in	O
dedicated	O
databases	O
were	O
detected	O
by	O
sequence	O
alignment	O
.	O

An	O
average	O
of	O
2	O
million	O
reads	O
per	O
sample	O
with	O
a	O
size	O
of	O
21	O
-	O
24	O
nucleotides	O
was	O
obtained	O
from	O
six	O
libraries	O
representing	O
three	O
biological	O
replicates	O
of	O
infected	O
and	O
mock	O
-	O
infected	O
DCs	O
.	O

A	O
catalogue	O
of	O
porcine	O
and	O
viral	O
miRNAs	O
,	O
expressed	O
eight	O
hours	O
post	O
-	O
infection	O
,	O
was	O
established	O
by	O
deep	O
sequencing	O
.	O

The	O
present	O
study	O
focussed	O
on	O
the	O
interactions	O
between	O
porcine	O
dendritic	O
cells	O
(	O
DCs	O
)	O
and	O
the	O
Pseudorabies	O
virus	O
(	O
PRV	O
)	O
,	O
an	O
alpha	O
-	O
herpesvirus	O
causing	O
Aujeszky	O
's	O
disease	O
in	O
pigs	O
.	O

In	O
silico	O
prediction	O
allowed	O
the	O
identification	O
of	O
unknown	O
porcine	O
as	O
well	O
as	O
of	O
five	O
miRNAs	O
transcribed	O
by	O
the	O
Large	O
Latency	O
Transcript	O
(	O
LLT	O
)	O
of	O
PRV	O
.	O

The	O
gene	O
target	O
prediction	O
of	O
the	O
viral	O
miRNAs	O
and	O
the	O
Ingenuity	O
Pathway	O
Analysis	O
of	O
differentially	O
expressed	O
pig	O
miRNAs	O
were	O
conducted	O
to	O
contextualize	O
the	O
identified	O
small	O
RNA	O
molecules	O
and	O
functionally	O
characterize	O
their	O
involvement	O
in	O
the	O
post	O
-	O
transcriptional	O
regulation	O
of	O
gene	O
expression	O
.	O

The	O
results	O
support	O
a	O
role	O
for	O
PRV	O
miRNAs	O
in	O
the	O
maintenance	O
of	O
the	O
host	O
cell	O
latency	O
state	O
through	O
the	O
down	O
-	O
regulation	O
of	O
immediate	O
-	O
early	O
viral	O
genes	O
which	O
is	O
similar	O
to	O
other	O
herpesviruses	O
.	O

The	O
differentially	O
expressed	O
swine	O
miRNAs	O
identified	O
a	O
unique	O
network	O
of	O
target	O
genes	O
with	O
highly	O
significant	O
functions	O
in	O
the	O
development	O
and	O
function	O
of	O
the	O
nervous	O
system	O
and	O
in	O
infectious	O
mechanisms	O
,	O
suggesting	O
that	O
the	O
modulation	O
of	O
both	O
host	O
and	O
viral	O
miRNAs	O
is	O
necessary	O
for	O
the	O
establishment	O
of	O
PRV	O
latency	O
.	O

The	O
RAKE	O
assay	O
is	O
theoretically	O
versatile	O
and	O
may	O
be	O
used	O
for	O
other	O
applications	O
,	O
such	O
as	O
viral	O
gene	O
profiling	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
miRNAs	O
can	O
be	O
isolated	O
and	O
profiled	O
from	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
,	O
which	O
opens	O
up	O
new	O
opportunities	O
for	O
analyses	O
of	O
small	O
RNAs	O
from	O
archival	O
human	O
tissue	O
.	O

RAKE	O
offers	O
unique	O
advantages	O
for	O
specificity	O
over	O
northern	O
blots	O
or	O
other	O
microarray	O
-	O
based	O
expression	O
profiling	O
platforms	O
.	O

We	O
show	O
that	O
the	O
RAKE	O
assay	O
is	O
sensitive	O
and	O
specific	O
for	O
miRNAs	O
and	O
is	O
ideally	O
suited	O
for	O
rapid	O
expression	O
profiling	O
of	O
all	O
known	O
miRNAs	O
.	O

We	O
used	O
RAKE	O
to	O
study	O
human	O
cell	O
lines	O
and	O
brain	O
tumors	O
.	O

The	O
technique	O
is	O
termed	O
the	O
RNA	O
-	O
primed	O
,	O
array	O
-	O
based	O
Klenow	O
enzyme	O
(	O
RAKE	O
)	O
assay	O
,	O
because	O
it	O
involves	O
on	O
-	O
slide	O
application	O
of	O
the	O
Klenow	O
fragment	O
of	O
DNA	O
polymerase	O
I	O
to	O
extend	O
unmodified	O
miRNAs	O
hybridized	O
to	O
immobilized	O
DNA	O
probes	O
.	O

We	O
describe	O
a	O
new	O
method	O
for	O
high	O
-	O
throughput	O
miRNA	O
detection	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
regulatory	O
RNAs	O
that	O
serve	O
fundamental	O
biological	O
roles	O
across	O
eukaryotic	O
species	O
.	O

Microarray	O
-	O
based	O
,	O
high	O
-	O
throughput	O
gene	O
expression	O
profiling	O
of	O
microRNAs	O
.	O

Brain	O
cells	O
maintain	O
distinct	O
populations	O
of	O
miRNAs	O
that	O
support	O
physiologically	O
normal	O
patterns	O
of	O
expression	O
,	O
however	O
,	O
certain	O
miRNA	O
abundances	O
are	O
significantly	O
altered	O
in	O
neurodegenerative	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Here	O
we	O
provide	O
evidence	O
in	O
human	O
neural	O
(	O
HN	O
)	O
cells	O
of	O
an	O
aluminum	O
-	O
sulfate-	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
-mediated	O
up	O
-	O
regulation	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
sensitive	O
miRNA-146a	O
that	O
down	O
-	O
regulates	O
the	O
expression	O
of	O
complement	B
factor	I
H	I
(	O
CFH	B
)	O
,	O
an	O
important	O
repressor	O
of	O
inflammation	O
.	O

Characterization	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
regulated	O
,	O
miRNA-146a	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
complement	B
factor	I
H	I
(	O
CFH	B
)	O
in	O
metal	O
-	O
sulfate	O
-	O
stressed	O
human	O
brain	O
cells	O
.	O

Micro	O
RNAs	O
(	O
miRNAs	O
)	O
represent	O
a	O
family	O
of	O
small	O
ribonucleic	O
acids	O
(	O
RNAs	O
)	O
that	O
are	O
post	O
-	O
transcriptional	O
regulators	O
of	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
complexity	O
.	O

An	O
NF	O
-	O
kappaB	O
-	O
containing	O
miRNA-146a	O
-	O
promoter	O
-	O
luciferase	O
reporter	O
construct	O
transfected	O
into	O
HN	O
cells	O
showed	O
significant	O
up	O
-	O
regulation	O
of	O
miRNA-146a	O
after	O
aluminum	O
-	O
sulfate	O
treatment	O
that	O
corresponded	O
to	O
decreased	O
CFH	B
gene	O
expression	O
.	O

These	O
data	O
suggest	O
that	O
(	O
1	O
)	O
as	O
in	O
AD	O
brain	O
,	O
NF	O
-	O
kappaB	O
-	O
sensitive	O
,	O
miRNA-146a	O
-	O
mediated	O
,	O
modulation	O
of	O
CFH	B
gene	O
expression	O
may	O
contribute	O
to	O
inflammatory	O
responses	O
in	O
aluminum	O
-	O
stressed	O
HN	O
cells	O
,	O
and	O
(	O
2	O
)	O
underscores	O
the	O
potential	O
of	O
nanomolar	O
aluminum	O
to	O
drive	O
genotoxic	O
mechanisms	O
characteristic	O
of	O
neurodegenerative	O
disease	O
processes	O
.	O

This	O
NF	O
-	O
kappaB	O
-	O
miRNA-146a	O
-	O
CFH	B
signaling	O
circuit	O
is	O
known	O
to	O
be	O
similarly	O
affected	O
by	O
Abeta42	B
peptides	O
and	O
in	O
AD	O
brain	O
.	O

These	O
aluminum	O
-	O
sulfate	O
-	O
inducible	O
events	O
were	O
not	O
observed	O
in	O
parallel	O
experiments	O
using	O
iron-	O
,	O
magnesium-	O
,	O
or	O
zinc	O
-	O
sulfate	O
-	O
stressed	O
HN	O
cells	O
.	O

A	O
specific	O
subset	O
of	O
five	O
miRNAs	O
revealed	O
by	O
in	O
silico	O
target	O
prediction	O
was	O
significantly	O
overexpressed	O
in	O
NFA	O
samples	O
;	O
three	O
miRs	O
(	O
miR-128a	O
,	O
miR-155	O
,	O
and	O
miR-516a-3p	O
)	O
targeted	O
the	O
3'-untranslated	O
region	O
of	O
the	O
Wee1	B
transcript	O
,	O
and	O
exogenous	O
overexpression	O
of	O
these	O
miRs	O
inhibited	O
Wee1	B
protein	O
expression	O
and	O
HeLa	O
cell	O
proliferation	O
.	O

RESULTS	O
:	O
Wee1	B
protein	O
expression	O
was	O
decreased	O
in	O
NFAs	O
and	O
GH	O
-	O
producing	O
tumors	O
with	O
or	O
without	O
prolactin	B
production	O
,	O
but	O
no	O
change	O
in	O
mRNA	O
expression	O
was	O
observed	O
with	O
qRT	O
-	O
PCR	O
.	O

CONCLUSIONS	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
suggesting	O
that	O
regulation	O
of	O
Wee1	B
kinase	O
by	O
miRs	O
may	O
be	O
linked	O
to	O
pituitary	O
tumorigenesis	O
.	O

CONTEXT	O
:	O
The	O
tumorigenic	O
mechanisms	O
involved	O
in	O
pituitary	O
adenomas	O
,	O
especially	O
of	O
nonfunctional	O
pituitary	O
adenomas	O
(	O
NFAs	O
)	O
,	O
remains	O
unclear	O
.	O

Down	O
-	O
regulation	O
of	O
Wee1	B
kinase	O
by	O
a	O
specific	O
subset	O
of	O
microRNA	O
in	O
human	O
sporadic	O
pituitary	O
adenomas	O
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
examine	O
the	O
expression	O
of	O
Wee1	B
in	O
pituitary	O
tumors	O
and	O
to	O
identify	O
microRNAs	O
(	O
miRs	O
)	O
that	O
can	O
regulate	O
its	O
expression	O
.	O

Various	O
cell	O
cycle	O
inhibitors	O
have	O
been	O
found	O
to	O
be	O
underexpressed	O
in	O
pituitary	O
tumors	O
;	O
however	O
,	O
Wee1	B
kinase	O
,	O
a	O
nuclear	O
protein	O
that	O
delays	O
mitosis	O
and	O
was	O
recently	O
recognized	O
as	O
a	O
tumor	O
suppressor	O
gene	O
,	O
has	O
not	O
been	O
previously	O
investigated	O
in	O
pituitary	O
tumors	O
.	O

Identification	O
of	O
miRs	O
targeting	O
the	O
Wee1	B
3'-untranslated	O
region	O
was	O
performed	O
by	O
miR	O
array	O
followed	O
by	O
expression	O
analysis	O
of	O
identified	O
miRs	O
using	O
qRT	O
-	O
PCR	O
.	O

DESIGN	O
:	O
Expression	O
of	O
Wee1	B
was	O
examined	O
by	O
immunohistochemistry	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
.	O

PATIENTS	O
:	O
A	O
total	O
of	O
57	O
pituitary	O
tissue	O
samples	O
including	O
27	O
NFAs	O
,	O
15	O
GH	O
-	O
producing	O
adenomas	O
with	O
or	O
without	O
prolactin	B
overproduction	O
,	O
and	O
15	O
normal	O
pituitary	O
glands	O
were	O
analyzed	O
.	O

Dual	O
-	O
luciferase	O
assay	O
and	O
transient	O
transfection	O
of	O
miRs	O
into	O
Hela	O
cells	O
followed	O
by	O
immunoblot	O
analysis	O
of	O
Wee1	B
protein	O
and	O
cell	O
proliferation	O
analysis	O
were	O
carried	O
out	O
.	O

In	O
this	O
review	O
article	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
role	O
and	O
function	O
of	O
miRNAs	O
in	O
the	O
regulation	O
of	O
genes	O
involved	O
in	O
neurological	O
and	O
neurodegenerative	O
diseases	O
will	O
be	O
discussed	O
,	O
with	O
a	O
focus	O
on	O
the	O
fragile	O
X	O
syndrome	O
,	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
and	O
prion	O
disease	O
.	O

Likely	O
to	O
play	O
a	O
central	O
role	O
in	O
health	O
and	O
disease	O
,	O
a	O
dysfunctional	O
miRNA	O
-	O
based	O
regulation	O
of	O
gene	O
expression	O
may	O
represent	O
the	O
main	O
etiologic	O
factor	O
underlying	O
diseases	O
affecting	O
major	O
organs	O
,	O
such	O
as	O
the	O
brain	O
.	O

MicroRNAs	O
as	O
a	O
molecular	O
basis	O
for	O
mental	O
retardation	O
,	O
Alzheimer	O
's	O
and	O
prion	O
diseases	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
,	O
approximately	O
21-	O
to	O
23-nucleotide	O
(	O
nt	O
)	O
non	O
-	O
coding	O
RNA	O
species	O
that	O
act	O
as	O
key	O
regulators	O
of	O
gene	O
expression	O
along	O
a	O
central	O
and	O
well	O
-	O
defined	O
cellular	O
process	O
known	O
as	O
RNA	O
silencing	O
,	O
and	O
involving	O
the	O
recognition	O
and	O
translational	O
control	O
of	O
specific	O
messenger	O
RNA	O
(	O
mRNAs	O
)	O
.	O

Generated	O
through	O
the	O
well	O
-	O
orchestrated	O
and	O
sequential	O
processing	O
of	O
miRNA	O
precursor	O
molecules	O
,	O
mature	O
miRNAs	O
are	O
subsequently	O
incorporated	O
into	O
miRNA	O
-	O
containing	O
ribonucleoprotein	O
effector	O
complexes	O
to	O
regulate	O
mRNA	O
translation	O
through	O
the	O
recognition	O
of	O
specific	O
binding	O
sites	O
of	O
imperfect	O
complementarity	O
located	O
mainly	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
.	O

Predicted	O
to	O
regulate	O
up	O
to	O
90	O
%	O
of	O
the	O
genes	O
in	O
humans	O
,	O
miRNAs	O
may	O
thus	O
control	O
cellular	O
processes	O
in	O
all	O
cells	O
and	O
tissues	O
of	O
the	O
human	O
body	O
.	O

High	O
levels	O
of	O
high	B
-	I
mobility	I
group	I
A2	I
expression	O
also	O
significantly	O
correlated	O
with	O
the	O
proliferation	B
marker	I
Ki-67	I
(	O
P<0.0001	O
)	O
.	O

High	O
levels	O
of	O
high	B
-	I
mobility	I
group	I
A2	I
expression	O
were	O
more	O
frequently	O
observed	O
in	O
macroadenomas	O
than	O
in	O
microadenomas	O
(	O
P<0.05	O
)	O
.	O

Overexpression	O
of	O
high	B
-	I
mobility	I
group	I
A2	I
was	O
observed	O
in	O
39	O
%	O
(	O
38	O
/	O
98	O
)	O
of	O
pituitary	O
adenomas	O
compared	O
with	O
normal	O
adenohypophysial	O
tissue	O
and	O
was	O
frequently	O
found	O
in	O
adenomas	O
including	O
prolactin	B
(	O
PRL	B
)	O
,	O
adrenocorticotrophic	B
hormone	I
,	O
or	O
follicle	B
-	I
stimulating	I
hormone	I
/	O
luteinizing	B
hormone	I
and	O
in	O
null	O
cell	O
adenomas	O
,	O
but	O
relatively	O
rare	O
in	O
growth	B
hormone	I
(	O
GH	O
)	O
and	O
mixed	O
GH	O
/	O
PRL	B
adenomas	O
.	O

High	B
-	I
mobility	I
group	I
A2	I
expression	O
was	O
significantly	O
associated	O
with	O
tumor	O
invasion	O
(	O
P<0.05	O
)	O
and	O
was	O
significantly	O
higher	O
in	O
grade	O
IV	O
than	O
in	O
grades	O
I	O
,	O
II	O
,	O
and	O
III	O
adenomas	O
(	O
P<0.05	O
)	O
.	O

However	O
,	O
no	O
studies	O
have	O
investigated	O
the	O
clinical	O
significance	O
of	O
high	B
-	I
mobility	I
group	I
A2	I
and	O
its	O
relationship	O
to	O
the	O
let-7	O
miRNA	O
family	O
in	O
human	O
pituitary	O
adenomas	O
.	O

Using	O
immunohistochemistry	O
,	O
we	O
analyzed	O
high	B
-	I
mobility	I
group	I
A2	I
expression	O
with	O
respect	O
to	O
various	O
clinicopathologic	O
factors	O
in	O
98	O
pituitary	O
adenomas	O
.	O

Recent	O
studies	O
report	O
that	O
high	B
-	I
mobility	I
group	I
A2	I
is	O
negatively	O
regulated	O
by	O
the	O
let-7	O
microRNAs	O
(	O
miRNAs	O
)	O
family	O
in	O
vitro	O
.	O

The	O
development	O
of	O
pituitary	O
adenomas	O
in	O
high	B
-	I
mobility	I
group	I
A2	I
transgenic	O
mice	O
showed	O
that	O
high	B
-	I
mobility	I
group	I
A2	I
may	O
be	O
involved	O
in	O
pituitary	O
tumorigenesis	O
.	O

Overexpression	O
of	O
HMGA2	B
relates	O
to	O
reduction	O
of	O
the	O
let-7	O
and	O
its	O
relationship	O
to	O
clinicopathological	O
features	O
in	O
pituitary	O
adenomas	O
.	O

High	B
-	I
mobility	I
group	I
A2	I
is	O
highly	O
expressed	O
during	O
embryogenesis	O
and	O
in	O
various	O
benign	O
and	O
malignant	O
tumors	O
.	O

Real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
analysis	O
was	O
carried	O
out	O
to	O
evaluate	O
the	O
expression	O
of	O
let-7	O
in	O
55	O
pituitary	O
adenomas	O
.	O

Subsequently	O
,	O
decreased	O
expression	O
of	O
let-7	O
was	O
confirmed	O
in	O
23	O
of	O
55	O
(	O
42	O
%	O
)	O
adenomas	O
and	O
was	O
correlated	O
with	O
high	O
-	O
grade	O
tumors	O
(	O
P<0.05	O
)	O
.	O

An	O
inverse	O
correlation	O
between	O
let-7	O
and	O
high	B
-	I
mobility	I
group	I
A2	I
expression	O
was	O
evident	O
(	O
R=-0.33	O
,	O
P<0.05	O
)	O
.	O

These	O
findings	O
support	O
a	O
causal	O
link	O
between	O
let-7	O
and	O
high	B
-	I
mobility	I
group	I
A2	I
whereby	O
loss	O
of	O
let-7	O
expression	O
induces	O
high	B
-	I
mobility	I
group	I
A2	I
upregulation	O
that	O
represents	O
an	O
important	O
mechanism	O
in	O
pituitary	O
tumorigenesis	O
and	O
progression	O
.	O

The	O
proliferation	O
inhibition	O
and	O
induced	O
apoptosis	O
by	O
this	O
recombinant	O
with	O
an	O
apoptosis	O
ratio	O
of	O
21.89	O
%	O
in	O
U87	O
cell	O
were	O
also	O
observed	O
.	O

The	O
results	O
of	O
Western	O
blot	O
indicated	O
the	O
expression	O
of	O
Flag	O
of	O
No	O
1	O
recombinant	O
plasmid	O
group	O
was	O
inhibited	O
heavily	O
with	O
a	O
34.3	O
%	O
expression	O
level	O
by	O
compared	O
with	O
control	O
group	O
.	O

The	O
expressed	O
Flag	O
protein	O
was	O
detected	O
by	O
Western	O
blot	O
to	O
evaluate	O
the	O
inhibition	O
effect	O
of	O
targeting	O
sequences	O
.	O

The	O
confirmed	O
pGCSIL	O
-	O
GFP	O
recombinants	O
by	O
combining	O
with	O
pEGFP	O
-	O
miR-221	O
were	O
transfected	O
into	O
293	O
T	O
cells	O
seperately	O
.	O

RESULTS	O
:	O
The	O
resulting	O
recombinants	O
were	O
confirmed	O
by	O
sequencing	O
which	O
demonstrated	O
that	O
the	O
recombinant	O
plasmids	O
contained	O
the	O
correct	O
sequences	O
of	O
designed	O
transcript	O
templates	O
.	O

Then	O
a	O
recombinant	O
with	O
the	O
highest	O
anti	O
-	O
miR-221	O
effect	O
was	O
screened	O
and	O
transfected	O
into	O
U87	O
glioma	O
cell	O
,	O
and	O
its	O
anti	O
-	O
tumor	O
effect	O
was	O
evaluated	O
by	O
MTT	O
and	O
FCM	O
.	O

[	O
Construction	O
and	O
screening	O
an	O
effective	O
anti	O
-	O
miR-221	O
RNAi	O
vector	O
in	O
vitro	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
construct	O
and	O
screen	O
an	O
effective	O
anti	O
-	O
miR-221	O
vector	O
of	O
siRNA	O
.	O

METHODS	O
:	O
Four	O
hairpin	O
structure	O
of	O
siRNA	O
transcript	O
templates	O
targeting	O
miR-221	O
and	O
a	O
negative	O
control	O
were	O
synthesized	O
,	O
then	O
ligated	O
with	O
pGCSIL	O
-	O
GFP	O
vector	O
and	O
a	O
pEGFP	O
-	O
miR-221	O
which	O
express	O
pre	O
-	O
miR-221	O
was	O
also	O
constructed	O
.	O

All	O
the	O
recombinants	O
were	O
sequenced	O
.	O

CONCLUSION	O
:	O
The	O
anti	O
-	O
miR-221	O
expression	O
siRNA	O
espression	O
recombinants	O
were	O
constructed	O
successfully	O
,	O
and	O
one	O
sequence	O
with	O
the	O
highest	O
inhibition	O
efficiency	O
was	O
screened	O
out	O
,	O
which	O
could	O
inhibit	O
U87	O
cell	O
proliferation	O
and	O
induce	O
cell	O
apoptosis	O
,	O
and	O
could	O
be	O
used	O
to	O
suppress	O
target	O
gene	O
for	O
further	O
study	O
in	O
tumor	O
biology	O
.	O

Expression	O
profiling	O
showed	O
strong	O
miRNA	O
and	O
isomiR	O
expression	O
deregulation	O
in	O
HD	O
,	O
most	O
being	O
common	O
to	O
both	O
FC	O
and	O
ST	O
.	O

Around	O
80	O
-	O
90	O
%	O
of	O
the	O
miRNAs	O
presented	O
modifications	O
in	O
the	O
3'-terminus	O
mainly	O
in	O
the	O
form	O
of	O
trimming	O
and/or	O
as	O
nucleotide	O
addition	O
variants	O
,	O
while	O
the	O
5'-terminus	O
of	O
the	O
miRNAs	O
was	O
specially	O
protected	O
from	O
changes	O
.	O

Deep	O
sequencing	O
revealed	O
length	O
and	O
sequence	O
heterogeneity	O
(	O
IsomiRs	O
)	O
for	O
the	O
vast	O
majority	O
of	O
miRNAs	O
.	O

More	O
than	O
80	O
%	O
of	O
the	O
small	O
-	O
RNAs	O
were	O
annotated	O
as	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
all	O
samples	O
.	O

We	O
have	O
applied	O
the	O
Illumina	O
massively	O
parallel	O
sequencing	O
to	O
deeply	O
analyze	O
the	O
small	O
RNA	O
populations	O
of	O
two	O
different	O
forebrain	O
areas	O
,	O
the	O
frontal	O
cortex	O
(	O
FC	O
)	O
and	O
the	O
striatum	O
(	O
ST	O
)	O
of	O
healthy	O
individuals	O
and	O
individuals	O
with	O
HD	O
.	O

Huntington	O
disease	O
(	O
HD	O
)	O
is	O
a	O
neurodegenerative	O
disorder	O
that	O
predominantly	O
affects	O
neurons	O
of	O
the	O
forebrain	O
.	O

A	O
myriad	O
of	O
miRNA	O
variants	O
in	O
control	O
and	O
Huntington	O
's	O
disease	O
brain	O
regions	O
detected	O
by	O
massively	O
parallel	O
sequencing	O
.	O

Our	O
results	O
show	O
that	O
miRNA	O
variability	O
is	O
a	O
ubiquitous	O
phenomenon	O
in	O
the	O
adult	O
human	O
brain	O
,	O
which	O
may	O
influence	O
gene	O
expression	O
in	O
physiological	O
and	O
pathological	O
conditions	O
.	O

The	O
putative	O
targets	O
of	O
deregulated	O
miRNAs	O
and	O
seed	O
-	O
region	O
IsomiRs	O
strongly	O
suggest	O
that	O
their	O
altered	O
expression	O
contributes	O
to	O
the	O
aberrant	O
gene	O
expression	O
in	O
HD	O
.	O

The	O
analysis	O
of	O
the	O
upstream	O
regulatory	O
regions	O
in	O
co	O
-	O
regulated	O
miRNAs	O
suggests	O
a	O
role	O
for	O
RE1-Silencing	B
Transcription	I
Factor	I
(	O
REST	B
)	O
and	O
P53	B
in	O
miRNAs	O
downregulation	O
in	O
HD	O
.	O

Moreover	O
,	O
LPS	O
stimulation	O
decreased	O
expression	O
of	O
microRNAs	O
(	O
miRNA	O
)	O
--miR-17	O
-	O
5	O
,	O
miR-20a	O
,	O
and	O
miR-93	O
-	O
-which	O
target	O
MICA	B
,	O
implicating	O
a	O
novel	O
role	O
for	O
miRNAs	O
in	O
NKG2D	O
ligand	O
expression	O
.	O

However	O
,	O
it	O
was	O
not	O
sufficient	O
for	O
surface	O
protein	O
expression	O
,	O
which	O
was	O
controlled	O
posttranscriptionally	O
via	O
a	O
separate	O
pathway	O
involving	O
the	O
ataxia	B
telangiectasia	I
mutated	I
/	O
ataxia	B
telangiectasia	I
and	I
Rad3	I
related	I
kinases	O
.	O

Thus	O
,	O
TLR	O
stimulation	O
allows	O
expression	O
of	O
NKG2D	O
ligands	O
through	O
multiple	O
pathways	O
,	O
including	O
downmodulation	O
of	O
specific	O
miRNAs	O
.	O

In	O
this	O
paper	O
,	O
we	O
clarify	O
that	O
LPS	O
,	O
which	O
ligates	O
TLR-4	B
,	O
preferentially	O
upregulated	O
MICA	B
and	O
not	O
MICB	B
;	O
CL097	B
,	O
which	O
ligates	O
TLR-7	B
/	I
8	I
,	O
upregulated	O
both	O
MICA	B
and	O
MICB	B
;	O
and	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
,	O
which	O
ligates	O
TLR-3	B
,	O
upregulated	O
neither	O
.	O

However	O
,	O
NKG2D	O
ligands	O
can	O
also	O
be	O
induced	O
on	O
human	O
macrophages	O
by	O
TLR	O
stimulation	O
,	O
which	O
has	O
been	O
far	O
less	O
studied	O
.	O

This	O
finding	O
suggests	O
that	O
increased	O
levels	O
of	O
MICA	B
mRNA	O
following	O
LPS	O
stimulation	O
resulted	O
from	O
increased	O
transcription	O
.	O

To	O
probe	O
how	O
LPS	O
stimulation	O
triggers	O
MICA	B
expression	O
,	O
we	O
determined	O
that	O
the	O
stability	O
of	O
MICA	B
mRNA	O
was	O
much	O
longer	O
than	O
that	O
of	O
MICB	B
mRNA	O
,	O
but	O
neither	O
was	O
changed	O
by	O
LPS	O
stimulation	O
.	O

Multiple	O
mechanisms	O
downstream	O
of	O
TLR-4	B
stimulation	O
allow	O
expression	O
of	O
NKG2D	O
ligands	O
to	O
facilitate	O
macrophage	O
/	O
NK	O
cell	O
crosstalk	O
.	O

This	O
establishes	O
recognition	O
of	O
""""	O
induced	O
self	O
""""	O
as	O
an	O
important	O
strategy	O
for	O
surveillance	O
of	O
infections	O
or	O
tumor	O
transformation	O
.	O

The	O
activating	O
receptor	O
NKG2D	B
recognizes	O
proteins	O
that	O
are	O
not	O
normally	O
expressed	O
at	O
the	O
surface	O
of	O
most	O
cells	O
but	O
are	O
expressed	O
during	O
a	O
cellular	O
""""	O
stress	O
""""	O
response	O
(	O
e.g.	O
,	O
upon	O
induction	O
of	O
the	O
DNA	O
damage	O
pathway	O
)	O
.	O

MicroRNA	O
in	O
Situ	O
Hybridization	O
in	O
the	O
Human	O
Entorhinal	O
and	O
Transentorhinal	O
Cortex	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
play	O
key	O
roles	O
in	O
gene	O
expression	O
regulation	O
in	O
both	O
healthy	O
and	O
disease	O
brains	O
.	O

To	O
better	O
understand	O
those	O
roles	O
,	O
it	O
is	O
necessary	O
to	O
characterize	O
the	O
miRNAs	O
that	O
are	O
expressed	O
in	O
particular	O
cell	O
types	O
under	O
a	O
range	O
of	O
conditions	O
.	O

In	O
situ	O
hybridization	O
(	O
ISH	O
)	O
can	O
demonstrate	O
cell-	O
and	O
lamina	O
-	O
specific	O
patterns	O
of	O
miRNA	O
expression	O
that	O
would	O
be	O
lost	O
in	O
tissue	O
-	O
level	O
expression	O
profiling	O
.	O

In	O
the	O
present	O
study	O
,	O
ISH	O
was	O
performed	O
with	O
special	O
focus	O
on	O
the	O
human	O
entorhinal	O
cortex	O
(	O
EC	O
)	O
and	O
transentorhinal	O
cortex	O
(	O
TEC	O
)	O
.	O

The	O
TEC	O
is	O
the	O
area	O
of	O
the	O
cerebral	O
cortex	O
that	O
first	O
develops	O
neurofibrillary	O
tangles	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

However	O
,	O
the	O
reason	O
for	O
TEC	O
's	O
special	O
vulnerability	O
to	O
AD	O
-	O
type	O
pathology	O
is	O
unknown	O
.	O

MiRNA	O
ISH	O
was	O
performed	O
on	O
three	O
human	O
brains	O
with	O
well	O
-	O
characterized	O
clinical	O
and	O
pathological	O
parameters	O
.	O

Locked	O
nucleic	O
acid	O
ISH	O
probes	O
were	O
used	O
referent	O
to	O
miR-107	O
,	O
miR-124	O
,	O
miR-125b	O
,	O
and	O
miR-320	O
.	O

In	O
order	O
to	O
correlate	O
the	O
ISH	O
data	O
with	O
AD	O
pathology	O
,	O
the	O
ISH	O
staining	O
was	O
compared	O
with	O
near	O
-	O
adjacent	O
slides	O
processed	O
using	O
Thioflavine	O
stains	O
.	O

MiRNA	O
ISH	O
is	O
among	O
the	O
first	O
methods	O
to	O
show	O
special	O
staining	O
characteristics	O
of	O
cells	O
and	O
laminae	O
of	O
the	O
human	O
TEC	O
.	O

As	O
with	O
other	O
areas	O
of	O
brain	O
,	O
the	O
TEC	O
and	O
EC	O
have	O
characteristic	O
miRNA	O
expression	O
patterns	O
.	O

Not	O
all	O
neurons	O
or	O
cortical	O
lamina	O
stain	O
with	O
equal	O
intensity	O
for	O
individual	O
miRNAs	O
.	O

Our	O
in	O
vitro	O
results	O
suggested	O
that	O
AŒ≤42	O
oligomer	O
-	O
induced	O
miR-106b	O
leads	O
to	O
impairment	O
in	O
TGF	B
-	I
Œ≤	I
signaling	O
through	O
TŒ≤R	B
II	I
,	O
concomitant	O
with	O
retinoic	O
acid	O
-	O
induced	O
neurodegeneration	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

These	O
results	O
show	O
that	O
TŒ≤R	B
II	I
is	O
a	O
functional	O
target	O
of	O
miR-106b	O
and	O
that	O
miR-106b	O
may	O
influence	O
TGF	B
-	I
Œ≤	I
signaling	O
,	O
thereby	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
AD	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
abundantly	O
expressed	O
in	O
the	O
brain	O
and	O
play	O
an	O
important	O
role	O
in	O
disorders	O
of	O
the	O
brain	O
,	O
including	O
Alzheimer	O
's	O
diseases	O
(	O
AD	O
)	O
.	O

miR-106b	O
aberrantly	O
expressed	O
in	O
a	O
double	O
transgenic	O
mouse	O
model	O
for	O
Alzheimer	O
's	O
disease	O
targets	O
TGF	B
-	I
Œ≤	I
type	I
II	I
receptor	I
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
miRNAs	O
involved	O
in	O
AD	O
pathogenesis	O
by	O
regulating	O
TGF	B
-	I
Œ≤	I
signaling	O
.	O

Growing	O
body	O
of	O
evidence	O
suggests	O
that	O
the	O
TGF	B
-	I
Œ≤	I
signaling	O
pathway	O
plays	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
AD	O
.	O

Sequence	O
analysis	O
revealed	O
two	O
putative	O
binding	O
sites	O
for	O
miR-106b	O
in	O
the	O
3	O
'	O
UTR	O
of	O
the	O
TŒ≤R	B
II	I
mRNA	O
.	O

Here	O
we	O
found	O
that	O
miR-106b	O
and	O
TGF	B
-	I
Œ≤	I
type	I
II	I
receptor	I
(	O
TŒ≤R	B
II	I
)	O
were	O
aberrantly	O
expressed	O
in	O
APPswe	O
/	O
PS‚àÜE9	O
mice	O
(	O
a	O
double	O
transgenic	O
mouse	O
model	O
for	O
AD	O
)	O
.	O

After	O
induced	O
neurodifferentiation	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
,	O
we	O
observed	O
significant	O
neurodegeneration	O
in	O
SH	O
-	O
SY5Y	O
cells	O
stably	O
transfected	O
with	O
miR-106b	O
.	O

Our	O
results	O
showed	O
that	O
the	O
expression	O
of	O
miR-106b	O
was	O
inversely	O
correlated	O
with	O
TŒ≤R	B
II	I
protein	O
levels	O
and	O
miR-106b	O
can	O
directly	O
inhibit	O
the	O
TŒ≤R	B
II	I
translation	O
in	O
vitro	O
.	O

Exposure	O
of	O
SH	O
-	O
SY5Y	O
cells	O
to	O
AŒ≤42	O
oligomers	O
led	O
to	O
the	O
expression	O
of	O
miR-106b	O
was	O
first	O
increased	O
and	O
then	O
decreased	O
and	O
TŒ≤R	B
II	I
levels	O
reduced	O
.	O

Western	O
blot	O
analysis	O
revealed	O
unchanged	O
total	O
Smad2	B
/	I
3	I
protein	O
levels	O
,	O
but	O
reduced	O
phospho	B
-	I
Smad2	I
/	I
3	I
(	O
p	B
-	I
Smad2	I
/	I
3	I
)	O
and	O
increased	O
Smad6	B
/	I
7	I
protein	O
levels	O
in	O
the	O
miR-106b	O
stably	O
transfected	O
cell	O
line	O
.	O

Nuclear	O
factor	O
TDP-43	B
can	O
affect	O
selected	O
microRNA	O
levels	O
.	O

TDP-43	B
has	O
recently	O
been	O
described	O
as	O
the	O
major	O
component	O
of	O
the	O
inclusions	O
found	O
in	O
the	O
brain	O
of	O
patients	O
with	O
a	O
variety	O
of	O
neurodegenerative	O
diseases	O
,	O
such	O
as	O
frontotemporal	O
lobar	O
degeneration	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
.	O

Apart	O
from	O
its	O
involvement	O
in	O
transcription	O
,	O
splicing	O
and	O
mRNA	O
stability	O
,	O
TDP-43	B
has	O
also	O
been	O
described	O
as	O
a	O
Drosha	B
-	O
associated	O
protein	O
.	O

TDP-43	B
is	O
a	O
ubiquitous	O
protein	O
whose	O
specific	O
functions	O
are	O
probably	O
crucial	O
to	O
establishing	O
its	O
pathogenic	O
role	O
.	O

Here	O
we	O
report	O
for	O
the	O
first	O
time	O
which	O
changes	O
occur	O
in	O
the	O
total	O
miRNA	O
population	O
following	O
TDP-43	B
knockdown	O
in	O
culture	O
cells	O
.	O

However	O
,	O
our	O
knowledge	O
of	O
the	O
role	O
of	O
TDP-43	B
in	O
the	O
microRNA	O
(	O
miRNA	O
)	O
synthesis	O
pathway	O
is	O
limited	O
to	O
the	O
association	O
mentioned	O
above	O
.	O

Interestingly	O
,	O
both	O
miRNAs	O
are	O
capable	O
of	O
binding	O
directly	O
to	O
TDP-43	B
in	O
different	O
positions	O
:	O
within	O
the	O
miRNA	O
sequence	O
itself	O
(	O
let-7b	O
)	O
or	O
in	O
the	O
hairpin	O
precursor	O
(	O
miR-663	O
)	O
.	O

In	O
particular	O
,	O
we	O
have	O
observed	O
that	O
let-7b	O
and	O
miR-663	O
expression	O
levels	O
are	O
down-	O
and	O
upregulated	O
,	O
respectively	O
.	O

Using	O
microarray	O
data	O
and	O
real	O
-	O
time	O
PCR	O
we	O
have	O
also	O
identified	O
several	O
candidate	O
transcripts	O
whose	O
expression	O
levels	O
are	O
selectively	O
affected	O
by	O
these	O
TDP-43-miRNA	B
interactions	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
demonstrate	O
that	O
tissue	O
-	O
specific	O
miRNAs	O
may	O
serve	O
as	O
diagnostically	O
sensitive	O
plasma	O
biomarkers	O
of	O
tissue	O
injury	O
.	O

The	O
miR-124	O
concentration	O
increased	O
in	O
the	O
plasma	O
of	O
rats	O
8	O
h	O
after	O
surgery	O
to	O
produce	O
brain	O
injury	O
and	O
peaked	O
at	O
24	O
h	O
,	O
while	O
the	O
miR-122	O
and	O
miR-133a	O
concentrations	O
remained	O
at	O
baseline	O
values	O
.	O

Furthermore	O
,	O
miR-122	O
exhibited	O
a	O
diagnostic	O
sensitivity	O
superior	O
to	O
that	O
of	O
ALT	O
when	O
the	O
results	O
were	O
correlated	O
to	O
the	O
liver	O
histopathologic	O
results	O
.	O

Plasma	O
MicroRNAs	O
as	O
sensitive	O
and	O
specific	O
biomarkers	O
of	O
tissue	O
injury	O
.	O

BACKGROUND	O
:	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
,	O
small	O
noncoding	O
RNAs	O
.	O

Because	O
of	O
their	O
size	O
,	O
abundance	O
,	O
tissue	O
specificity	O
,	O
and	O
relative	O
stability	O
in	O
plasma	O
,	O
miRNAs	O
hold	O
promise	O
as	O
unique	O
accessible	O
biomarkers	O
to	O
monitor	O
tissue	O
injury	O
.	O

METHODS	O
:	O
We	O
investigated	O
the	O
use	O
of	O
liver-	O
,	O
muscle-	O
and	O
brain	O
-	O
specific	O
miRNAs	O
as	O
circulating	O
biomarkers	O
of	O
tissue	O
injury	O
.	O

We	O
used	O
a	O
highly	O
sensitive	O
quantitative	O
PCR	O
assay	O
to	O
measure	O
specific	O
miRNAs	O
(	O
miR-122	O
,	O
miR-133a	O
,	O
and	O
miR-124	O
)	O
in	O
plasma	O
samples	O
from	O
rats	O
treated	O
with	O
liver	O
or	O
muscle	O
toxicants	O
and	O
from	O
a	O
rat	O
surgical	O
model	O
of	O
stroke	O
.	O

RESULTS	O
:	O
We	O
observed	O
increases	O
in	O
plasma	O
concentrations	O
of	O
miR-122	O
,	O
miR-133a	O
,	O
and	O
miR-124	O
corresponding	O
to	O
injuries	O
in	O
liver	O
,	O
muscle	O
,	O
and	O
brain	O
,	O
respectively	O
.	O

miR-122	O
and	O
miR-133a	O
illustrated	O
specificity	O
for	O
liver	O
and	O
muscle	O
toxicity	O
,	O
respectively	O
,	O
because	O
they	O
were	O
not	O
detectable	O
in	O
the	O
plasma	O
of	O
animals	O
with	O
toxicity	O
to	O
the	O
other	O
organ	O
.	O

This	O
result	O
contrasted	O
with	O
the	O
results	O
for	O
alanine	B
aminotransferase	I
(	O
ALT	O
)	O
and	O
aspartate	B
aminotransferase	I
,	O
which	O
were	O
both	O
increased	O
with	O
either	O
organ	O
toxicity	O
.	O

Meanwhile	O
,	O
3NP	O
rats	O
showed	O
dynamic	O
changes	O
in	O
the	O
miRNA	O
profiles	O
during	O
disease	O
development	O
and	O
a	O
few	O
miRNAs	O
with	O
altered	O
expression	O
.	O

In	O
10-week	O
-	O
old	O
R6	O
/	O
2	O
mice	O
,	O
downregulation	O
was	O
dominant	O
in	O
the	O
miRNA	O
expressions	O
and	O
the	O
level	O
of	O
Drosha	B
decreased	O
concomitantly	O
.	O

Nine	O
miRNAs	O
(	O
miR-22	O
,	O
miR-29c	O
,	O
miR-128	O
,	O
miR-132	O
,	O
miR-138	O
,	O
miR-218	O
,	O
miR-222	O
,	O
miR-344	O
,	O
and	O
miR-674	O
*	O
)	O
were	O
commonly	O
down	O
-	O
regulated	O
in	O
both	O
the	O
12-month	O
-	O
old	O
YAC128	O
and	O
10-week	O
-	O
old	O
R6	O
/	O
2	O
mice	O
.	O

Concomitantly	O
,	O
the	O
expressions	O
of	O
Drosha	B
-	O
DGCR8	B
,	O
Exportin-5	B
,	O
and	O
Dcp1	O
were	O
increased	O
at	O
5months	O
,	O
and	O
the	O
expression	O
of	O
Dicer	B
was	O
decreased	O
at	O
12	O
months	O
.	O

YAC128	O
mice	O
showed	O
upregulation	O
-	O
dominant	O
miRNA	O
expressions	O
at	O
5	O
months	O
and	O
downregulation	O
-	O
dominant	O
expressions	O
at	O
12	O
months	O
.	O

After	O
characterizing	O
the	O
phenotypes	O
by	O
behavioral	O
tests	O
and	O
histological	O
analyses	O
,	O
we	O
profiled	O
striatal	O
miRNAs	O
using	O
a	O
miRNA	O
microarray	O
and	O
we	O
measured	O
the	O
key	O
molecules	O
involved	O
in	O
miRNA	O
biogenesis	O
and	O
function	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
miRNA	O
expression	O
and	O
miRNA	O
regulators	O
in	O
two	O
transgenic	O
models	O
of	O
HD	O
,	O
YAC128	O
and	O
R6	O
/	O
2	O
mice	O
,	O
and	O
in	O
a	O
3-nitropropionic	O
acid	O
(	O
3NP	O
)	O
-induced	O
striatal	O
degeneration	O
rat	O
model	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
short	O
RNA	O
molecules	O
regulating	O
gene	O
expression	O
,	O
and	O
are	O
implicated	O
in	O
a	O
variety	O
of	O
diseases	O
including	O
HD	O
.	O
However	O
,	O
the	O
profiles	O
and	O
regulation	O
of	O
miRNAs	O
in	O
HD	O
are	O
not	O
fully	O
understood	O
.	O

Huntington	O
's	O
disease	O
(	O
HD	O
)	O
is	O
a	O
genetic	O
neurodegenerative	O
disease	O
caused	O
by	O
abnormal	O
CAG	O
expansion	O
.	O

Altered	O
microRNA	O
regulation	O
in	O
Huntington	O
's	O
disease	O
models	O
.	O

This	O
information	O
should	O
aid	O
in	O
future	O
studies	O
on	O
therapeutic	O
application	O
of	O
miRNAs	O
in	O
HD	O
.	O

Our	O
results	O
show	O
that	O
transgenic	O
HD	O
mice	O
have	O
abnormal	O
miRNA	O
biogenesis	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
miRNA	O
profiles	O
in	O
A.	O
cantonensis	O
,	O
which	O
may	O
represent	O
a	O
new	O
platform	O
for	O
studying	O
regulation	O
of	O
genes	O
and	O
their	O
networks	O
in	O
A.	O
cantonensis	O
.	O

Nucleotide	O
bias	O
analysis	O
showed	O
that	O
uracil	O
was	O
the	O
prominent	O
nucleotide	O
,	O
particularly	O
at	O
positions	O
of	O
1	O
,	O
10	O
,	O
14	O
,	O
17	O
and	O
22	O
,	O
approximately	O
at	O
the	O
beginning	O
,	O
middle	O
and	O
the	O
end	O
of	O
the	O
conserved	O
miRNAs	O
.	O

No	O
new	O
miRNA	O
sequence	O
was	O
found	O
.	O

A	O
total	O
of	O
8861,260	O
and	O
10,957,957	O
high	O
quality	O
reads	O
with	O
20	O
and	O
23	O
conserved	O
miRNAs	O
were	O
obtained	O
in	O
females	O
and	O
males	O
,	O
respectively	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
and	O
characterize	O
miRNAs	O
of	O
female	O
and	O
male	O
adults	O
of	O
A.	O
cantonensis	O
by	O
Solexa	O
deep	O
sequencing	O
.	O

They	O
have	O
been	O
identified	O
in	O
a	O
diverse	O
range	O
of	O
organisms	O
.	O

microRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
small	O
non	O
-	O
coding	O
RNAs	O
that	O
play	O
crucial	O
roles	O
in	O
gene	O
expression	O
regulation	O
,	O
cellular	O
function	O
and	O
defense	O
,	O
homeostasis	O
and	O
pathogenesis	O
.	O

Angiostrongylus	O
cantonensis	O
causes	O
eosinophilic	O
meningitis	O
and	O
eosinophilic	O
pleocytosis	O
in	O
humans	O
and	O
is	O
of	O
significant	O
socio	O
-	O
economic	O
importance	O
globally	O
.	O

Angiostrongylus	O
cantonensis	O
:	O
Identification	O
and	O
characterization	O
of	O
microRNAs	O
in	O
male	O
and	O
female	O
adults	O
.	O

However	O
,	O
none	O
of	O
these	O
individuals	O
reported	O
here	O
have	O
epilepsy	O
,	O
although	O
two	O
have	O
an	O
abnormal	O
EEG	O
.	O

CONCLUSIONS	O
:	O
The	O
phenotype	O
of	O
chromosome	O
15q13.2q13.3	O
BP4-BP5	O
microdeletion	O
/	O
duplication	O
syndrome	O
may	O
include	O
features	O
of	O
autism	O
spectrum	O
disorder	O
,	O
a	O
variety	O
of	O
neuropsychiatric	O
disorders	O
,	O
and	O
cognitive	O
impairment	O
.	O

Recognition	O
of	O
this	O
broader	O
phenotype	O
has	O
implications	O
for	O
clinical	O
diagnostic	O
testing	O
and	O
efforts	O
to	O
understand	O
the	O
underlying	O
aetiology	O
of	O
this	O
syndrome	O
.	O

PATIENTS	O
:	O
DNA	O
samples	O
from	O
1445	O
unrelated	O
patients	O
submitted	O
consecutively	O
for	O
clinical	O
array	O
comparative	O
genomic	O
hybridisation	O
(	O
CGH	O
)	O
testing	O
at	O
Children	O
's	O
Hospital	O
Boston	O
and	O
DNA	O
samples	O
from	O
1441	O
individuals	O
with	O
autism	O
from	O
751	O
families	O
in	O
the	O
Autism	O
Genetic	O
Resource	O
Exchange	O
(	O
AGRE	O
)	O
repository	O
.	O

RESULTS	O
:	O
We	O
report	O
the	O
clinical	O
features	O
of	O
five	O
patients	O
with	O
a	O
BP4-BP5	O
deletion	O
,	O
three	O
with	O
a	O
BP4-BP5	O
duplication	O
,	O
and	O
two	O
with	O
an	O
overlapping	O
but	O
smaller	O
duplication	O
identified	O
by	O
whole	O
genome	O
high	O
resolution	O
oligonucleotide	O
array	O
CGH	O
.	O

Microdeletion	O
/	O
duplication	O
at	O
15q13.2q13.3	O
among	O
individuals	O
with	O
features	O
of	O
autism	O
and	O
other	O
neuropsychiatric	O
disorders	O
.	O

BACKGROUND	O
:	O
Segmental	O
duplications	O
at	O
breakpoints	O
(	O
BP4-BP5	O
)	O
of	O
chromosome	O
15q13.2q13.3	O
mediate	O
a	O
recurrent	O
genomic	O
imbalance	O
syndrome	O
associated	O
with	O
mental	O
retardation	O
,	O
epilepsy	O
,	O
and/or	O
electroencephalogram	O
(	O
EEG	O
)	O
abnormalities	O
.	O

BP4-BP5	O
covers	O
approximately	O
1.5	O
Mb	O
(	O
chr15:28.719	O
-	O
30.298	O
Mb	O
)	O
and	O
includes	O
six	O
reference	O
genes	O
and	O
1	O
miRNA	O
gene	O
,	O
while	O
the	O
smaller	O
duplications	O
cover	O
approximately	O
500	O
kb	O
(	O
chr15:28.902	O
-	O
29.404	O
Mb	O
)	O
and	O
contain	O
three	O
reference	O
genes	O
and	O
one	O
miRNA	O
gene	O
.	O

Cognitive	O
impairment	O
varied	O
from	O
moderate	O
mental	O
retardation	O
to	O
normal	O
IQ	O
with	O
learning	O
disability	O
.	O

These	O
BP4-BP5	O
deletion	O
cases	O
exhibit	O
minor	O
dysmorphic	O
features	O
,	O
significant	O
expressive	O
language	O
deficits	O
,	O
and	O
a	O
spectrum	O
of	O
neuropsychiatric	O
impairments	O
that	O
include	O
autism	O
spectrum	O
disorder	O
,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
,	O
anxiety	O
disorder	O
,	O
and	O
mood	O
disorder	O
.	O

The	O
BP4-BP5	O
deletion	O
and	O
duplication	O
events	O
span	O
CHRNA7	O
,	O
a	O
candidate	O
gene	O
for	O
seizures	O
.	O

The	O
KIAA0226	B
gene	O
encodes	O
a	O
protein	O
that	O
we	O
named	O
rundataxin	B
,	O
with	O
two	O
conserved	O
domains	O
:	O
an	O
N	O
-	O
terminal	O
RUN	O
domain	O
and	O
a	O
C	O
-	O
terminal	O
domain	O
containing	O
a	O
diacylglycerol	O
binding	O
-	O
like	O
motif	O
.	O

Mutation	O
screening	O
of	O
all	O
coding	O
sequences	O
revealed	O
a	O
single	O
nucleotide	O
deletion	O
,	O
2927delC	O
,	O
in	O
exon	O
19	O
of	O
the	O
KIAA0226	B
gene	O
,	O
which	O
results	O
in	O
a	O
frame	O
shift	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
p	O
.	O
Ala943ValfsX146	O
)	O
.	O

The	O
rundataxin	O
pathway	O
appears	O
therefore	O
distinct	O
from	O
the	O
ataxia	O
pathways	O
involving	O
deficiency	O
in	O
mitochondrial	O
or	O
nuclear	O
proteins	O
and	O
broadens	O
the	O
range	O
of	O
mechanisms	O
leading	O
to	O
recessive	O
ataxias	O
.	O

The	O
closest	O
paralogue	O
of	O
rundataxin	B
,	O
the	O
plekstrin	O
homology	O
domain	O
family	O
member	O
M1	O
,	O
has	O
been	O
shown	O
to	O
colocalize	O
with	O
Rab7	O
,	O
a	O
small	O
GTPase	O
associated	O
with	O
late	O
endosomes	O
/	O
lysosomes	O
,	O
suggesting	O
that	O
rundataxin	B
may	O
also	O
be	O
associated	O
with	O
vesicular	O
trafficking	O
and	O
signalling	O
pathways	O
through	O
its	O
RUN	O
and	O
diacylglycerol	O
binding	O
-	O
like	O
domains	O
.	O

The	O
three	O
patients	O
presented	O
with	O
childhood	O
onset	O
gait	O
and	O
limb	O
ataxia	O
,	O
dysarthria	O
and	O
had	O
limited	O
walking	O
without	O
aid	O
into	O
their	O
teenage	O
years	O
.	O

We	O
have	O
identified	O
a	O
novel	O
form	O
of	O
recessive	O
ataxia	O
that	O
segregates	O
in	O
three	O
children	O
of	O
a	O
large	O
consanguineous	O
Saudi	O
Arabian	O
family	O
.	O

Linkage	O
studies	O
allowed	O
us	O
to	O
identify	O
a	O
single	O
locus	O
that	O
segregated	O
with	O
the	O
disease	O
on	O
chromosome	O
3q28-qter	O
.	O

Two	O
patients	O
developed	O
epilepsy	O
at	O
7	O
months	O
without	O
relapse	O
after	O
treatment	O
,	O
and	O
mental	O
retardation	O
.	O

Rundataxin	B
,	O
a	O
novel	O
protein	O
with	O
RUN	O
and	O
diacylglycerol	O
binding	O
domains	O
,	O
is	O
mutant	O
in	O
a	O
new	O
recessive	O
ataxia	O
.	O

A	O
novel	O
microRNA	O
and	O
transcription	O
factor	O
mediated	O
regulatory	O
network	O
in	O
schizophrenia	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
changes	O
in	O
gene	O
expression	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
schizophrenia	O
,	O
and	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
and	O
transcription	O
factors	O
(	O
TFs	O
)	O
are	O
primary	O
regulators	O
of	O
this	O
gene	O
expression	O
.	O

BACKGROUND	O
:	O
Schizophrenia	O
is	O
a	O
complex	O
brain	O
disorder	O
with	O
molecular	O
mechanisms	O
that	O
have	O
yet	O
to	O
be	O
elucidated	O
.	O

We	O
hypothesized	O
that	O
miRNAs	O
and	O
TFs	O
might	O
play	O
combinatory	O
regulatory	O
roles	O
for	O
schizophrenia	O
genes	O
and	O
,	O
thus	O
,	O
explored	O
miRNA	O
-	O
TF	O
regulatory	O
networks	O
in	O
schizophrenia	O
.	O

So	O
far	O
,	O
several	O
miRNA	O
-	O
TF	O
mediated	O
regulatory	O
modules	O
have	O
been	O
verified	O
.	O

Our	O
evaluation	O
revealed	O
that	O
these	O
observed	O
FFLs	O
were	O
significantly	O
enriched	O
in	O
schizophrenia	O
genes	O
.	O

RESULTS	O
:	O
We	O
identified	O
32	O
feed	O
-	O
forward	O
loops	O
(	O
FFLs	O
)	O
among	O
our	O
compiled	O
schizophrenia	O
-	O
related	O
miRNAs	O
,	O
TFs	O
and	O
genes	O
.	O

By	O
converging	O
the	O
FFLs	O
and	O
mutual	O
feedback	O
loops	O
,	O
we	O
constructed	O
a	O
novel	O
miRNA	O
-	O
TF	O
regulatory	O
network	O
for	O
schizophrenia	O
.	O

Our	O
analysis	O
revealed	O
EGR3	B
and	O
hsa	O
-	O
miR-195	O
were	O
core	O
regulators	O
in	O
this	O
regulatory	O
network	O
.	O

We	O
next	O
proposed	O
a	O
model	O
highlighting	O
EGR3	B
and	O
miRNAs	O
involved	O
in	O
signaling	O
pathways	O
and	O
regulatory	O
networks	O
in	O
the	O
nervous	O
system	O
.	O

It	O
represents	O
the	O
first	O
investigation	O
of	O
a	O
miRNA	O
-	O
TF	O
regulatory	O
network	O
for	O
a	O
complex	O
disease	O
,	O
as	O
demonstrated	O
in	O
schizophrenia	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
many	O
insights	O
on	O
the	O
regulatory	O
mechanisms	O
of	O
genes	O
involved	O
in	O
schizophrenia	O
.	O

Finally	O
,	O
we	O
suggested	O
several	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
located	O
on	O
miRNAs	O
,	O
their	O
target	O
sites	O
,	O
and	O
TFBSs	O
,	O
which	O
may	O
have	O
an	O
effect	O
in	O
schizophrenia	O
gene	O
regulation	O
.	O

MicroRNA	O
expression	O
in	O
ACTH	B
-	O
producing	O
pituitary	O
tumors	O
:	O
up	O
-	O
regulation	O
of	O
microRNA-122	O
and	O
-493	O
in	O
pituitary	O
carcinomas	O
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
in	O
situ	O
hybridization	O
were	O
used	O
to	O
confirm	O
and	O
independently	O
validate	O
miRNAs	O
that	O
were	O
significantly	O
up	O
-	O
regulated	O
or	O
down	O
-	O
regulated	O
between	O
the	O
pituitary	O
tissues	O
.	O

We	O
used	O
miRNA	O
profiling	O
with	O
1,145	O
probes	O
to	O
study	O
miRNA	O
expression	O
in	O
normal	O
anterior	O
pituitary	O
(	O
6	O
cases	O
)	O
,	O
adrenocorticotropin	B
(	O
ACTH	B
)	O
-producing	O
adenomas	O
(	O
8	O
cases	O
)	O
,	O
and	O
ACTH	B
-	O
producing	O
pituitary	O
carcinomas	O
(	O
two	O
cases	O
)	O
.	O

The	O
expression	O
of	O
miRNAs	O
in	O
pituitary	O
carcinomas	O
has	O
not	O
been	O
previously	O
examined	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
involved	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
,	O
and	O
can	O
function	O
as	O
tumor	O
suppressor	O
genes	O
or	O
oncogenes	O
.	O

MiRNA-493	O
was	O
also	O
up	O
-	O
regulated	O
in	O
carcinomas	O
compared	O
to	O
ACTH	B
adenomas	O
.	O

Analysis	O
of	O
genes	O
that	O
miRNA-493	O
interacts	O
with	O
included	O
LGALS3	B
and	O
RUNX2	B
(	O
http://microrna.sanger.ac.uk	O
)	O
both	O
of	O
which	O
have	O
been	O
shown	O
to	O
have	O
roles	O
in	O
pituitary	O
tumor	O
cell	O
growth	O
.	O

There	O
were	O
more	O
miRNAs	O
up-	O
(	O
188	O
)	O
or	O
down	O
-	O
regulated	O
(	O
160	O
)	O
between	O
adenomas	O
and	O
normal	O
pituitaries	O
compared	O
to	O
carcinomas	O
and	O
normal	O
pituitaries	O
(	O
92	O
up-	O
and	O
91	O
down	O
-	O
regulated	O
)	O
or	O
between	O
carcinomas	O
and	O
adenomas	O
(	O
46	O
up-	O
and	O
52	O
down	O
-	O
regulated	O
)	O
.	O

Both	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
in	O
situ	O
hybridization	O
showed	O
significant	O
up	O
-	O
regulation	O
of	O
miRNA-122	O
between	O
pituitary	O
carcinomas	O
and	O
adenomas	O
.	O

These	O
results	O
provide	O
information	O
about	O
marker	O
miRNAs	O
that	O
may	O
lead	O
to	O
further	O
insights	O
into	O
the	O
regulation	O
of	O
pituitary	O
tumor	O
growth	O
and	O
development	O
.	O

Vascular	O
injury	O
triggers	O
dedifferentiation	O
and	O
cytoskeletal	O
remodeling	O
of	O
smooth	O
muscle	O
cells	O
(	O
SMCs	O
)	O
,	O
culminating	O
in	O
vessel	O
occlusion	O
.	O

MicroRNAs	O
miR-143	O
and	O
miR-145	O
modulate	O
cytoskeletal	O
dynamics	O
and	O
responsiveness	O
of	O
smooth	O
muscle	O
cells	O
to	O
injury	O
.	O

Serum	B
response	I
factor	I
(	O
SRF	B
)	O
and	O
its	O
coactivator	O
,	O
myocardin	B
,	O
play	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
smooth	O
muscle	O
phenotypes	O
by	O
regulating	O
the	O
expression	O
of	O
cytoskeletal	O
genes	O
.	O

We	O
show	O
that	O
SRF	B
and	O
myocardin	B
regulate	O
a	O
cardiovascular	O
-	O
specific	O
microRNA	O
(	O
miRNA	O
)	O
cluster	O
encoding	O
miR-143	O
and	O
miR-145	O
.	O

To	O
assess	O
the	O
functions	O
of	O
these	O
miRNAs	O
in	O
vivo	O
,	O
we	O
systematically	O
deleted	O
them	O
singly	O
and	O
in	O
combination	O
in	O
mice	O
.	O

Mice	O
lacking	O
both	O
miR-143	O
and	O
miR-145	O
are	O
viable	O
and	O
do	O
not	O
display	O
overt	O
abnormalities	O
in	O
smooth	O
muscle	O
differentiation	O
,	O
although	O
they	O
show	O
a	O
significant	O
reduction	O
in	O
blood	O
pressure	O
due	O
to	O
reduced	O
vascular	O
tone	O
.	O

Remarkably	O
,	O
however	O
,	O
neointima	O
formation	O
in	O
response	O
to	O
vascular	O
injury	O
is	O
profoundly	O
impeded	O
in	O
mice	O
lacking	O
these	O
miRNAs	O
,	O
due	O
to	O
disarray	O
of	O
actin	O
stress	O
fibers	O
and	O
diminished	O
migratory	O
activity	O
of	O
SMCs	O
.	O

These	O
abnormalities	O
reflect	O
the	O
regulation	O
of	O
a	O
cadre	O
of	O
modulators	O
of	O
SRF	B
activity	O
and	O
actin	O
dynamics	O
by	O
miR-143	O
and	O
miR-145	O
.	O

Thus	O
,	O
miR-143	O
and	O
miR-145	O
act	O
as	O
integral	O
components	O
of	O
the	O
regulatory	O
network	O
whereby	O
SRF	B
controls	O
cytoskeletal	O
remodeling	O
and	O
phenotypic	O
switching	O
of	O
SMCs	O
during	O
vascular	O
disease	O
.	O

Plasma	O
concentrations	O
of	O
miR-124	O
were	O
significantly	O
elevated	O
at	O
6	O
h	O
,	O
and	O
remained	O
elevated	O
at	O
48	O
h	O
after	O
MCAO	O
introduction	O
.	O

Thus	O
,	O
plasma	O
concentration	O
of	O
miR-124	O
provides	O
a	O
promising	O
candidate	O
biomarker	O
for	O
early	O
detection	O
of	O
cerebral	O
infarction	O
.	O

In	O
this	O
study	O
,	O
miRNA	O
array	O
analysis	O
in	O
various	O
tissues	O
showed	O
that	O
miR-124	O
is	O
almost	O
exclusively	O
expressed	O
in	O
the	O
central	O
nervous	O
system	O
and	O
neuronal	O
cells	O
,	O
suggesting	O
that	O
it	O
might	O
be	O
useful	O
as	O
a	O
potential	O
biomarker	O
for	O
neurological	O
diseases	O
.	O

We	O
examined	O
whether	O
plasma	O
concentrations	O
of	O
brain	O
-	O
specific	O
miRNA	O
can	O
serve	O
as	O
a	O
biomarker	O
for	O
cerebral	O
infarction	O
,	O
where	O
the	O
cerebral	O
infarction	O
was	O
modeled	O
by	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
MCAO	O
)	O
in	O
the	O
rat	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
small	O
RNAs	O
that	O
play	O
an	O
important	O
role	O
in	O
various	O
physiological	O
processes	O
by	O
downregulating	O
target	O
genes	O
.	O

Recently	O
,	O
plasma	O
miRNAs	O
have	O
been	O
investigated	O
as	O
biomarkers	O
for	O
various	O
diseases	O
.	O

Plasma	O
miR-124	O
as	O
a	O
biomarker	O
for	O
cerebral	O
infarction	O
.	O

METHODS	O
:	O
Surgical	O
outcome	O
data	O
were	O
prospectively	O
collected	O
for	O
2	O
to	O
11	O
years	O
in	O
161	O
consecutive	O
patients	O
with	O
MTLE	O
/	O
HS	O
.	O
Eighty	O
patients	O
underwent	O
an	O
ATL	O
and	O
81	O
an	O
SA	O
.	O
Seizure	O
control	O
achieved	O
with	O
each	O
technique	O
was	O
compared	O
using	O
the	O
Engel	O
classification	O
scheme	O
.	O

Postoperative	O
memory	O
testing	O
was	O
performed	O
in	O
86	O
patients	O
(	O
53	O
%	O
)	O
.	O

At	O
the	O
last	O
follow	O
up	O
,	O
72	O
%	O
of	O
the	O
patients	O
who	O
had	O
undergone	O
an	O
ATL	O
(	O
mean	O
follow	O
up	O
6.7	O
years	O
)	O
and	O
71	O
%	O
of	O
those	O
who	O
had	O
undergone	O
an	O
SA	O
(	O
mean	O
follow	O
up	O
4.5	O
years	O
)	O
were	O
seizure	O
free	O
(	O
Engle	O
Class	O
IA	O
)	O
.	O

Estimated	O
survival	O
in	O
patients	O
in	O
Engel	O
Classes	O
I	O
,	O
IA	O
,	O
and	O
I	O
and	O
II	O
combined	O
did	O
not	O
differ	O
between	O
the	O
two	O
surgical	O
techniques	O
.	O

Preoperatively	O
,	O
58	O
%	O
of	O
the	O
patients	O
had	O
verbal	O
memory	O
scores	O
one	O
standard	O
deviation	O
(	O
SD	O
)	O
below	O
the	O
normal	O
mean	O
.	O

One	O
third	O
of	O
the	O
patients	O
with	O
preoperative	O
scores	O
in	O
the	O
normal	O
range	O
worsened	O
after	O
surgery	O
,	O
although	O
this	O
outcome	O
was	O
not	O
related	O
to	O
the	O
surgical	O
technique	O
.	O

In	O
contrast	O
,	O
one	O
third	O
of	O
those	O
whose	O
preoperative	O
scores	O
were	O
less	O
than	O
-1	O
SD	O
experienced	O
improvement	O
after	O
surgery	O
.	O

Nine	O
(	O
18	O
%	O
)	O
of	O
the	O
50	O
patients	O
whose	O
left	O
side	O
had	O
been	O
surgically	O
treated	O
improved	O
their	O
verbal	O
memory	O
scores	O
by	O
more	O
than	O
one	O
SD	O
.	O
Seven	O
(	O
78	O
%	O
)	O
of	O
these	O
nine	O
underwent	O
an	O
SA	O
(	O
p	O
=	O
0.05	O
)	O
.	O

OBJECT	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
seizure	O
and	O
memory	O
outcome	O
in	O
patients	O
with	O
medically	O
refractory	O
mesial	O
temporal	O
lobe	O
epilepsy	O
due	O
to	O
hippocampal	O
sclerosis	O
(	O
MTLE	O
/	O
HS	O
)	O
treated	O
using	O
an	O
anterior	O
temporal	O
lobectomy	O
(	O
ATL	O
)	O
or	O
a	O
selective	O
amygdalohippocampectomy	O
(	O
SA	O
)	O
.	O

Seizure	O
and	O
memory	O
outcome	O
following	O
temporal	O
lobe	O
surgery	O
:	O
selective	O
compared	O
with	O
nonselective	O
approaches	O
for	O
hippocampal	O
sclerosis	O
.	O

Preliminary	O
data	O
suggest	O
that	O
postoperative	O
verbal	O
memory	O
scores	O
may	O
improve	O
in	O
patients	O
who	O
undergo	O
selective	O
resection	O
of	O
a	O
sclerotic	O
hippocampus	O
in	O
the	O
dominant	O
temporal	O
lobe	O
.	O

CONCLUSIONS	O
:	O
Both	O
ATL	O
and	O
SA	O
can	O
lead	O
to	O
similar	O
favorable	O
seizure	O
control	O
in	O
patients	O
with	O
MTLE	O
/	O
HS	O
.	O

These	O
data	O
suggest	O
a	O
role	O
for	O
HSV-1-induced	O
miRNA-146a	O
in	O
the	O
evasion	O
of	O
HSV-1	O
from	O
the	O
complement	O
system	O
,	O
and	O
the	O
activation	O
of	O
key	O
elements	O
of	O
the	O
arachidonic	O
acid	O
cascade	O
known	O
to	O
contribute	O
to	O
Alzheimer	O
-	O
type	O
neuropathological	O
change	O
.	O

A	O
known	O
miRNA-146a	O
target	O
in	O
the	O
brain	O
,	O
complement	B
factor	I
H	I
,	O
was	O
downregulated	O
.	O

Expression	O
of	O
cytoplasmic	O
phospholipase	O
A2	O
,	O
the	O
inducible	O
prostaglandin	B
synthase	I
cyclooxygenase-2	I
,	O
and	O
the	O
neuroinflammatory	O
cytokine	O
interleukin-1beta	B
were	O
each	O
upregulated	O
.	O

We	O
report	O
that	O
infection	O
of	O
human	O
primary	O
neural	O
cells	O
with	O
a	O
high	O
phenotypic	O
reactivator	O
HSV-1	O
(	O
17syn+	O
)	O
induces	O
upregulation	O
of	O
a	O
brain	O
-	O
enriched	O
microRNA	O
(	O
miRNA	O
)	O
-146a	O
that	O
is	O
associated	O
with	O
proinflammatory	O
signaling	O
in	O
stressed	O
brain	O
cells	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Herpes	O
simplex	O
virus	O
type-1	O
(	O
HSV-1	O
)	O
infection	O
of	O
human	O
brain	O
cells	O
induces	O
changes	O
in	O
gene	O
expression	O
favorable	O
to	O
the	O
propagation	O
of	O
the	O
infecting	O
agent	O
and	O
detrimental	O
to	O
the	O
function	O
of	O
the	O
host	O
cells	O
.	O

HSV-1	O
infection	O
of	O
human	O
brain	O
cells	O
induces	O
miRNA-146a	O
and	O
Alzheimer	O
-	O
type	O
inflammatory	O
signaling	O
.	O

This	O
study	O
reveals	O
the	O
occurrence	O
of	O
novel	O
mechanisms	O
of	O
HIF	O
regulation	O
,	O
which	O
might	O
contribute	O
to	O
developing	O
novel	O
strategies	O
for	O
therapeutic	O
intervention	O
of	O
HIF	O
-	O
related	O
pathologies	O
,	O
including	O
heart	O
attack	O
,	O
cancer	O
,	O
and	O
stroke	O
.	O

One	O
remarkable	O
hit	O
was	O
the	O
argonaute	B
1	I
(	O
ago1	B
)	O
gene	O
,	O
a	O
central	O
element	O
of	O
the	O
microRNA	O
(	O
miRNA	O
)	O
translational	O
silencing	O
machinery	O
.	O

Further	O
studies	O
confirmed	O
the	O
physiological	O
role	O
of	O
the	O
miRNA	O
machinery	O
in	O
HIF	O
-	O
dependent	O
transcription	O
.	O

After	O
3	O
rounds	O
of	O
selection	O
,	O
30	O
genes	O
emerged	O
as	O
critical	O
HIF	O
regulators	O
in	O
hypoxia	O
,	O
most	O
of	O
which	O
had	O
not	O
been	O
previously	O
associated	O
with	O
HIF	O
biology	O
.	O

The	O
list	O
of	O
genes	O
includes	O
components	O
of	O
chromatin	O
remodeling	O
complexes	O
,	O
transcription	O
elongation	O
factors	O
,	O
and	O
translational	O
regulators	O
.	O

Molecular	O
mechanisms	O
that	O
mediate	O
oxygen	O
-	O
dependent	O
HIF	O
regulation	O
operate	O
at	O
the	O
level	O
of	O
the	O
alpha	O
subunit	O
,	O
controlling	O
protein	O
stability	O
,	O
subcellular	O
localization	O
,	O
and	O
transcriptional	O
coactivator	O
recruitment	O
.	O

We	O
have	O
conducted	O
an	O
unbiased	O
genome	O
-	O
wide	O
RNA	O
interference	O
(	O
RNAi	O
)	O
screen	O
in	O
Drosophila	O
cells	O
aimed	O
to	O
the	O
identification	O
of	O
genes	O
required	O
for	O
HIF	O
activity	O
.	O

Drosophila	O
genome	O
-	O
wide	O
RNAi	O
screen	O
identifies	O
multiple	O
regulators	O
of	O
HIF	O
-	O
dependent	O
transcription	O
in	O
hypoxia	O
.	O

Hypoxia	O
-	O
inducible	O
factors	O
(	O
HIFs	O
)	O
are	O
a	O
family	O
of	O
evolutionary	O
conserved	O
alpha	O
-	O
beta	O
heterodimeric	O
transcription	O
factors	O
that	O
induce	O
a	O
wide	O
range	O
of	O
genes	O
in	O
response	O
to	O
low	O
oxygen	O
tension	O
.	O

Follow	O
up	O
functional	O
enrichment	O
analysis	O
of	O
these	O
FFLs	O
uncovered	O
some	O
functions	O
important	O
to	O
carcinogenesis	O
but	O
also	O
some	O
unique	O
functions	O
specific	O
to	O
the	O
FFLs	O
we	O
identified	O
.	O

Transcriptional	O
aberrations	O
may	O
play	O
a	O
vital	O
role	O
in	O
the	O
etiology	O
of	O
glioblastoma	O
,	O
which	O
might	O
be	O
caused	O
by	O
both	O
genomic	O
alterations	O
and	O
other	O
regulation	O
molecules	O
.	O

Illustrating	O
the	O
functions	O
being	O
disturbed	O
during	O
carcinogenesis	O
and	O
how	O
they	O
are	O
deregulated	O
is	O
very	O
important	O
for	O
us	O
to	O
understand	O
its	O
underlying	O
mechanism	O
.	O

We	O
searched	O
glioblastoma	O
-	O
specific	O
regulatory	O
networks	O
by	O
integrating	O
glioblastoma	O
related	O
miRNAs	O
,	O
TFs	O
and	O
genes	O
,	O
and	O
identified	O
54	O
feed	O
-	O
forward	O
loops	O
(	O
FFLs	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
possible	O
cooperative	O
deregulation	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
and	O
transcription	O
factors	O
(	O
TFs	O
)	O
in	O
glioblastoma	O
,	O
under	O
the	O
hypothesis	O
that	O
miRNAs	O
and	O
TFs	O
might	O
have	O
a	O
combinational	O
regulatory	O
effect	O
on	O
glioblastoma	O
genes	O
.	O

Glioblastoma	O
is	O
the	O
most	O
common	O
and	O
most	O
lethal	O
brain	O
tumour	O
in	O
humans	O
.	O

Gene	O
regulation	O
in	O
glioblastoma	O
:	O
a	O
combinatorial	O
analysis	O
of	O
microRNAs	O
and	O
transcription	O
factors	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
patterns	O
of	O
miRNA	O
expression	O
in	O
cortical	O
GM	O
may	O
contribute	O
to	O
AD	O
pathogenetically	O
,	O
because	O
the	O
aggregate	O
change	O
in	O
miRNA	O
expression	O
observed	O
early	O
in	O
the	O
disease	O
would	O
be	O
predicted	O
to	O
cause	O
profound	O
changes	O
in	O
gene	O
expression	O
.	O

Patterns	O
of	O
microRNA	O
expression	O
in	O
normal	O
and	O
early	O
Alzheimer	O
's	O
disease	O
human	O
temporal	O
cortex	O
:	O
white	O
matter	O
versus	O
gray	O
matter	O
.	O

MicroRNA	O
(	O
miRNA	O
)	O
expression	O
was	O
assessed	O
in	O
human	O
cerebral	O
cortical	O
gray	O
matter	O
(	O
GM	O
)	O
and	O
white	O
matter	O
(	O
WM	O
)	O
in	O
order	O
to	O
provide	O
the	O
first	O
insights	O
into	O
the	O
difference	O
between	O
GM	O
and	O
WM	O
miRNA	O
repertoires	O
across	O
a	O
range	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
pathology	O
.	O

RNA	O
was	O
isolated	O
separately	O
from	O
GM	O
and	O
WM	O
portions	O
of	O
superior	O
and	O
middle	O
temporal	O
cerebral	O
cortex	O
(	O
N	O
=	O
10	O
elderly	O
females	O
,	O
postmortem	O
interval	O
<	O
4	O
h	O
)	O
.	O

miRNA	O
profiling	O
experiments	O
were	O
performed	O
using	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
Exiqon	O
(	O
¬©	O
)	O
LNA	O
-	O
microarrays	O
.	O

A	O
subset	O
of	O
miRNAs	O
that	O
appeared	O
to	O
be	O
strongly	O
expressed	O
according	O
to	O
the	O
microarrays	O
did	O
not	O
appear	O
to	O
be	O
conventional	O
miRNAs	O
according	O
to	O
Northern	O
blot	O
analyses	O
.	O

Some	O
well	O
-	O
characterized	O
miRNAs	O
were	O
substantially	O
enriched	O
in	O
WM	O
as	O
expected	O
.	O

However	O
,	O
most	O
of	O
the	O
miRNA	O
expression	O
variability	O
that	O
correlated	O
with	O
the	O
presence	O
of	O
early	O
AD	O
-	O
related	O
pathology	O
was	O
seen	O
in	O
GM	O
.	O

We	O
confirm	O
that	O
downregulation	O
of	O
a	O
set	O
of	O
miRNAs	O
in	O
GM	O
(	O
including	O
several	O
miR-15	O
/	O
107	O
genes	O
and	O
miR-29	O
paralogs	O
)	O
correlated	O
strongly	O
with	O
the	O
density	O
of	O
diffuse	O
amyloid	O
plaques	O
detected	O
in	O
adjacent	O
tissue	O
.	O

A	O
few	O
miRNAs	O
were	O
differentially	O
expressed	O
in	O
WM	O
,	O
including	O
miR-212	O
that	O
is	O
downregulated	O
in	O
AD	O
and	O
miR-424	O
which	O
is	O
upregulated	O
in	O
AD	O
.	O

The	O
expression	O
of	O
certain	O
miRNAs	O
correlates	O
with	O
other	O
miRNAs	O
across	O
different	O
cases	O
,	O
and	O
particular	O
subsets	O
of	O
miRNAs	O
are	O
coordinately	O
expressed	O
in	O
relation	O
to	O
AD	O
-	O
related	O
pathology	O
.	O

Leukodystrophy	O
and	O
gene	O
therapy	O
with	O
a	O
dimmer	O
switch	O
.	O

The	O
authors	O
reviewed	O
the	O
records	O
of	O
nineteen	O
consecutive	O
children	O
with	O
newly	O
diagnosed	O
IIH	O
in	O
order	O
to	O
compare	O
demographic	O
characteristics	O
,	O
clinical	O
pictures	O
and	O
ophthalmologic	O
aspects	O
as	O
optic	O
disc	O
evaluation	O
and	O
visual	O
field	O
evaluation	O
,	O
as	O
well	O
as	O
treatment	O
modalities	O
and	O
follow	O
up	O
.	O

Beside	O
obesity	O
and	O
female	O
gender	O
,	O
potential	O
alternative	O
risk	O
factors	O
remains	O
to	O
be	O
investigated	O
,	O
which	O
need	O
a	O
good	O
collaboration	O
between	O
neuro	O
-	O
ophthalmologists	O
and	O
pediatric	O
neurologists	O
.	O

Idiopathic	O
intracranial	O
hypertension	O
(	O
IIH	O
)	O
is	O
a	O
clinical	O
condition	O
characterized	O
by	O
elevated	O
intracranial	O
pressure	O
and	O
absence	O
of	O
clinical	O
,	O
laboratory	O
or	O
radiographic	O
evidence	O
of	O
central	O
nervous	O
system	O
infection	O
,	O
vascular	O
malformation	O
,	O
intracranial	O
space	O
occupying	O
lesion	O
or	O
hydrocephalus	O
.	O

In	O
the	O
last	O
years	O
the	O
raising	O
understanding	O
of	O
pediatric	O
IIH	O
,	O
especially	O
concerning	O
its	O
demographics	O
and	O
epidemiology	O
,	O
has	O
brought	O
up	O
to	O
a	O
redefinition	O
of	O
diagnostic	O
criteria	O
and	O
reevaluation	O
of	O
pathogenesis	O
and	O
treatment	O
.	O

Pediatric	O
idiopathic	O
intracranial	O
hypertension	O
:	O
clinical	O
and	O
demographic	O
features	O
.	O

Although	O
microRNAs	O
are	O
expressed	O
extensively	O
in	O
the	O
central	O
nervous	O
system	O
in	O
physiological	O
and	O
pathological	O
conditions	O
,	O
their	O
expression	O
in	O
neurological	O
disorder	O
of	O
epilepsy	O
has	O
not	O
been	O
well	O
characterized	O
.	O

Expression	O
profile	O
of	O
microRNAs	O
in	O
rat	O
hippocampus	O
following	O
lithium	O
-	O
pilocarpine	O
-	O
induced	O
status	O
epilepticus	O
.	O

Rat	O
MicroRNA	O
array	O
and	O
differential	O
analysis	O
had	O
detected	O
19	O
up	O
-	O
regulated	O
microRNAs	O
and	O
7	O
down	O
-	O
regulated	O
microRNAs	O
in	O
rat	O
hippocampus	O
,	O
and	O
four	O
randomly	O
selected	O
deregulated	O
microRNAs	O
(	O
microRNA-34a	O
,	O
microRNA-22	O
,	O
microRNA-125a	O
,	O
microRNA-21	O
)	O
were	O
confirmed	O
by	O
qRT	O
-	O
PCR	O
,	O
then	O
their	O
expression	O
alterations	O
in	O
rat	O
peripheral	O
blood	O
were	O
analyzed	O
.	O

Here	O
we	O
investigated	O
microRNA	O
expression	O
pattern	O
in	O
post	O
status	O
epilepticus	O
rats	O
(	O
24h	O
after	O
status	O
)	O
.	O

Thus	O
,	O
our	O
results	O
have	O
not	O
only	O
characterized	O
the	O
microRNA	O
expression	O
profile	O
in	O
post	O
status	O
epilepticus	O
rat	O
hippocampus	O
but	O
also	O
demonstrated	O
that	O
some	O
rat	O
hippocampal	O
microRNAs	O
were	O
probably	O
associated	O
with	O
rat	O
peripheral	O
blood	O
microRNAs	O
.	O

We	O
found	O
that	O
these	O
four	O
deregulated	O
microRNAs	O
were	O
also	O
differentially	O
expressed	O
in	O
rat	O
peripheral	O
blood	O
,	O
and	O
trends	O
for	O
their	O
blood	O
expression	O
alterations	O
were	O
just	O
the	O
same	O
as	O
their	O
counterparts	O
in	O
rat	O
hippocampus	O
.	O

Moreover	O
,	O
targets	O
of	O
these	O
deregulated	O
microRNAs	O
were	O
analyzed	O
using	O
bioinformatics	O
and	O
the	O
identified	O
enriched	O
MAPK	O
pathway	O
and	O
long	O
-	O
term	O
potentiation	O
pathway	O
might	O
have	O
been	O
involved	O
in	O
molecular	O
mechanisms	O
concerning	O
neuronal	O
death	O
,	O
inflammation	O
and	O
epileptogenesis	O
.	O

Remarks	O
are	O
also	O
provided	O
to	O
point	O
out	O
the	O
unanswered	O
questions	O
and	O
to	O
outline	O
the	O
new	O
directions	O
for	O
the	O
future	O
research	O
of	O
the	O
field	O
.	O

Speculations	O
on	O
the	O
development	O
of	O
miRNAs	O
as	O
potential	O
therapeutic	O
targets	O
are	O
also	O
presented	O
.	O

These	O
small	O
molecules	O
act	O
by	O
repressing	O
the	O
expression	O
of	O
either	O
the	O
proapoptotic	O
or	O
antiapoptotic	O
genes	O
to	O
produce	O
antiapoptotic	O
or	O
proapoptotic	O
effects	O
.	O

Appealing	O
evidence	O
has	O
been	O
accumulating	O
for	O
the	O
involvement	O
of	O
miRNAs	O
in	O
human	O
diseases	O
associated	O
with	O
apoptotic	O
cell	O
death	O
and	O
the	O
potential	O
of	O
miRNAs	O
as	O
novel	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
the	O
diseases	O
.	O

The	O
importance	O
of	O
miRNAs	O
has	O
steadily	O
gained	O
appreciation	O
and	O
miRNA	O
biology	O
has	O
exploded	O
into	O
a	O
massive	O
swell	O
of	O
interest	O
with	O
enormous	O
range	O
and	O
potential	O
in	O
almost	O
every	O
biological	O
discipline	O
because	O
of	O
their	O
widespread	O
expression	O
and	O
diverse	O
functions	O
in	O
both	O
animals	O
and	O
humans	O
.	O

It	O
has	O
been	O
established	O
that	O
miRNAs	O
are	O
critical	O
regulators	O
of	O
apoptosis	O
of	O
various	O
cell	O
types	O
.	O

Tremendous	O
efforts	O
have	O
been	O
made	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
and	O
signaling	O
pathways	O
involved	O
in	O
apoptosistic	O
cell	O
death	O
.	O

Once	O
ignored	O
completely	O
or	O
overlooked	O
as	O
cellular	O
detritus	O
,	O
microRNAs	O
(	O
miRNAs	O
)	O
that	O
were	O
discovered	O
only	O
a	O
decade	O
ago	O
,	O
have	O
recently	O
taken	O
many	O
by	O
surprise	O
.	O

MicroRNA	O
:	O
A	O
matter	O
of	O
life	O
or	O
death	O
.	O

Progressive	O
cell	O
loss	O
due	O
to	O
apoptosis	O
is	O
a	O
pathological	O
hallmark	O
implicated	O
in	O
a	O
wide	O
spectrum	O
of	O
degenerative	O
diseases	O
such	O
as	O
heart	O
disease	O
,	O
atherosclerotic	O
arteries	O
and	O
hypertensive	O
vessels	O
,	O
Alzheimer	O
's	O
disease	O
and	O
other	O
neurodegenerative	O
disorders	O
.	O

This	O
editorial	O
aims	O
to	O
convey	O
this	O
message	O
and	O
to	O
boost	O
up	O
the	O
research	O
interest	O
by	O
providing	O
a	O
timely	O
,	O
comprehensive	O
overview	O
on	O
regulation	O
of	O
apoptosis	O
by	O
miRNAs	O
and	O
a	O
synopsis	O
on	O
the	O
pathophysiologic	O
implications	O
of	O
this	O
novel	O
regulatory	O
network	O
based	O
on	O
the	O
currently	O
available	O
data	O
in	O
the	O
literature	O
.	O

It	O
begins	O
with	O
a	O
brief	O
introduction	O
to	O
apoptosis	O
and	O
miRNAs	O
,	O
followed	O
by	O
the	O
description	O
of	O
the	O
fundamental	O
aspects	O
of	O
miRNA	O
biogenesis	O
and	O
action	O
,	O
and	O
the	O
role	O
of	O
miRNAs	O
in	O
regulating	O
apoptosis	O
of	O
cancer	O
cells	O
and	O
cardiovascular	O
cells	O
.	O

The	O
accurate	O
diagnosis	O
of	O
brain	O
malignancies	O
is	O
essential	O
for	O
selection	O
of	O
proper	O
treatment	O
.	O

A	O
recurring	O
challenge	O
for	O
brain	O
pathologists	O
is	O
to	O
diagnose	O
whether	O
a	O
brain	O
malignancy	O
is	O
a	O
primary	O
tumor	O
or	O
a	O
metastasis	O
from	O
some	O
other	O
tissue	O
.	O

MiR-92b	O
and	O
miR-9	O
/	O
9	O
*	O
are	O
specifically	O
expressed	O
in	O
brain	O
primary	O
tumors	O
and	O
can	O
be	O
used	O
to	O
differentiate	O
primary	O
from	O
metastatic	O
brain	O
tumors	O
.	O

These	O
microRNAs	O
thus	O
represent	O
excellent	O
biomarkers	O
for	O
brain	O
primary	O
tumors	O
.	O

By	O
considering	O
the	O
expression	O
of	O
only	O
these	O
two	O
microRNAs	O
,	O
it	O
is	O
possible	O
to	O
distinguish	O
between	O
primary	O
and	O
metastatic	O
brain	O
tumors	O
with	O
very	O
high	O
accuracy	O
.	O

Using	O
microRNA	O
expression	O
profiling	O
,	O
we	O
found	O
that	O
hsa	O
-	O
miR-92b	O
and	O
hsa	O
-	O
miR-9	O
/	O
hsa	O
-	O
miR-9	O
*	O
are	O
over	O
-	O
expressed	O
,	O
specifically	O
in	O
brain	O
primary	O
tumors	O
,	O
as	O
compared	O
to	O
primary	O
tumors	O
from	O
other	O
tissues	O
and	O
their	O
metastases	O
to	O
the	O
brain	O
.	O

MicroRNAs	O
are	O
a	O
class	O
of	O
small	O
non	O
-	O
coding	O
RNA	O
species	O
that	O
regulate	O
gene	O
expression	O
;	O
many	O
exhibit	O
tissue	O
-	O
specific	O
expression	O
and	O
are	O
misregulated	O
in	O
cancer	O
.	O

Previous	O
reports	O
have	O
found	O
that	O
hsa	O
-	O
miR-92b	O
and	O
hsa	O
-	O
miR-9	O
/	O
hsa	O
-	O
miR-9	O
*	O
are	O
expressed	O
more	O
strongly	O
in	O
developing	O
neurons	O
and	O
brain	O
than	O
in	O
adult	O
brain	O
.	O

Thus	O
,	O
their	O
specific	O
over	O
-	O
expression	O
in	O
brain	O
primary	O
tumors	O
supports	O
a	O
functional	O
role	O
for	O
these	O
microRNAs	O
or	O
a	O
link	O
between	O
neuronal	O
stem	O
cells	O
and	O
brain	O
tumorigenesis	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
levels	O
of	O
human	O
APP	B
can	O
be	O
regulated	O
by	O
miRNAs	O
.	O

Over	O
-	O
expression	O
of	O
these	O
miRNAs	O
,	O
but	O
not	O
control	O
miRNAs	O
,	O
results	O
in	O
translational	O
repression	O
of	O
APP	B
mRNA	O
and	O
significantly	O
reduces	O
APP	B
protein	O
levels	O
.	O

Here	O
we	O
test	O
the	O
hypothesis	O
that	O
APP	B
protein	O
levels	O
can	O
be	O
regulated	O
by	O
miRNAs	O
,	O
evolutionarily	O
conserved	O
small	O
noncoding	O
RNA	O
molecules	O
that	O
play	O
an	O
important	O
role	O
in	O
regulating	O
gene	O
expression	O
.	O

Utilizing	O
human	O
cell	O
lines	O
,	O
we	O
demonstrate	O
that	O
miRNAs	O
hsa	O
-	O
mir-106a	O
and	O
hsa	O
-	O
mir-520c	O
bind	O
to	O
their	O
predicted	O
target	O
sequences	O
in	O
the	O
APP	B
3'UTR	O
and	O
negatively	O
regulate	O
reporter	O
gene	O
expression	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
studies	O
have	O
shown	O
that	O
increased	O
APP	B
levels	O
,	O
resulting	O
from	O
either	O
a	O
genomic	O
locus	O
duplication	O
or	O
alteration	O
in	O
APP	O
regulatory	O
sequences	O
,	O
can	O
lead	O
to	O
development	O
of	O
early	O
-	O
onset	O
dementias	O
,	O
including	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Therefore	O
,	O
understanding	O
how	O
APP	B
levels	O
are	O
regulated	O
could	O
provide	O
valuable	O
insight	O
into	O
the	O
genetic	O
basis	O
of	O
AD	O
and	O
illuminate	O
novel	O
therapeutic	O
avenues	O
for	O
AD	O
.	O

MicroRNAs	O
can	O
regulate	O
human	O
APP	B
levels	O
.	O

MicroRNA	O
expression	O
profiling	O
for	O
molecular	O
classification	O
of	O
pediatric	O
brain	O
tumors	O
.	O

The	O
transcription	O
factor	O
REST	B
silences	O
neuronal	O
gene	O
expression	O
in	O
non	O
-	O
neuronal	O
cells	O
.	O

The	O
bifunctional	O
microRNA	O
miR-9	O
/	O
miR-9	O
*	O
regulates	O
REST	B
and	O
CoREST	B
and	O
is	O
downregulated	O
in	O
Huntington	O
's	O
disease	O
.	O

Polyglutamine	O
expansions	O
in	O
huntingtin	B
,	O
which	O
causes	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
,	O
abrogates	O
REST	B
-	O
huntingtin	B
binding	O
.	O

In	O
neurons	O
,	O
the	O
protein	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
in	O
part	O
through	O
binding	O
to	O
huntingtin	B
.	O

In	O
this	O
work	O
,	O
we	O
found	O
that	O
levels	O
of	O
several	O
microRNAs	O
(	O
miRNAs	O
)	O
with	O
upstream	O
RE1	O
sites	O
are	O
decreased	O
in	O
HD	O
patient	O
cortices	O
relative	O
to	O
healthy	O
controls	O
.	O

Consequently	O
,	O
REST	B
translocates	O
to	O
the	O
nucleus	O
,	O
occupies	O
RE1	O
repressor	O
sequences	O
and	O
decreases	O
neuronal	O
gene	O
expression	O
.	O

Interestingly	O
,	O
one	O
of	O
these	O
,	O
the	O
bifunctional	O
brain	O
enriched	O
miR-9	O
/	O
miR-9	O
*	O
,	O
targets	O
two	O
components	O
of	O
the	O
REST	O
complex	O
:	O
miR-9	O
targets	O
REST	B
and	O
miR-9	O
*	O
targets	O
CoREST	B
.	O

These	O
data	O
provide	O
evidence	O
for	O
a	O
double	O
negative	O
feedback	O
loop	O
between	O
the	O
REST	O
silencing	O
complex	O
and	O
the	O
miRNAs	O
it	O
regulates	O
.	O

Specificity	O
,	O
duplex	O
degradation	O
and	O
subcellular	O
localization	O
of	O
antagomirs	O
.	O

Finally	O
,	O
we	O
show	O
that	O
antagomirs	O
,	O
although	O
incapable	O
of	O
silencing	O
miRNAs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
when	O
injected	O
systemically	O
,	O
efficiently	O
target	O
miRNAs	O
when	O
injected	O
locally	O
into	O
the	O
mouse	O
cortex	O
.	O

Our	O
data	O
further	O
validate	O
the	O
effectiveness	O
of	O
antagomirs	O
in	O
vivo	O
and	O
should	O
facilitate	O
future	O
studies	O
to	O
silence	O
miRNAs	O
for	O
functional	O
analysis	O
and	O
in	O
clinically	O
relevant	O
settings	O
.	O

We	O
demonstrate	O
that	O
antagomirs	O
harbor	O
optimized	O
phosphorothioate	O
modifications	O
,	O
require	O
>	O
19-nt	O
length	O
for	O
highest	O
efficiency	O
and	O
can	O
discriminate	O
between	O
single	O
nucleotide	O
mismatches	O
of	O
the	O
targeted	O
miRNA	O
.	O

Degradation	O
of	O
different	O
chemically	O
protected	O
miRNA	O
/	O
antagomir	O
duplexes	O
in	O
mouse	O
livers	O
and	O
localization	O
of	O
antagomirs	O
in	O
a	O
cytosolic	O
compartment	O
that	O
is	O
distinct	O
from	O
processing	O
(	O
P	O
)	O
-bodies	O
indicates	O
a	O
degradation	O
mechanism	O
independent	O
of	O
the	O
RNA	O
interference	O
(	O
RNAi	O
)	O
pathway	O
.	O

We	O
recently	O
demonstrated	O
silencing	O
miRNA	O
function	O
in	O
mice	O
using	O
chemically	O
modified	O
and	O
cholesterol	O
-	O
conjugated	O
RNAs	O
termed	O
'	O
antagomirs	O
'	O
.	O

Here	O
,	O
we	O
further	O
characterize	O
the	O
properties	O
and	O
function	O
of	O
antagomirs	O
in	O
mice	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
an	O
abundant	O
class	O
of	O
20	O
-	O
23-nt	O
long	O
regulators	O
of	O
gene	O
expression	O
.	O

The	O
study	O
of	O
miRNA	O
function	O
in	O
mice	O
and	O
potential	O
therapeutic	O
approaches	O
largely	O
depend	O
on	O
modified	O
oligonucleotides	O
.	O

Altered	O
microRNAs	O
in	O
STHdh	O
(	O
Q111	O
)	O
/	O
Hdh	O
(	O
Q111	O
)	O
cells	O
:	O
miR-146a	O
targets	O
TBP	B
.	O

We	O
studied	O
expression	O
of	O
90	O
miRNAs	O
in	O
STHdh	O
(	O
Q111	O
)	O
/	O
Hdh	O
(	O
Q111	O
)	O
cells	O
,	O
a	O
model	O
for	O
Huntington	O
's	O
disease	O
and	O
compared	O
with	O
that	O
obtained	O
in	O
STHdh	O
(	O
Q7	O
)	O
/	O
Hdh	O
(	O
Q7	O
)	O
cells	O
.	O

Fifteen	O
miRNAs	O
were	O
down	O
regulated	O
and	O
12	O
miRNAs	O
were	O
up	O
regulated	O
more	O
than	O
2-fold	O
.	O

Such	O
changes	O
were	O
statistically	O
significant	O
.	O

One	O
hundred	O
and	O
forty	O
-	O
two	O
genes	O
are	O
experimentally	O
known	O
targets	O
of	O
these	O
altered	O
miRNAs	O
.	O

Using	O
luciferase	O
reporter	O
assays	O
with	O
3'-UTRs	O
of	O
TBP	B
,	O
over	O
-	O
expression	O
and	O
inhibition	O
of	O
miR-146a	O
,	O
we	O
showed	O
that	O
miR-146a	O
targets	O
TBP	B
.	O

It	O
has	O
been	O
predicted	O
that	O
miR-146a	O
may	O
target	O
Tata	B
Binding	I
Protein	I
(	O
TBP	B
)	O
.	O

Regulation	O
of	O
TBP	B
by	O
miR-146a	O
may	O
contribute	O
to	O
HD	O
pathogenesis	O
.	O

Many	O
of	O
these	O
pathways	O
were	O
first	O
identified	O
in	O
genetic	O
screens	O
in	O
Drosophila	O
and	O
other	O
lower	O
organisms	O
.	O

In	O
the	O
last	O
20	O
years	O
,	O
it	O
has	O
become	O
clear	O
that	O
developmental	O
genes	O
and	O
their	O
regulators	O
,	O
noncoding	O
RNAs	O
including	O
microRNAs	O
and	O
long	O
-	O
noncoding	O
RNAs	O
,	O
within	O
signaling	O
pathways	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
cancer	O
.	O

Genes	O
and	O
pathways	O
expressed	O
during	O
embryonic	O
development	O
,	O
including	O
the	O
Notch	O
,	O
Wnt	O
/	O
Œ≤	B
-	I
Catenin	I
,	O
TGF	B
-	I
Œ≤	I
/	O
BMP	O
,	O
Shh	B
/	O
Patched	O
,	O
and	O
Hippo	O
pathways	O
are	O
mutated	O
,	O
lost	O
,	O
or	O
aberrantly	O
regulated	O
in	O
a	O
wide	O
variety	O
of	O
human	O
cancers	O
,	O
including	O
skin	O
,	O
breast	O
,	O
blood	O
,	O
and	O
brain	O
cancers	O
,	O
including	O
medulloblastoma	O
.	O

Mammalian	O
orthologs	O
were	O
subsequently	O
identified	O
and	O
genes	O
within	O
the	O
pathways	O
cloned	O
and	O
found	O
to	O
regulate	O
cell	O
growth	O
.	O

Cerebellum	O
development	O
and	O
medulloblastoma	O
.	O

Medulloblastoma	O
,	O
the	O
most	O
common	O
malignant	O
nervous	O
system	O
tumor	O
in	O
childhood	O
,	O
are	O
thought	O
to	O
arise	O
from	O
disruptions	O
in	O
cerebellar	O
development	O
[	O
reviewed	O
by	O
Marino	O
,	O
S.	O
(	O
2005	O
)	O
]	O
.	O

These	O
biochemical	O
pathways	O
affect	O
cell	O
fate	O
determination	O
,	O
axis	O
formation	O
,	O
and	O
patterning	O
during	O
development	O
and	O
regulate	O
tissue	O
homeostasis	O
and	O
regeneration	O
in	O
adults	O
.	O

In	O
this	O
chapter	O
,	O
we	O
will	O
review	O
the	O
development	O
of	O
the	O
cerebellar	O
cortex	O
,	O
highlighting	O
signaling	O
pathways	O
of	O
potential	O
relevance	O
to	O
tumorigenesis	O
.	O

Defining	O
the	O
extracellular	O
cues	O
and	O
intracellular	O
signaling	O
pathways	O
that	O
control	O
cerebellar	O
neurogenesis	O
,	O
especially	O
granule	O
cell	O
progenitor	O
(	O
GCP	O
)	O
proliferation	O
and	O
differentiation	O
has	O
been	O
useful	O
for	O
developing	O
models	O
to	O
unravel	O
the	O
mechanisms	O
underlying	O
medulloblastoma	O
formation	O
and	O
growth	O
.	O

This	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
case	O
of	O
this	O
kind	O
found	O
in	O
Argentina	O
and	O
is	O
additional	O
evidence	O
that	O
HAM	O
/	O
TSP	O
solely	O
related	O
to	O
HTLV	O
-	O
II	O
infection	O
occurs	O
in	O
HTLV	O
-	O
I	O
-	O
negative	O
subjects	O
.	O

A	O
case	O
of	O
neurological	O
disease	O
featuring	O
human	O
T	O
lymphocyte	O
virus	O
-	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
(	O
HAM	O
/	O
TSP	O
)	O
was	O
diagnosed	O
by	O
serological	O
(	O
Western	O
blot	O
)	O
and	O
molecular	O
(	O
polymerase	O
chain	O
reaction	O
)	O
criteria	O
as	O
related	O
to	O
human	O
T	O
lymphocyte	O
virus	O
(	O
HTLV	O
)	O
-II	O
infection	O
.	O

A	O
possible	O
case	O
of	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
in	O
an	O
Argentinian	O
woman	O
with	O
human	O
T	O
lymphocyte	O
virus	O
type	O
II	O
.	O

Co	O
-	O
suppression	O
of	O
miR-221	O
/	O
222	O
directly	O
resulted	O
in	O
the	O
up	O
-	O
regulation	O
of	O
p27Kip1	B
in	O
the	O
tested	O
cells	O
,	O
consequently	O
,	O
affects	O
their	O
growth	O
potential	O
by	O
reducing	O
a	O
G1	O
to	O
S	O
shift	O
in	O
the	O
cell	O
cycle	O
.	O

Consistently	O
,	O
miR-221	O
/	O
222	O
knocked	O
-	O
down	O
through	O
antisense	O
2'-OME	O
-	O
oligonucleotides	O
increased	O
p27Kip1	B
in	O
U251	O
glioma	O
subcutaneous	O
mice	O
and	O
strongly	O
reduced	O
tumor	O
growth	O
in	O
vivo	O
through	O
up	O
regulation	O
of	O
p27Kip1	B
.	O

Our	O
results	O
suggest	O
that	O
miR-221	O
/	O
222	O
is	O
a	O
regulator	O
of	O
the	O
tumor	O
suppressor	O
gene	O
p27Kip1	B
,	O
and	O
co	O
-	O
suppression	O
of	O
miR-221	O
/	O
222	O
expression	O
in	O
advanced	O
gliomas	O
may	O
inhibit	O
glioma	O
cell	O
proliferation	O
by	O
a	O
mechanism	O
involving	O
the	O
up	O
-	O
regulation	O
of	O
p27Kip1	B
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Co	O
-	O
suppression	O
of	O
miR-221	O
/	O
222	O
cluster	O
suppresses	O
human	O
glioma	O
cell	O
growth	O
by	O
targeting	O
p27kip1	B
in	O
vitro	O
and	O
in	O
vivo	O
.	O

MicroRNAs	O
are	O
short	O
regulatory	O
RNAs	O
that	O
negatively	O
modulate	O
protein	O
expression	O
at	O
a	O
post	O
-	O
transcriptional	O
level	O
.	O

Emerging	O
evidence	O
suggests	O
that	O
altered	O
regulation	O
of	O
miRNA	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
several	O
types	O
of	O
cancers	O
.	O

In	O
the	O
current	O
study	O
,	O
an	O
inverse	O
relationship	O
between	O
the	O
expression	O
of	O
miR-221	O
/	O
miR-222	O
and	O
the	O
cell	O
cycle	O
inhibitor	O
p27Kip1	B
was	O
identified	O
in	O
U251	O
glioma	O
cells	O
.	O

The	O
mRNA	O
expression	O
of	O
the	O
RNases	O
Drosha	B
and	O
Dicer	B
,	O
cofactor	O
Pasha	O
,	O
and	O
the	O
pre	O
-	O
miRNA	O
transporter	O
exportin-5	B
,	O
which	O
modulate	O
miRNA	O
biogenesis	O
,	O
were	O
not	O
altered	O
after	O
transient	O
middle	O
cerebral	O
artery	O
occlusion	O
.	O

Thus	O
,	O
the	O
present	O
studies	O
indicate	O
a	O
critical	O
role	O
of	O
miRNAs	O
in	O
controlling	O
mRNA	O
transcription	O
and	O
translation	O
in	O
the	O
postischemic	O
brain	O
.	O

Bioinformatics	O
analysis	O
indicated	O
a	O
correlation	O
between	O
miRNAs	O
altered	O
to	O
several	O
mRNAs	O
known	O
to	O
mediate	O
inflammation	O
,	O
transcription	O
,	O
neuroprotection	O
,	O
receptors	O
function	O
,	O
and	O
ionic	O
homeostasis	O
.	O

Of	O
those	O
,	O
17	O
showed	O
>	O
5	O
fold	O
change	O
.	O

In	O
silico	O
analysis	O
showed	O
sequence	O
complementarity	O
of	O
eight	O
miRNAs	O
induced	O
after	O
focal	O
ischemia	O
to	O
877	O
promoters	O
indicating	O
the	O
possibility	O
of	O
noncoding	O
RNA	O
-	O
induced	O
activation	O
of	O
gene	O
expression	O
.	O

Antagomir	O
-	O
mediated	O
prevention	O
of	O
mir-145	O
expression	O
led	O
to	O
an	O
increased	O
protein	O
expression	O
of	O
its	O
downstream	O
target	O
superoxide	B
dismutase-2	I
in	O
the	O
postischemic	O
brain	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
approximately	O
22	O
nucleotides	O
long	O
,	O
noncoding	O
RNAs	O
that	O
control	O
cellular	O
function	O
by	O
either	O
degrading	O
mRNAs	O
or	O
arresting	O
their	O
translation	O
.	O

Transient	O
focal	O
ischemia	O
induces	O
extensive	O
temporal	O
changes	O
in	O
rat	O
cerebral	O
microRNAome	O
.	O

Of	O
the	O
238	O
miRNAs	O
evaluated	O
,	O
8	O
showed	O
increased	O
and	O
12	O
showed	O
decreased	O
expression	O
at	O
least	O
at	O
4	O
out	O
of	O
5	O
reperfusion	O
time	O
points	O
studied	O
between	O
3	O
h	O
and	O
3	O
days	O
compared	O
with	O
sham	O
.	O

To	O
understand	O
their	O
functional	O
significance	O
in	O
ischemic	O
pathophysiology	O
,	O
we	O
profiled	O
miRNAs	O
in	O
adult	O
rat	O
brain	O
as	O
a	O
function	O
of	O
reperfusion	O
time	O
after	O
transient	O
middle	O
cerebral	O
artery	O
occlusion	O
.	O

The	O
therapy	O
employed	O
,	O
in	O
a	O
single	O
baculoviral	O
vector	O
,	O
a	O
glial	B
fibrillary	I
acidic	I
protein	I
(	O
GFAP	B
)	O
gene	O
promoter	O
and	O
the	O
repeated	O
target	O
sequences	O
of	O
three	O
miRNAs	O
that	O
are	O
enriched	O
in	O
astrocytes	O
but	O
downregulated	O
in	O
glioblastoma	O
cells	O
to	O
control	O
the	O
expression	O
of	O
the	O
herpes	O
simplex	O
virus	O
thymidine	O
kinase	O
(	O
HSVtk	O
)	O
gene	O
.	O

This	O
resulted	O
in	O
significantly	O
improved	O
in	O
vivo	O
selectivity	O
over	O
the	O
use	O
of	O
a	O
control	O
vector	O
without	O
miRNA	O
regulation	O
,	O
enabling	O
effective	O
elimination	O
of	O
human	O
glioma	O
xenografts	O
while	O
producing	O
negligible	O
toxic	O
effects	O
on	O
normal	O
astrocytes	O
.	O

In	O
the	O
context	O
of	O
cancer	O
suicide	O
gene	O
therapy	O
,	O
this	O
approach	O
may	O
lead	O
to	O
cytotoxic	O
effects	O
in	O
both	O
cancer	O
and	O
nontarget	O
normal	O
cells	O
.	O

Considering	O
microRNA	O
(	O
miRNA	O
)	O
function	O
in	O
post	O
-	O
transcriptional	O
regulation	O
of	O
gene	O
expression	O
,	O
we	O
have	O
developed	O
a	O
viral	O
vector	O
platform	O
combining	O
cellular	O
promoter	O
-	O
based	O
transcriptional	O
targeting	O
with	O
miRNA	O
regulation	O
for	O
a	O
glioma	O
suicide	O
gene	O
therapy	O
in	O
the	O
mouse	O
brain	O
.	O

Thus	O
,	O
incorporating	O
miRNA	O
regulation	O
into	O
a	O
transcriptional	O
targeting	O
vector	O
adds	O
an	O
extra	O
layer	O
of	O
security	O
to	O
prevent	O
off	O
-	O
target	O
transgene	O
expression	O
and	O
should	O
be	O
useful	O
for	O
the	O
development	O
of	O
gene	O
delivery	O
vectors	O
with	O
high	O
targeting	O
specificity	O
for	O
cancer	O
therapy	O
.	O

Transcriptional	O
targeting	O
using	O
a	O
tissue	O
-	O
specific	O
cellular	O
promoter	O
is	O
proving	O
to	O
be	O
a	O
powerful	O
means	O
for	O
restricting	O
transgene	O
expression	O
in	O
targeted	O
tissues	O
.	O

Combinatorial	O
control	O
of	O
suicide	O
gene	O
expression	O
by	O
tissue	O
-	O
specific	O
promoter	O
and	O
microRNA	O
regulation	O
for	O
cancer	O
therapy	O
.	O

The	O
possible	O
use	O
of	O
RNAi	O
in	O
the	O
treatment	O
of	O
spinocerebellar	O
ataxia	O
or	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
with	O
its	O
advantages	O
and	O
pitfalls	O
and	O
possible	O
extensions	O
to	O
other	O
diseases	O
are	O
discussed	O
.	O

RNAi	O
has	O
moved	O
from	O
a	O
purely	O
experimental	O
technique	O
to	O
the	O
stage	O
of	O
potential	O
clinical	O
applications	O
.	O

RNAi	O
utilises	O
cellular	O
machinery	O
associated	O
with	O
the	O
processing	O
of	O
naturally	O
occurring	O
micro	O
RNA	O
(	O
miRNAs	O
)	O
.	O

RNAi	O
has	O
both	O
admirers	O
and	O
detractors	O
,	O
but	O
is	O
undeniably	O
a	O
technique	O
with	O
great	O
potential	O
,	O
which	O
has	O
come	O
a	O
long	O
way	O
in	O
the	O
short	O
time	O
since	O
its	O
discovery	O
.	O

RNA	O
interference	O
has	O
become	O
the	O
tool	O
of	O
choice	O
to	O
analyse	O
the	O
loss	O
-	O
of	O
-	O
function	O
of	O
individual	O
genes	O
and	O
has	O
been	O
exploited	O
to	O
identify	O
complex	O
regulatory	O
pathways	O
following	O
genomic	O
screening	O
.	O

Design	O
of	O
shRNAs	O
for	O
RNAi	O
-	O
A	O
lesson	O
from	O
pre	O
-	O
miRNA	O
processing	O
:	O
possible	O
clinical	O
applications	O
.	O

The	O
cellular	O
processing	O
of	O
shRNAs	O
shares	O
common	O
features	O
with	O
the	O
biogenesis	O
of	O
naturally	O
occurring	O
miRNA	O
such	O
as	O
cleavage	O
by	O
nuclear	O
RNase	O
Drosha	B
,	O
export	O
from	O
the	O
nucleus	O
,	O
processing	O
by	O
a	O
cytoplasmic	O
RNase	O
Dicer	B
,	O
and	O
incorporation	O
into	O
the	O
RNA	O
-	O
induced	O
silencing	O
complex	O
(	O
RISC	O
)	O
.	O

Each	O
step	O
has	O
a	O
crucial	O
influence	O
on	O
the	O
efficiency	O
of	O
RNAi	O
and	O
their	O
consideration	O
should	O
be	O
a	O
part	O
of	O
a	O
standard	O
experimental	O
design	O
.	O

More	O
recently	O
an	O
introduction	O
of	O
short	O
approximately	O
22	O
nucleotide	O
RNA	O
duplexes	O
has	O
become	O
the	O
standard	O
in	O
short	O
-	O
term	O
experiments	O
,	O
but	O
is	O
insufficient	O
for	O
long	O
-	O
term	O
knock	O
-	O
down	O
assays	O
.	O

Long	O
-	O
term	O
expression	O
of	O
siRNAs	O
has	O
been	O
achieved	O
by	O
in	O
vivo	O
transcription	O
from	O
plasmids	O
coding	O
for	O
short	O
hairpin	O
RNAs	O
(	O
shRNAs	O
)	O
.	O

Effective	O
use	O
of	O
RNAi	O
requires	O
detailed	O
knowledge	O
of	O
the	O
individual	O
steps	O
and	O
the	O
proteins	O
involved	O
,	O
as	O
well	O
as	O
the	O
similarities	O
and	O
distinctions	O
between	O
miRNA	O
and	O
siRNA	O
pathways	O
.	O

RNAi	O
was	O
originally	O
induced	O
by	O
the	O
introduction	O
of	O
long	O
double	O
stranded	O
RNAs	O
(	O
dsRNAs	O
)	O
into	O
cells	O
in	O
which	O
the	O
RNA	O
was	O
cleaved	O
into	O
short	O
RNAs	O
which	O
effectively	O
interfered	O
with	O
a	O
transcription	O
of	O
cognate	O
mRNA	O
.	O

[	O
AD	O
-	O
FTLD	O
spectrum	O
--	O
new	O
findings	O
on	O
risk	O
genes	O
in	O
neurodegenerative	O
diseases	O
]	O
.	O

Our	O
microarray	O
based	O
analysis	O
of	O
microRNA	O
expression	O
in	O
rat	O
cerebral	O
cortex	O
after	O
traumatic	O
brain	O
injury	O
has	O
shown	O
that	O
some	O
microRNA	O
such	O
as	O
miR-21	O
could	O
be	O
involved	O
in	O
the	O
intricate	O
process	O
of	O
TBI	O
course	O
.	O

Furthermore	O
,	O
we	O
revealed	O
global	O
up	O
-	O
regulation	O
of	O
miR-21	O
expression	O
within	O
all	O
the	O
four	O
time	O
points	O
post	O
injury	O
.	O

Our	O
research	O
revealed	O
that	O
136	O
miRNAs	O
were	O
expressing	O
at	O
6	O
h	O
post	O
injury	O
,	O
in	O
which	O
13	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
14	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
;	O
118	O
miRNAs	O
were	O
expressing	O
at	O
24	O
h	O
post	O
injury	O
,	O
in	O
which	O
4	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
23	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
;	O
149	O
miRNAs	O
were	O
expressing	O
at	O
48	O
h	O
post	O
injury	O
,	O
in	O
which	O
16	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
11	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
;	O
and	O
203	O
miRNAs	O
were	O
expressing	O
at	O
72	O
h	O
post	O
injury	O
,	O
in	O
which	O
19	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
5	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
.	O

The	O
qRT	O
-	O
PCR	O
results	O
indicated	O
good	O
consistency	O
with	O
the	O
results	O
of	O
the	O
microarray	O
method	O
.	O

Finally	O
,	O
we	O
utilized	O
qRT	O
-	O
PCR	O
methods	O
to	O
verify	O
the	O
microarray	O
results	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
very	O
important	O
regulators	O
of	O
biological	O
processes	O
such	O
as	O
development	O
,	O
cellular	O
differentiation	O
,	O
and	O
tumor	O
generation	O
.	O

MiRNA	O
microarray	O
has	O
been	O
found	O
to	O
be	O
a	O
high	O
throughput	O
global	O
analysis	O
tool	O
for	O
detecting	O
miRNA	O
expression	O
profiling	O
,	O
and	O
miRNA	O
expression	O
profiling	O
will	O
facilitate	O
the	O
study	O
of	O
the	O
biological	O
function	O
of	O
miRNAs	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
miRNA	O
expression	O
level	O
in	O
rat	O
cerebral	O
cortex	O
after	O
traumatic	O
brain	O
injury	O
using	O
microarray	O
method	O
.	O

We	O
choose	O
several	O
time	O
points	O
post	O
brain	O
injury	O
:	O
6	O
h	O
,	O
24	O
h	O
,	O
48	O
h	O
and	O
72	O
h	O
,	O
respectively	O
,	O
to	O
reveal	O
differential	O
expression	O
of	O
miRNAs	O
in	O
rat	O
brain	O
cortex	O
compared	O
with	O
control	O
groups	O
.	O

Microarray	O
based	O
analysis	O
of	O
microRNA	O
expression	O
in	O
rat	O
cerebral	O
cortex	O
after	O
traumatic	O
brain	O
injury	O
.	O

Ectopic	O
expression	O
of	O
miR-29b	O
decreased	O
hPGRN	O
expression	O
at	O
the	O
both	O
mRNA	O
and	O
protein	O
levels	O
.	O

To	O
examine	O
the	O
direct	O
effect	O
of	O
manipulating	O
endogenous	O
miR-29b	O
on	O
hPGRN	O
expression	O
,	O
we	O
established	O
a	O
stable	O
NIH3T3	O
cell	O
line	O
that	O
expresses	O
hPGRN	O
under	O
the	O
control	O
of	O
the	O
cytomegalovirus	O
promoter	O
.	O

Endogenous	O
hPGRN	O
in	O
HEK	O
293	O
cells	O
was	O
also	O
regulated	O
by	O
miR-29b	O
.	O

Conversely	O
,	O
knockdown	O
of	O
endogenous	O
miR-29b	O
with	O
locked	O
nucleic	O
acid	O
increased	O
the	O
production	O
and	O
secretion	O
of	O
hPGRN	O
in	O
NIH3T3	O
cells	O
.	O

How	O
progranulin	B
(	O
PGRN	B
)	O
expression	O
is	O
regulated	O
is	O
largely	O
unknown	O
.	O

Progranulin	B
deficiency	O
is	O
thought	O
to	O
cause	O
some	O
forms	O
of	O
frontotemporal	O
dementia	O
(	O
FTD	O
)	O
,	O
a	O
major	O
early	O
-	O
onset	O
age	O
-	O
dependent	O
neurodegenerative	O
disease	O
.	O

miR-29b	O
downregulates	O
the	O
expression	O
of	O
luciferase	O
through	O
hPGRN	O
or	O
mouse	O
PGRN	B
(	O
mPGRN	O
)	O
3'UTRs	O
,	O
and	O
the	O
regulation	O
was	O
abolished	O
by	O
mutations	O
in	O
the	O
miR-29b	O
binding	O
site	O
.	O

We	O
identified	O
an	O
evolutionarily	O
conserved	O
binding	O
site	O
for	O
microRNA-29b	O
(	O
miR-29b	O
)	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3'UTR	O
)	O
of	O
the	O
human	O
PGRN	B
(	O
hPGRN	O
)	O
mRNA	O
.	O

MicroRNA-29b	O
regulates	O
the	O
expression	O
level	O
of	O
human	O
progranulin	B
,	O
a	O
secreted	O
glycoprotein	O
implicated	O
in	O
frontotemporal	O
dementia	O
.	O

These	O
findings	O
identify	O
miR-29b	O
as	O
a	O
novel	O
posttranscriptional	O
regulator	O
of	O
PGRN	B
expression	O
,	O
raising	O
the	O
possibility	O
that	O
miR-29b	O
or	O
other	O
miRNAs	O
might	O
be	O
targeted	O
therapeutically	O
to	O
increase	O
hPGRN	O
levels	O
in	O
some	O
FTD	O
patients	O
.	O

We	O
studied	O
the	O
expression	O
of	O
selected	O
miRNAs	O
following	O
infection	O
of	O
CBA	O
mice	O
with	O
Plasmodium	O
berghei	O
ANKA	O
(	O
PbA	O
)	O
,	O
which	O
causes	O
cerebral	O
malaria	O
(	O
CM	O
)	O
,	O
or	O
Plasmodium	O
berghei	O
K173	O
(	O
PbK	O
)	O
,	O
which	O
causes	O
severe	O
malaria	O
but	O
without	O
cerebral	O
complications	O
,	O
termed	O
non	O
-	O
CM	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
posttranscriptional	O
regulatory	O
molecules	O
that	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
immune	O
responses	O
,	O
but	O
their	O
role	O
in	O
the	O
immune	O
response	O
to	O
Plasmodium	O
infection	O
is	O
unknown	O
.	O

Differential	O
MicroRNA	O
Expression	O
in	O
Experimental	O
Cerebral	O
and	O
Noncerebral	O
Malaria	O
.	O

To	O
investigate	O
the	O
involvement	O
of	O
let-7i	O
,	O
miR-27a	O
,	O
and	O
miR-150	O
in	O
CM	O
-	O
resistant	O
mice	O
,	O
we	O
assessed	O
the	O
expression	O
levels	O
in	O
gamma	B
interferon	I
knockout	O
(	O
IFN	B
-	O
Œ≥	O
(	O
-	O
/	O
-	O
)	O
)	O
mice	O
on	O
a	O
C57BL	O
/	O
6	O
genetic	O
background	O
.	O

In	O
contrast	O
,	O
no	O
miRNA	O
changes	O
were	O
detected	O
in	O
the	O
heart	O
,	O
an	O
organ	O
with	O
no	O
known	O
pathology	O
during	O
acute	O
malaria	O
.	O

We	O
identified	O
three	O
miRNAs	O
that	O
were	O
differentially	O
expressed	O
in	O
the	O
brain	O
of	O
PbA	O
-	O
infected	O
CBA	O
mice	O
:	O
let7i	O
,	O
miR-27a	O
,	O
and	O
miR-150	O
.	O

The	O
differential	O
expression	O
profiles	O
of	O
selected	O
miRNAs	O
(	O
let-7i	O
,	O
miR-27a	O
,	O
miR-150	O
,	O
miR-126	O
,	O
miR-210	O
,	O
and	O
miR-155	O
)	O
were	O
analyzed	O
in	O
mouse	O
brain	O
and	O
heart	O
tissue	O
by	O
quantitative	O
reverse	O
transcription	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
in	O
the	O
CBA	O
mouse	O
at	O
least	O
,	O
miRNA	O
may	O
have	O
a	O
regulatory	O
role	O
in	O
the	O
pathogenesis	O
of	O
severe	O
malaria	O
.	O

Overexpression	O
of	O
these	O
three	O
miRNAs	O
during	O
PbA	O
,	O
but	O
not	O
PbK	O
,	O
infection	O
in	O
WT	O
mice	O
may	O
be	O
critical	O
for	O
the	O
triggering	O
of	O
the	O
neurological	O
syndrome	O
via	O
regulation	O
of	O
their	O
potential	O
downstream	O
targets	O
.	O

The	O
expression	O
of	O
let-7i	O
,	O
miR-27a	O
,	O
and	O
miR-150	O
was	O
unchanged	O
in	O
both	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
IFN	B
-	O
Œ≥	O
(	O
-	O
/	O
-	O
)	O
mice	O
following	O
infection	O
.	O

[	O
Genetic	O
and	O
molecular	O
abnormalities	O
of	O
glioblastomas	O
(	O
GBM	O
)	O
]	O
.	O

This	O
presentation	O
reports	O
a	O
series	O
of	O
data	O
dealing	O
with	O
recurrent	O
genetic	O
abnormalities	O
and	O
gene	O
expression	O
profiles	O
that	O
characterize	O
primary	O
glioblastomas	O
and	O
secondary	O
glioblastomas	O
resulting	O
from	O
the	O
transformation	O
of	O
low	O
grade	O
tumors	O
(	O
grade	O
II	O
and	O
III	O
astrocytomas	O
and	O
oligodendrogliomas	O
)	O
.	O

Finally	O
,	O
a	O
short	O
description	O
of	O
exosomes	O
as	O
vectors	O
of	O
tumor	O
information	O
will	O
be	O
presented	O
.	O

The	O
most	O
recent	O
aspects	O
of	O
the	O
concept	O
of	O
tumor	O
stem	O
cells	O
that	O
may	O
explain	O
the	O
relentless	O
growth	O
of	O
GBM	O
will	O
be	O
reported	O
.	O

Molecular	O
features	O
of	O
tumor	O
neoangiogenesis	O
will	O
be	O
described	O
.	O

Epigenetic	O
alterations	O
and	O
deregulation	O
of	O
gene	O
expression	O
by	O
microRNAs	O
(	O
miRs	O
)	O
will	O
be	O
also	O
included	O
.	O

Some	O
aspects	O
of	O
tumor	O
predisposition	O
will	O
be	O
also	O
discussed	O
.	O

In	O
an	O
effort	O
to	O
shed	O
light	O
on	O
consequences	O
mediated	O
by	O
p53	B
inactivation	O
in	O
gliomas	O
,	O
we	O
established	O
the	O
Tet	O
-	O
On	O
system	O
for	O
p53	B
in	O
the	O
LN	O
-	O
Z308	O
glioblastoma	O
cell	O
line	O
.	O

p53	B
is	O
activated	O
upon	O
various	O
kinds	O
of	O
cellular	O
stress	O
leading	O
to	O
apoptosis	O
or	O
cell	O
cycle	O
arrest	O
,	O
but	O
is	O
also	O
implicated	O
in	O
complex	O
biological	O
processes	O
such	O
as	O
inhibition	O
of	O
angiogenesis	O
and	O
metastasis	O
.	O

Oxygen	O
deprivation	O
,	O
an	O
important	O
cellular	O
stress	O
,	O
revealed	O
MIC-1	B
as	O
an	O
anoxia	O
responsive	O
gene	O
in	O
glioblastoma	O
cell	O
lines	O
.	O

The	O
macrophage	B
inhibitory	I
cytokine-1	I
(	O
MIC-1	B
)	O
gene	O
was	O
identified	O
as	O
a	O
most	O
prominent	O
p53	B
target	O
gene	O
upon	O
gene	O
expression	O
profiling	O
.	O

Furthermore	O
,	O
ectopic	O
expression	O
of	O
MIC-1	B
in	O
LN	O
-	O
Z308	O
cell	O
line	O
completely	O
abolished	O
its	O
inherent	O
tumorigenicity	O
in	O
nude	O
mice	O
,	O
while	O
proliferation	O
in	O
vitro	O
was	O
not	O
affected	O
.	O

MIC-1	B
up	O
-	O
regulation	O
by	O
anoxia	O
is	O
mediated	O
through	O
an	O
alternative	O
,	O
p53	B
and	O
hypoxia	O
inducible	O
factor	O
1	O
(	O
HIF-1	O
)	O
independent	O
pathway	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
MIC-1	B
is	O
an	O
important	O
downstream	O
mediator	O
of	O
p53	B
function	O
,	O
while	O
acting	O
itself	O
as	O
an	O
intercessor	O
of	O
cellular	O
stress	O
signaling	O
and	O
exerting	O
anti	O
-	O
tumorigenic	O
activities	O
.	O

In	O
the	O
present	O
experimental	O
model	O
MIC-1	B
may	O
exert	O
its	O
anti	O
-	O
tumorigenic	O
properties	O
via	O
a	O
paracrine	O
mechanism	O
mediated	O
by	O
host	O
cells	O
in	O
vivo	O
.	O

Human	O
astrocytic	O
brain	O
tumors	O
select	O
for	O
mutations	O
in	O
the	O
p53	B
tumor	O
suppressor	O
gene	O
early	O
in	O
malignant	O
progression	O
.	O

Anoxia	O
induces	O
macrophage	B
inhibitory	I
cytokine-1	I
(	O
MIC-1	B
)	O
in	O
glioblastoma	O
cells	O
independently	O
of	O
p53	B
and	O
HIF-1	O
.	O

Reduction	O
of	O
miR-21	O
induces	O
glioma	O
cell	O
apoptosis	O
via	O
activating	O
caspase	B
9	I
and	O
3	O
.	O
Extensive	O
data	O
indicate	O
that	O
miR-21	O
plays	O
a	O
critical	O
role	O
in	O
gliomagenesis	O
,	O
however	O
,	O
knowledge	O
is	O
limited	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
miR-21	O
,	O
including	O
cell	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
migration	O
.	O

Moreover	O
,	O
reduction	O
of	O
miR-21	O
activated	O
caspase	B
9	I
and	O
3	O
,	O
which	O
may	O
be	O
mediated	O
by	O
modulating	O
multiple	O
potential	O
target	O
genes	O
,	O
such	O
as	O
TIMP3	B
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
down	O
-	O
regulation	O
of	O
miR-21	O
expression	O
by	O
antisense	O
oligonucleotides	O
inhibited	O
glioma	O
cell	O
proliferation	O
and	O
induced	O
cell	O
apoptosis	O
.	O

Together	O
,	O
these	O
findings	O
indicate	O
that	O
miR-21	O
plays	O
a	O
key	O
role	O
in	O
regulating	O
cell	O
apoptosis	O
in	O
gliomas	O
and	O
may	O
serve	O
as	O
a	O
target	O
for	O
effective	O
therapies	O
.	O

Membership	O
in	O
this	O
group	O
is	O
defined	O
based	O
on	O
sequence	O
similarity	O
near	O
the	O
mature	O
miRNAs	O
'	O
5	O
'	O
end	O
:	O
all	O
include	O
the	O
sequence	O
AGCAGC	O
.	O

Here	O
we	O
provide	O
an	O
overview	O
of	O
the	O
following	O
:	O
(	O
1	O
)	O
the	O
evolution	O
of	O
miR-15	O
/	O
107	O
group	O
member	O
genes	O
;	O
(	O
2	O
)	O
the	O
expression	O
levels	O
of	O
miRNAs	O
in	O
mammalian	O
tissues	O
;	O
(	O
3	O
)	O
evidence	O
for	O
overlapping	O
gene	O
-	O
regulatory	O
functions	O
by	O
different	O
miRNAs	O
;	O
(	O
4	O
)	O
the	O
normal	O
biochemical	O
pathways	O
regulated	O
by	O
miR-15	O
/	O
107	O
group	O
miRNAs	O
;	O
and	O
(	O
5	O
)	O
the	O
roles	O
played	O
by	O
these	O
miRNAs	O
in	O
human	O
diseases	O
.	O

While	O
all	O
vertebrates	O
studied	O
to	O
date	O
express	O
miR-15a	O
,	O
miR-15b	O
,	O
miR-16	O
,	O
miR-103	O
,	O
and	O
miR-107	O
,	O
mammals	O
alone	O
are	O
known	O
to	O
express	O
miR-195	O
,	O
miR-424	O
,	O
miR-497	O
,	O
miR-503	O
,	O
and	O
miR-646	O
.	O

Phylogeny	O
of	O
this	O
group	O
of	O
miRNAs	O
is	O
incomplete	O
;	O
thus	O
,	O
a	O
definitive	O
taxonomic	O
classification	O
(	O
e.g.	O
,	O
designation	O
as	O
a	O
""""	O
superfamily	O
""""	O
)	O
is	O
currently	O
not	O
possible	O
.	O

We	O
present	O
data	O
on	O
the	O
expression	O
of	O
all	O
known	O
miR-15	O
/	O
107	O
group	O
members	O
in	O
human	O
cerebral	O
cortical	O
gray	O
matter	O
and	O
white	O
matter	O
using	O
new	O
miRNA	O
profiling	O
microarrays	O
.	O

Multiple	O
different	O
miRNAs	O
in	O
the	O
miR-15	O
/	O
107	O
group	O
are	O
expressed	O
at	O
moderate	O
to	O
high	O
levels	O
in	O
human	O
tissues	O
.	O

The	O
miR-15	O
/	O
107	O
group	O
of	O
microRNA	O
genes	O
:	O
evolutionary	O
biology	O
,	O
cellular	O
functions	O
,	O
and	O
roles	O
in	O
human	O
diseases	O
.	O

The	O
miR-15	O
/	O
107	O
group	O
of	O
microRNA	O
(	O
miRNA	O
)	O
gene	O
is	O
increasingly	O
appreciated	O
to	O
serve	O
key	O
functions	O
in	O
humans	O
.	O

These	O
miRNAs	O
regulate	O
gene	O
expression	O
involved	O
in	O
cell	O
division	O
,	O
metabolism	O
,	O
stress	O
response	O
,	O
and	O
angiogenesis	O
in	O
vertebrate	O
species	O
.	O

The	O
miR-15	O
/	O
107	O
group	O
has	O
also	O
been	O
implicated	O
in	O
human	O
cancers	O
,	O
cardiovascular	O
disease	O
and	O
neurodegenerative	O
disease	O
,	O
including	O
Alzheimer	O
's	O
disease	O
.	O

In	O
conclusion	O
,	O
the	O
miR-15	O
/	O
107	O
group	O
of	O
miRNA	O
genes	O
is	O
a	O
fascinating	O
topic	O
of	O
study	O
for	O
evolutionary	O
biologists	O
,	O
miRNA	O
biochemists	O
,	O
and	O
clinically	O
oriented	O
translational	O
researchers	O
alike	O
.	O

We	O
show	O
new	O
data	O
from	O
cultured	O
H4	O
cancer	O
cells	O
that	O
demonstrate	O
similarities	O
in	O
mRNAs	O
targeted	O
by	O
miR-16	O
and	O
miR-103	O
and	O
also	O
support	O
the	O
importance	O
of	O
the	O
mature	O
miRNAs	O
'	O
5	O
'	O
seed	O
region	O
in	O
mRNA	O
target	O
recognition	O
.	O

There	O
is	O
extensive	O
overlap	O
in	O
the	O
mRNAs	O
targeted	O
by	O
miR-15	O
/	O
107	O
group	O
members	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
noncoding	O
RNAs	O
comprising	O
21	O
-	O
23	O
nucleotides	O
that	O
regulate	O
gene	O
expression	O
by	O
transcriptionally	O
repressing	O
their	O
complementary	O
mRNAs	O
.	O

Let-7	O
microRNA	O
inhibits	O
the	O
proliferation	O
of	O
human	O
glioblastoma	O
cells	O
.	O

Transfection	O
of	O
let-7	O
miRNA	O
reduced	O
expression	O
of	O
pan	B
-	I
RAS	I
,	O
N	B
-	I
RAS	I
,	O
and	O
K	B
-	I
RAS	I
in	O
the	O
glioblastoma	O
cells	O
.	O

Human	O
glioblastoma	O
cells	O
(	O
U251	O
or	O
U87	O
cells	O
)	O
were	O
transfected	O
with	O
let-7	O
miRNA	O
and	O
assayed	O
for	O
in	O
-	O
vitro	O
proliferation	O
,	O
migration	O
,	O
and	O
in	O
-	O
vivo	O
tumor	O
formation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
anti	O
-	O
tumorigenic	O
effect	O
of	O
let-7	O
miRNA	O
in	O
glioblastoma	O
cells	O
.	O

In	O
particular	O
,	O
let-7	O
miRNA	O
has	O
been	O
postulated	O
to	O
function	O
as	O
a	O
tumor	O
suppressor	O
in	O
various	O
cancer	O
cells	O
,	O
but	O
not	O
yet	O
in	O
glioblastoma	O
.	O

These	O
results	O
indicate	O
that	O
let-7	O
miRNA	O
has	O
an	O
anti	O
-	O
tumorigenic	O
effect	O
on	O
glioblastoma	O
cells	O
,	O
and	O
suggest	O
possible	O
use	O
of	O
let-7	O
miRNA	O
for	O
treating	O
glioblastoma	O
.	O

However	O
,	O
let-7	O
miRNA	O
exerted	O
no	O
effect	O
on	O
the	O
proliferation	O
of	O
normal	O
human	O
astrocytes	O
.	O

Let-7	O
miRNA	O
also	O
reduced	O
the	O
in	O
-	O
vitro	O
proliferation	O
and	O
migration	O
of	O
the	O
cells	O
,	O
and	O
reduced	O
the	O
sizes	O
of	O
the	O
tumors	O
produced	O
after	O
transplantation	O
into	O
nude	O
mice	O
.	O

MiRNAs	O
microarray	O
analysis	O
results	O
showed	O
that	O
125	O
miRNAs	O
were	O
detected	O
in	O
the	O
hippocampus	O
of	O
lithium	O
-	O
pilocarpine	O
-	O
induced	O
TLE	O
rats	O
and	O
normal	O
rats	O
.	O

To	O
understand	O
the	O
role	O
of	O
miRNAs	O
in	O
the	O
molecular	O
mechanisms	O
of	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
,	O
we	O
investigated	O
the	O
changes	O
in	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
profiles	O
of	O
chronic	O
TLE	O
rat	O
models	O
.	O

Temporal	O
lobe	O
epilepsy	O
induces	O
differential	O
expression	O
of	O
hippocampal	O
miRNAs	O
including	O
let-7e	O
and	O
miR-23a	O
/	O
b	O
.	O

let-7e	O
was	O
detected	O
down	O
-	O
regulated	O
expression	O
at	O
0h	O
,	O
1h	O
,	O
6h	O
,	O
2days	O
,	O
7days	O
,	O
50days	O
after	O
SE	O
and	O
up	O
-	O
regulated	O
expression	O
at	O
12h	O
,	O
24h	O
,	O
10days	O
,	O
30days	O
after	O
SE	O
,	O
which	O
was	O
significantly	O
up	O
-	O
regulated	O
expression	O
at	O
24h	O
after	O
SE	O
(	O
10.49	O
folds	O
,	O
P<0.01	O
)	O
.	O

miR-23a	O
/	O
b	O
was	O
detected	O
down	O
-	O
regulated	O
at	O
0h	O
,	O
1h	O
,	O
6h	O
,	O
12h	O
,	O
2days	O
,	O
7days	O
,	O
10days	O
,	O
30days	O
after	O
SE	O
and	O
significantly	O
up	O
-	O
regulated	O
at	O
24h	O
(	O
4.49	O
folds	O
P<0.01	O
)	O
,	O
50d	O
(	O
2.4	O
folds	O
,	O
P<0.01	O
)	O
after	O
SE	O
.	O
TLE	O
alters	O
the	O
expression	O
levels	O
of	O
a	O
subset	O
of	O
miRNAs	O
in	O
the	O
hippocampus	O
and	O
these	O
deregulated	O
miRNAs	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
epilepsy	O
directly	O
or	O
indirectly	O
.	O

Compared	O
with	O
normal	O
rats	O
(	O
control	O
group	O
)	O
,	O
23	O
of	O
the	O
125	O
miRNAs	O
were	O
expressed	O
differentially	O
in	O
TLE	O
rats	O
including	O
5	O
down	O
-	O
regulated	O
miRNAs	O
(	O
let-7e	O
included	O
)	O
and	O
18	O
up	O
-	O
regulated	O
miRNAs	O
(	O
miR-23a	O
/	O
b	O
included	O
)	O
.	O

Furthermore	O
,	O
let-7e	O
and	O
miR-23a	O
/	O
b	O
analysis	O
in	O
rat	O
hippocampus	O
were	O
performed	O
by	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
at	O
0h	O
,	O
1h	O
,	O
6h	O
,	O
12h	O
,	O
24h	O
,	O
2days	O
,	O
7days,10days	O
,	O
30days,50days	O
after	O
induction	O
of	O
status	O
epilepticus	O
(	O
SE	O
)	O
.	O

Also	O
the	O
temporal	O
change	O
of	O
the	O
let-7e	O
and	O
miR-23a	O
/	O
b	O
expression	O
in	O
the	O
epileptogenesis	O
indicated	O
their	O
underlying	O
functions	O
on	O
TLE	O
.	O

The	O
findings	O
also	O
indicate	O
that	O
allopregnanolone	O
and	O
perhaps	O
other	O
neurosteroid	O
-	O
like	O
compounds	O
might	O
represent	O
potential	O
biomarkers	O
or	O
therapies	O
for	O
multiple	O
sclerosis	O
.	O

These	O
multi	O
-	O
platform	O
studies	O
point	O
to	O
impaired	O
neurosteroidogenesis	O
in	O
both	O
multiple	O
sclerosis	O
and	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Allopregnanolone	O
treatment	O
of	O
the	O
experimental	O
autoimmune	O
encephalomyelitis	O
mouse	O
model	O
limited	O
the	O
associated	O
neuropathology	O
,	O
including	O
neuroinflammation	O
,	O
myelin	O
and	O
axonal	O
injury	O
and	O
reduced	O
neurobehavioral	O
deficits	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Levels	O
of	O
important	O
neurosteroids	O
,	O
including	O
allopregnanolone	O
,	O
were	O
suppressed	O
in	O
the	O
white	O
matter	O
of	O
patients	O
with	O
multiple	O
sclerosis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Induction	O
of	O
the	O
murine	O
micro	O
-	O
RNAs	O
,	O
miR-338	O
and	O
miR-155	O
,	O
accompanied	O
by	O
diminished	O
expression	O
of	O
neurosteroidogenic	O
enzymes	O
and	O
allopregnanolone	O
,	O
was	O
also	O
observed	O
in	O
the	O
brains	O
of	O
mice	O
with	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Analysis	O
of	O
the	O
neurosteroidogenic	O
pathways	O
targeted	O
by	O
micro	O
-	O
RNAs	O
revealed	O
suppression	O
of	O
enzyme	O
transcript	O
and	O
protein	O
levels	O
in	O
the	O
white	O
matter	O
of	O
patients	O
with	O
multiple	O
sclerosis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

This	O
was	O
confirmed	O
by	O
firefly	O
/	O
Renilla	O
luciferase	O
micro	O
-	O
RNA	O
target	O
knockdown	O
experiments	O
(	O
P	O
<	O
0.05	O
)	O
and	O
detection	O
of	O
specific	O
micro	O
-	O
RNAs	O
by	O
in	O
situ	O
hybridization	O
in	O
the	O
brains	O
of	O
patients	O
with	O
or	O
without	O
multiple	O
sclerosis	O
.	O

These	O
observations	O
were	O
verified	O
using	O
the	O
in	O
vivo	O
multiple	O
sclerosis	O
model	O
,	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Brains	O
of	O
patients	O
with	O
or	O
without	O
multiple	O
sclerosis	O
demonstrated	O
differential	O
expression	O
of	O
multiple	O
micro	O
-	O
RNAs	O
,	O
but	O
expression	O
of	O
three	O
neurosteroid	O
synthesis	O
enzyme	O
-	O
specific	O
micro	O
-	O
RNAs	O
(	O
miR-338	O
,	O
miR-155	O
and	O
miR-491	O
)	O
showed	O
a	O
bias	O
towards	O
induction	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

High	O
-	O
throughput	O
technologies	O
have	O
led	O
to	O
advances	O
in	O
the	O
recognition	O
of	O
disease	O
pathways	O
and	O
their	O
underlying	O
mechanisms	O
.	O

To	O
investigate	O
the	O
impact	O
of	O
micro	O
-	O
RNAs	O
on	O
the	O
disease	O
process	O
in	O
multiple	O
sclerosis	O
,	O
a	O
prototypic	O
inflammatory	O
neurological	O
disorder	O
,	O
we	O
examined	O
cerebral	O
white	O
matter	O
from	O
patients	O
with	O
or	O
without	O
the	O
disease	O
by	O
micro	O
-	O
RNA	O
profiling	O
,	O
together	O
with	O
confirmatory	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
immunoblotting	O
and	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

Impaired	O
neurosteroid	O
synthesis	O
in	O
multiple	O
sclerosis	O
.	O

This	O
review	O
reports	O
the	O
current	O
knowledge	O
of	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
in	O
pituitary	O
adenomas	O
,	O
focusing	O
on	O
recent	O
microarray	O
data	O
.	O

Moreover	O
,	O
a	O
discussion	O
is	O
provided	O
concerning	O
the	O
possible	O
role	O
of	O
validated	O
and	O
putative	O
targets	O
of	O
the	O
most	O
dysregulated	O
miRNA	O
in	O
pituitary	O
adenoma	O
pathogenesis	O
.	O

MicroRNAs	O
and	O
possible	O
role	O
in	O
pituitary	O
adenoma	O
.	O

These	O
findings	O
indicate	O
that	O
miR-107	O
contributes	O
to	O
GRN	B
expression	O
regulation	O
with	O
implications	O
for	O
brain	O
disorders	O
.	O

In	O
brain	O
tissue	O
subjacent	O
to	O
1.0	O
mm	O
depth	O
controlled	O
cortical	O
impact	O
,	O
surviving	O
hippocampal	O
neurons	O
show	O
decreased	O
miR-107	O
with	O
augmentation	O
of	O
neuronal	O
GRN	B
expression	O
.	O

We	O
also	O
tested	O
a	O
mouse	O
model	O
where	O
miR-107	O
has	O
been	O
shown	O
to	O
be	O
down	O
-	O
regulated	O
.	O

However	O
,	O
GRN	B
regulation	O
expression	O
is	O
poorly	O
understood	O
.	O

A	O
high	O
-	O
throughput	O
experimental	O
microRNA	O
assay	O
showed	O
that	O
GRN	B
is	O
the	O
strongest	O
target	O
for	O
miR-107	O
in	O
human	O
H4	O
neuroglioma	O
cells	O
.	O

miR-107	O
has	O
been	O
implicated	O
in	O
Alzheimer	O
's	O
disease	O
pathogenesis	O
,	O
and	O
sequence	O
elements	O
in	O
the	O
open	O
reading	O
frame	O
-	O
rather	O
than	O
the	O
3	O
'	O
untranslated	O
region	O
-	O
of	O
GRN	B
mRNA	O
are	O
recognized	O
by	O
miR-107	O
and	O
are	O
highly	O
conserved	O
among	O
vertebrate	O
species	O
.	O

To	O
better	O
understand	O
the	O
mechanism	O
of	O
this	O
interaction	O
,	O
FLAG	O
-	O
tagged	O
Argonaute	O
constructs	O
were	O
used	O
following	O
miR-107	O
transfection	O
.	O

miR-107	O
regulates	O
granulin	B
/	O
progranulin	B
with	O
implications	O
for	O
traumatic	O
brain	O
injury	O
and	O
neurodegenerative	O
disease	O
.	O

Granulin	B
(	O
GRN	B
,	O
or	O
progranulin	B
)	O
is	O
a	O
protein	O
involved	O
in	O
wound	O
repair	O
,	O
inflammation	O
,	O
and	O
neoplasia	O
.	O

GRN	B
has	O
also	O
been	O
directly	O
implicated	O
in	O
frontotemporal	O
dementia	O
and	O
may	O
contribute	O
to	O
Alzheimer	O
's	O
disease	O
pathogenesis	O
.	O

GRN	B
mRNA	O
interacts	O
preferentially	O
with	O
Argonaute	B
2	I
.	O
In	O
vitro	O
and	O
in	O
vivo	O
studies	O
indicate	O
that	O
regulation	O
of	O
GRN	B
by	O
miR-107	O
may	O
be	O
functionally	O
important	O
.	O

Glucose	O
supplementation	O
in	O
cultured	O
cells	O
that	O
leads	O
to	O
increased	O
miR-107	O
levels	O
also	O
results	O
in	O
decreased	O
GRN	B
expression	O
,	O
including	O
changes	O
in	O
cell	O
compartmentation	O
and	O
decreased	O
secretion	O
of	O
GRN	B
protein	O
.	O

This	O
effect	O
was	O
eliminated	O
following	O
miR-107	O
transfection	O
.	O

Many	O
miRNA	O
targets	O
have	O
been	O
computationally	O
predicted	O
but	O
only	O
a	O
limited	O
number	O
of	O
these	O
were	O
experimentally	O
validated	O
.	O

However	O
,	O
interactions	O
between	O
miRNAs	O
and	O
their	O
targets	O
are	O
complex	O
and	O
very	O
often	O
there	O
are	O
numerous	O
putative	O
miRNA	O
recognition	O
sites	O
in	O
mRNAs	O
.	O

Therefore	O
,	O
it	O
is	O
of	O
particular	O
interest	O
to	O
reliably	O
predict	O
potential	O
miRNA	O
targets	O
which	O
might	O
be	O
involved	O
in	O
these	O
diseases	O
.	O

Both	O
the	O
deregulation	O
of	O
genes	O
controlled	O
by	O
miRNAs	O
and	O
the	O
altered	O
miRNA	O
expression	O
have	O
been	O
linked	O
to	O
many	O
disorders	O
,	O
including	O
cancer	O
,	O
cardiovascular	O
,	O
metabolic	O
and	O
neurodegenerative	O
diseases	O
.	O

In	O
this	O
review	O
,	O
currently	O
available	O
and	O
frequently	O
used	O
computational	O
tools	O
for	O
miRNA	O
target	O
prediction	O
,	O
i.e.	O
,	O
PicTar	O
,	O
TargetScan	O
,	O
DIANA	O
-	O
microT	O
,	O
miRanda	O
,	O
rna22	O
and	O
PITA	O
are	O
outlined	O
and	O
various	O
practical	O
aspects	O
of	O
miRNA	O
target	O
analysis	O
are	O
extensively	O
discussed	O
.	O

Hence	O
,	O
finding	O
a	O
functional	O
miRNA	O
target	O
is	O
still	O
a	O
challenging	O
task	O
.	O

Although	O
a	O
variety	O
of	O
miRNA	O
target	O
prediction	O
algorithms	O
are	O
available	O
,	O
results	O
of	O
their	O
application	O
are	O
often	O
inconsistent	O
.	O

microRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
non	O
-	O
coding	O
RNAs	O
that	O
control	O
gene	O
expression	O
at	O
the	O
posttranscriptional	O
level	O
.	O

These	O
small	O
regulatory	O
molecules	O
play	O
a	O
key	O
role	O
in	O
the	O
majority	O
of	O
biological	O
processes	O
and	O
their	O
expression	O
is	O
also	O
tightly	O
regulated	O
.	O

Practical	O
Aspects	O
of	O
microRNA	O
Target	O
Prediction	O
.	O

Moreover	O
,	O
the	O
performance	O
of	O
three	O
algorithms	O
(	O
PicTar	O
,	O
TargetScan	O
and	O
DIANA	O
-	O
microT	O
)	O
is	O
both	O
demonstrated	O
and	O
evaluated	O
by	O
performing	O
an	O
in	O
-	O
depth	O
analysis	O
of	O
miRNA	O
interactions	O
with	O
mRNAs	O
derived	O
from	O
genes	O
triggering	O
hereditary	O
neurological	O
disorders	O
known	O
as	O
trinucleotide	O
repeat	O
expansion	O
diseases	O
(	O
TREDs	O
)	O
,	O
such	O
as	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
,	O
a	O
number	O
of	O
spinocerebellar	O
ataxias	O
(	O
SCAs	O
)	O
,	O
and	O
myotonic	O
dystrophy	O
type	O
1	O
(	O
DM1	O
)	O
.	O

Our	O
study	O
shows	O
that	O
one	O
aspect	O
of	O
miR-155	O
function	O
is	O
the	O
promotion	O
of	O
T	O
cell	O
-	O
dependent	O
tissue	O
inflammation	O
,	O
suggesting	O
that	O
miR-155	O
might	O
be	O
a	O
promising	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
autoimmune	O
disorders	O
.	O

miR-155	O
functions	O
in	O
the	O
hematopoietic	O
compartment	O
to	O
promote	O
the	O
development	O
of	O
inflammatory	O
T	O
cells	O
including	O
the	O
T	O
helper	O
17	O
(	O
Th17	O
)	O
cell	O
and	O
Th1	O
cell	O
subsets	O
.	O

Furthermore	O
,	O
the	O
major	O
contribution	O
of	O
miR-155	O
to	O
EAE	O
was	O
CD4	O
(	O
+	O
)	O
T	O
cell	O
intrinsic	O
,	O
whereas	O
miR-155	O
was	O
also	O
required	O
for	O
optimum	O
dendritic	O
cell	O
production	O
of	O
cytokines	O
that	O
promoted	O
Th17	O
cell	O
formation	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
miR-155	O
during	O
an	O
autoimmune	O
inflammatory	O
disease	O
.	O

Consistent	O
with	O
a	O
positive	O
role	O
for	O
miR-155	O
in	O
mediating	O
inflammatory	O
responses	O
,	O
Mir155	O
(	O
-	O
/	O
-	O
)	O
mice	O
were	O
highly	O
resistant	O
to	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
.	O

MicroRNA-155	O
promotes	O
autoimmune	O
inflammation	O
by	O
enhancing	O
inflammatory	O
T	O
cell	O
development	O
.	O

Mammalian	O
noncoding	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
class	O
of	O
gene	O
regulators	O
that	O
have	O
been	O
linked	O
to	O
immune	O
system	O
function	O
.	O

miR-15a	O
and	O
miR-16	O
-	O
1	O
in	O
cancer	O
:	O
discovery	O
,	O
function	O
and	O
future	O
perspectives	O
.	O

Expression	O
of	O
these	O
miRNAs	O
inhibits	O
cell	O
proliferation	O
,	O
promotes	O
apoptosis	O
of	O
cancer	O
cells	O
,	O
and	O
suppresses	O
tumorigenicity	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
encoded	O
by	O
the	O
miR-15	O
/	O
16	O
cluster	O
are	O
known	O
to	O
act	O
as	O
tumor	O
suppressors	O
.	O

Down	O
-	O
regulation	O
of	O
these	O
miRNAs	O
has	O
been	O
reported	O
in	O
chronic	O
lymphocytic	O
lymphoma	O
(	O
CLL	O
)	O
,	O
pituitary	O
adenomas	O
,	O
and	O
prostate	O
carcinoma	O
.	O

miR-15a	O
and	O
miR-16	O
-	O
1	O
function	O
by	O
targeting	O
multiple	O
oncogenes	O
,	O
including	O
BCL2	B
,	O
MCL1	B
,	O
CCND1	B
,	O
and	O
WNT3A	B
.	O

This	O
review	O
summarizes	O
the	O
discovery	O
,	O
functions	O
,	O
and	O
clinical	O
relevance	O
of	O
these	O
miRNAs	O
in	O
cancer	O
,	O
particularly	O
CLL	O
.	O

During	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
,	O
miR-124	O
was	O
downregulated	O
in	O
activated	O
microglia	O
.	O

Peripheral	O
administration	O
of	O
miR-124	O
in	O
EAE	O
caused	O
systemic	O
deactivation	O
of	O
macrophages	O
,	O
reduced	O
activation	O
of	O
myelin	O
-	O
specific	O
T	O
cells	O
and	O
marked	O
suppression	O
of	O
disease	O
.	O

Conversely	O
,	O
knockdown	O
of	O
miR-124	O
in	O
microglia	O
and	O
macrophages	O
resulted	O
in	O
activation	O
of	O
these	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

These	O
findings	O
identify	O
miR-124	O
both	O
as	O
a	O
key	O
regulator	O
of	O
microglia	O
quiescence	O
in	O
the	O
central	O
nervous	O
system	O
and	O
as	O
a	O
previously	O
unknown	O
modulator	O
of	O
monocyte	O
and	O
macrophage	O
activation	O
.	O

MicroRNA-124	O
promotes	O
microglia	O
quiescence	O
and	O
suppresses	O
EAE	O
by	O
deactivating	O
macrophages	O
via	O
the	O
C	O
/	O
EBP	O
-	O
Œ±	O
-	O
PU.1	O
pathway	O
.	O

MicroRNAs	O
are	O
a	O
family	O
of	O
regulatory	O
molecules	O
involved	O
in	O
many	O
physiological	O
processes	O
,	O
including	O
differentiation	O
and	O
activation	O
of	O
cells	O
of	O
the	O
immune	O
system	O
.	O

We	O
found	O
that	O
brain	O
-	O
specific	O
miR-124	O
is	O
expressed	O
in	O
microglia	O
but	O
not	O
in	O
peripheral	O
monocytes	O
or	O
macrophages	O
.	O

When	O
overexpressed	O
in	O
macrophages	O
,	O
miR-124	O
directly	O
inhibited	O
the	O
transcription	O
factor	O
CCAAT	O
/	O
enhancer	B
-	I
binding	I
protein	I
-	I
Œ±	I
(	O
C	B
/	I
EBP	I
-	I
Œ±	I
)	O
and	O
its	O
downstream	O
target	O
PU.1	B
,	O
resulting	O
in	O
transformation	O
of	O
these	O
cells	O
from	O
an	O
activated	O
phenotype	O
into	O
a	O
quiescent	O
CD45	O
(	O
low	O
)	O
,	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
(	O
low	O
)	O
phenotype	O
resembling	O
resting	O
microglia	O
.	O

Molecular	O
and	O
cellular	O
neurobiological	O
studies	O
of	O
the	O
miRNAs	O
in	O
neurodegeneration	O
represent	O
the	O
exploration	O
of	O
a	O
new	O
Frontier	O
of	O
miRNAs	O
biology	O
and	O
the	O
potential	O
development	O
of	O
new	O
diagnostic	O
tests	O
and	O
genetic	O
therapies	O
for	O
neurodegenerative	O
diseases	O
.	O

MiRNA	O
studies	O
in	O
neurobiology	O
showed	O
their	O
involvement	O
in	O
synaptic	O
plasticity	O
and	O
brain	O
diseases	O
.	O

In	O
this	O
review	O
,	O
correlations	O
between	O
miRNA	O
-	O
mediated	O
gene	O
silencing	O
and	O
Alzheimer	O
's	O
,	O
Parkinson	O
's	O
,	O
and	O
other	O
neurodegenerative	O
diseases	O
will	O
be	O
discussed	O
.	O

In	O
few	O
years	O
our	O
understanding	O
of	O
microRNA	O
(	O
miRNA	O
)	O
biogenesis	O
,	O
molecular	O
mechanisms	O
by	O
which	O
miRNAs	O
regulate	O
gene	O
expression	O
,	O
and	O
the	O
functional	O
roles	O
of	O
miRNAs	O
has	O
been	O
expanded	O
.	O

Interestingly	O
,	O
numerous	O
miRNAs	O
are	O
expressed	O
in	O
a	O
spatially	O
and	O
temporally	O
controlled	O
manner	O
in	O
the	O
nervous	O
system	O
,	O
suggesting	O
that	O
their	O
posttrascriptional	O
regulation	O
may	O
be	O
particularly	O
relevant	O
in	O
neural	O
development	O
and	O
function	O
.	O

Searching	O
for	O
MIND	O
:	O
microRNAs	O
in	O
neurodegenerative	O
diseases	O
.	O

In	O
gliomas	O
,	O
microRNA-21	O
(	O
miR-21	O
)	O
levels	O
have	O
been	O
reported	O
to	O
be	O
elevated	O
and	O
their	O
knockdown	O
is	O
associated	O
with	O
increased	O
apoptotic	O
activity	O
.	O

We	O
hypothesized	O
that	O
suppression	O
of	O
miR-21	O
might	O
sensitize	O
gliomas	O
for	O
cytotoxic	O
tumor	O
therapy	O
.	O

With	O
the	O
use	O
of	O
locked	O
nucleic	O
acid	O
(	O
LNA	O
)	O
-antimiR-21	O
oligonucleotides	O
,	O
bimodal	O
imaging	O
vectors	O
,	O
and	O
neural	O
precursor	O
cells	O
(	O
NPC	O
)	O
expressing	O
a	O
secretable	O
variant	O
of	O
the	O
cytotoxic	O
agent	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
inducing	O
ligand	O
(	O
S	O
-	O
TRAIL	O
)	O
,	O
we	O
show	O
that	O
the	O
combined	O
suppression	O
of	O
miR-21	O
and	O
NPC	O
-	O
S	O
-	O
TRAIL	O
leads	O
to	O
a	O
synergistic	O
increase	O
in	O
caspase	O
activity	O
and	O
significantly	O
decreased	O
cell	O
viability	O
in	O
human	O
glioma	O
cells	O
in	O
vitro	O
.	O

This	O
phenomenon	O
persists	O
in	O
vivo	O
,	O
as	O
we	O
observed	O
complete	O
eradication	O
of	O
LNA	O
-	O
antimiR-21-treated	O
gliomas	O
subjected	O
to	O
the	O
presence	O
of	O
NPC	O
-	O
S	O
-	O
TRAIL	O
in	O
the	O
murine	O
brain	O
.	O

Our	O
results	O
reveal	O
the	O
efficacy	O
of	O
miR-21	O
antagonism	O
in	O
murine	O
glioma	O
models	O
and	O
implicate	O
miR-21	O
as	O
a	O
target	O
for	O
therapeutic	O
intervention	O
.	O

Furthermore	O
,	O
our	O
findings	O
provide	O
the	O
basis	O
for	O
developing	O
combination	O
therapies	O
using	O
miRNA	O
modulation	O
and	O
cytotoxic	O
tumor	O
therapies	O
.	O

MicroRNA-21	O
knockdown	O
disrupts	O
glioma	O
growth	O
in	O
vivo	O
and	O
displays	O
synergistic	O
cytotoxicity	O
with	O
neural	O
precursor	O
cell	O
delivered	O
S	O
-	O
TRAIL	O
in	O
human	O
gliomas	O
.	O

Mounting	O
evidence	O
indicates	O
that	O
microRNAs	O
(	O
miRNA	O
)	O
might	O
play	O
a	O
fundamental	O
role	O
in	O
tumorigenesis	O
,	O
controlling	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

Despite	O
the	O
development	O
of	O
new	O
glioma	O
therapies	O
that	O
allow	O
for	O
tumor	O
-	O
targeted	O
in	O
situ	O
delivery	O
of	O
cytotoxic	O
drugs	O
,	O
tumor	O
resistance	O
to	O
apoptosis	O
remains	O
a	O
key	O
impediment	O
to	O
effective	O
treatment	O
.	O

CONCLUSIONS	O
:	O
The	O
irregularity	O
of	O
prolactin	B
secretion	O
in	O
patients	O
with	O
NPG	O
is	O
not	O
dependant	O
on	O
the	O
presence	O
of	O
a	O
pituitary	O
tumour	O
which	O
suggests	O
that	O
a	O
hypothalamic	O
dysfunction	O
underlies	O
this	O
condition	O
.	O

An	O
irregular	O
secretion	O
and	O
a	O
higher	O
daily	O
mass	O
production	O
of	O
prolactin	B
in	O
patients	O
with	O
NPG	O
could	O
explain	O
both	O
galactorrhea	O
and	O
infertility	O
.	O

BACKGROUND	O
:	O
Abnormal	O
frequency	O
and	O
pulse	O
amplitud	O
of	O
prolactin	B
secretion	O
in	O
micro	O
and	O
macroprolactinomas	O
has	O
been	O
atributed	O
to	O
a	O
dysfunctional	O
tumoral	O
lactotrope	O
.	O

[	O
Irregular	O
secretion	O
of	O
prolactin	B
in	O
infertile	O
women	O
with	O
normoprolactinemic	O
galactorrhea	O
]	O
.	O

The	O
regularity	O
of	O
prolactin	B
secretion	O
has	O
not	O
been	O
studied	O
with	O
cuantitative	O
methods	O
in	O
patients	O
with	O
normoprolactinemic	O
galactorrhea	O
(	O
NPG	O
)	O
which	O
could	O
be	O
considered	O
an	O
entity	O
that	O
precedes	O
non	O
tumoral	O
and	O
tumoral	O
hyperprolactinemia	O
.	O

Previous	O
evidence	O
suggests	O
that	O
non	O
tumoral	O
hyperprolactinemia	O
is	O
caused	O
by	O
a	O
hypothalamic	O
dysfunction	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
transversal	O
-	O
comparative	O
study	O
was	O
carried	O
out	O
in	O
6	O
infertile	O
women	O
with	O
normoprolactinemic	O
galactorrhea	O
and	O
4	O
healthy	O
women	O
as	O
controls	O
.	O

Objective	O
:	O
To	O
analyze	O
the	O
24-hour	O
prolactin	B
secretion	O
pattern	O
and	O
its	O
secretion	O
regularity	O
in	O
a	O
group	O
of	O
infertile	O
women	O
with	O
normoprolactinemic	O
galatorea	O
.	O

RESULTS	O
:	O
Blunting	O
of	O
the	O
nyctohemeral	O
rythm	O
and	O
nocturn	O
hyperprolactinaemia	O
occurred	O
in	O
patients	O
with	O
normoprolactinemic	O
galactorrhea	O
(	O
NPG	O
)	O
.	O

The	O
24	O
hour	O
prolactin	B
profile	O
,	O
the	O
ratio	O
night	O
time	O
mean	O
concentration	O
/	O
daytime	O
mean	O
concentrattion	O
(	O
NM	O
/	O
DM	O
ratio	O
)	O
and	O
apparent	O
entropy	O
(	O
Ap	O
En	O
,	O
Ap	O
En	O
ratio	O
)	O
were	O
compared	O
in	O
the	O
two	O
groups	O
.	O

Higher	O
irregularity	O
of	O
prolactin	B
secretion	O
was	O
found	O
in	O
patients	O
with	O
NPG	O
(	O
ApEn	O
:	O
0.853	O
+	O
/-	O
0.158	O
vs	O
0.608	O
+	O
/-	O
0.171	O
,	O
p=0.04	O
;	O
Ap	O
En	O
ratio	O
:	O
0.839	O
+	O
/-	O
0.11	O
vs	O
0.661	O
+	O
/-	O
0.14	O
;	O
p=0.04	O
)	O
.	O

NM	O
/	O
DM	O
ratio	O
was	O
lower	O
in	O
patients	O
with	O
NPG	O
than	O
in	O
controls	O
(	O
1.28	O
+	O
/-	O
0.25	O
vs.	O
1.75	O
+	O
/-	O
0.05	O
;	O
p=	O
0.01	O
)	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
whether	O
microRNA	O
targets	O
could	O
be	O
engineered	O
into	O
VSV	O
to	O
ameliorate	O
its	O
neuropathogenicity	O
.	O

Using	O
a	O
panel	O
of	O
recombinant	O
VSVs	O
incorporating	O
microRNA	O
target	O
sequences	O
corresponding	O
to	O
neuron	O
-	O
specific	O
or	O
control	O
microRNAs	O
(	O
in	O
forward	O
and	O
reverse	O
orientations	O
)	O
,	O
we	O
tested	O
viral	O
replication	O
kinetics	O
in	O
cell	O
lines	O
treated	O
with	O
microRNA	O
mimics	O
,	O
neurotoxicity	O
after	O
direct	O
intracerebral	O
inoculation	O
in	O
mice	O
,	O
and	O
antitumor	O
efficacy	O
.	O

Compared	O
to	O
picornaviruses	O
and	O
adenoviruses	O
,	O
the	O
engineered	O
VSVs	O
were	O
relatively	O
resistant	O
to	O
microRNA	O
-	O
mediated	O
inhibition	O
,	O
but	O
neurotoxicity	O
could	O
nevertheless	O
be	O
ameliorated	O
significantly	O
using	O
this	O
approach	O
,	O
without	O
compromise	O
to	O
antitumor	O
efficacy	O
.	O

Neurotoxicity	O
was	O
most	O
profoundly	O
reduced	O
in	O
a	O
virus	O
carrying	O
four	O
tandem	O
copies	O
of	O
a	O
neuronal	O
mir125	O
target	O
sequence	O
inserted	O
in	O
the	O
3'-untranslated	O
region	O
of	O
the	O
viral	O
polymerase	O
(	O
L	O
)	O
gene	O
.	O

Attenuation	O
of	O
vesicular	O
stomatitis	O
virus	O
encephalitis	O
through	O
microRNA	O
targeting	O
.	O

Vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
has	O
long	O
been	O
regarded	O
as	O
a	O
promising	O
recombinant	O
vaccine	O
platform	O
and	O
oncolytic	O
agent	O
but	O
has	O
not	O
yet	O
been	O
tested	O
in	O
humans	O
because	O
it	O
causes	O
encephalomyelitis	O
in	O
rodents	O
and	O
primates	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
specific	O
tropisms	O
of	O
several	O
viruses	O
could	O
be	O
eliminated	O
by	O
engineering	O
microRNA	O
target	O
sequences	O
into	O
their	O
genomes	O
,	O
thereby	O
inhibiting	O
spread	O
in	O
tissues	O
expressing	O
cognate	O
microRNAs	O
.	O

Alteration	O
of	O
miRNA	O
expression	O
by	O
disease	O
and	O
insult	O
also	O
holds	O
the	O
potential	O
for	O
improved	O
diagnostic	O
tools	O
.	O

Finally	O
,	O
miRNAs	O
have	O
been	O
shown	O
to	O
control	O
cellular	O
proliferation	O
and	O
specification	O
,	O
suggesting	O
that	O
manipulation	O
of	O
miRNAs	O
in	O
cultured	O
cells	O
could	O
result	O
in	O
more	O
convenient	O
generation	O
of	O
pure	O
cell	O
populations	O
for	O
transplantation	O
.	O

miRNAs	O
appear	O
to	O
be	O
dysregulated	O
in	O
a	O
number	O
of	O
neurodegenerative	O
diseases	O
,	O
developmental	O
disorders	O
,	O
and	O
as	O
a	O
result	O
of	O
stroke	O
.	O

MicroRNAS	O
(	O
miRNAs	O
)	O
have	O
been	O
suggested	O
to	O
play	O
important	O
roles	O
in	O
the	O
central	O
nervous	O
system	O
during	O
development	O
as	O
well	O
as	O
disease	O
.	O

The	O
therapeutic	O
potential	O
of	O
microRNAs	O
in	O
nervous	O
system	O
damage	O
,	O
degeneration	O
,	O
and	O
repair	O
.	O

Artificial	O
miRNAs	O
have	O
also	O
been	O
generated	O
for	O
the	O
repression	O
of	O
specific	O
transcripts	O
.	O

Both	O
viral	O
delivery	O
and	O
administration	O
of	O
modified	O
oligonucleotides	O
mimicking	O
or	O
inhibiting	O
specific	O
miRNAs	O
have	O
been	O
effective	O
in	O
model	O
systems	O
.	O

Recent	O
findings	O
suggest	O
that	O
it	O
may	O
eventually	O
be	O
possible	O
to	O
treat	O
some	O
neurological	O
disorders	O
by	O
restoring	O
or	O
inhibiting	O
miRNAs	O
altered	O
by	O
disease	O
pathology	O
.	O

Each	O
miRNA	O
has	O
the	O
ability	O
to	O
regulate	O
hundreds	O
of	O
messenger	O
RNA	O
transcripts	O
,	O
both	O
by	O
causing	O
degradation	O
of	O
the	O
mRNA	O
and	O
by	O
inhibition	O
of	O
protein	O
translation	O
.	O

MicroRNA-210	O
as	O
a	O
novel	O
blood	O
biomarker	O
in	O
acute	O
cerebral	O
ischemia	O
.	O

MicroRNA-210	O
(	O
miR-210	O
)	O
,	O
a	O
master	O
and	O
pleiotropic	O
hypoxia	O
-	O
microRNA	O
,	O
plays	O
multiple	O
roles	O
in	O
brain	O
ischemia	O
.	O

However	O
,	O
miR-210	O
expression	O
and	O
its	O
function	O
in	O
humans	O
have	O
not	O
been	O
explored	O
.	O

The	O
aim	O
of	O
our	O
study	O
is	O
to	O
evaluate	O
the	O
correlation	O
of	O
blood	O
miR-210	O
with	O
clinical	O
findings	O
in	O
acute	O
ischemic	O
stroke	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
stroke	O
patients	O
(	O
n=112	O
)	O
and	O
healthy	O
controls	O
(	O
n=	O
60	O
)	O
.	O

MiR-210	O
was	O
measured	O
at	O
within	O
3	O
,	O
7	O
and	O
14	O
days	O
after	O
stroke	O
using	O
a	O
quantitative	O
PCR	O
technique	O
.	O

Stroke	O
severity	O
and	O
clinical	O
outcome	O
were	O
evaluated	O
by	O
NIHSS	O
and	O
modified	O
Rankin	O
Score	O
.	O

Both	O
blood	O
and	O
brain	O
miR-210	O
in	O
ischemic	O
mice	O
was	O
examined	O
and	O
the	O
correlation	O
was	O
investigated	O
.	O

Compared	O
to	O
healthy	O
controls	O
,	O
blood	O
miRNA-210	O
was	O
significantly	O
decreased	O
in	O
stroke	O
patients	O
(	O
0.93	O
vs.	O
1.36	O
;	O
P=0.001	O
)	O
,	O
especially	O
at	O
7	O
days	O
(	O
0.56	O
vs.	O
1.36	O
;	O
P=0.001	O
)	O
and	O
14	O
days	O
of	O
stroke	O
onset	O
(	O
0.50	O
vs.	O
1.36	O
;	O
P=0.001	O
)	O
.	O

The	O
cut	O
off	O
point	O
of	O
miR-210	O
in	O
diagnosis	O
was	O
0.505	O
with	O
88.3	O
per	O
cent	O
sensitivity	O
.	O

MiR-210	O
level	O
in	O
stroke	O
patients	O
with	O
good	O
outcome	O
was	O
significantly	O
higher	O
than	O
patients	O
with	O
poor	O
outcome	O
(	O
1.2	O
vs.	O
0.44	O
;	O
P=0.012	O
)	O
.	O

The	O
correlation	O
between	O
blood	O
and	O
brain	O
miR-210	O
in	O
ischemic	O
mice	O
was	O
positive	O
(	O
R2=0.57	O
,	O
P=0.001	O
)	O
.	O

Blood	O
miR-210	O
is	O
a	O
novel	O
sensitive	O
biomarker	O
for	O
clinical	O
diagnosis	O
and	O
prognosis	O
in	O
acute	O
cerebral	O
ischemia	O
.	O

Out	O
of	O
the	O
5	O
positive	O
samples	O
,	O
one	O
was	O
an	O
HTLV	O
,	O
three	O
HTLV-1	O
and	O
one	O
HTLV-2	O
.	O

These	O
blood	O
donors	O
were	O
residents	O
of	O
Posadas	O
,	O
Eldorado	O
and	O
Ober√°	O
,	O
with	O
no	O
risk	O
antecedents	O
.	O

This	O
study	O
demonstrates	O
the	O
presence	O
of	O
HTLV-1	O
/	O
2	O
in	O
a	O
population	O
of	O
Misiones	O
with	O
a	O
prevalence	O
rate	O
similar	O
to	O
those	O
reported	O
among	O
blood	O
donors	O
from	O
non	O
-	O
endemic	O
areas	O
.	O

[	O
Seroprevalence	O
of	O
HTLV-1	O
/	O
2	O
in	O
blood	O
donors	O
from	O
Misiones	O
Province	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
seroprevalence	O
of	O
HTLV-1	O
/	O
2	O
in	O
a	O
blood	O
donor	O
population	O
from	O
Misiones	O
province	O
.	O

They	O
are	O
transmitted	O
through	O
sex	O
contact	O
,	O
parenterally	O
and	O
from	O
mother	O
to	O
child	O
.	O

HTLV-1	O
/	O
2	O
screening	O
was	O
performed	O
with	O
ELISA	O
and	O
particle	O
agglutination	O
,	O
and	O
reactive	O
samples	O
were	O
confirmed	O
by	O
Western	O
Blot	O
.	O

A	O
total	O
of	O
6912	O
accepted	O
blood	O
donations	O
in	O
2008	O
were	O
analyzed	O
.	O

It	O
is	O
endemic	O
worldwide	O
,	O
including	O
the	O
North	O
of	O
Argentina	O
where	O
both	O
associated	O
diseases	O
have	O
also	O
been	O
detected	O
.	O

Human	O
T	O
-	O
cell	O
Lymphotropic	O
viruses	O
type	O
1	O
(	O
HTLV-1	O
)	O
,	O
the	O
first	O
human	O
oncoretrovirus	O
to	O
be	O
discovered	O
,	O
is	O
the	O
etiologic	O
agent	O
of	O
Adult	O
T	O
-	O
cell	O
Leukemia	O
(	O
ATL	O
)	O
and	O
HTLV-1	O
Associated	O
Mielopathy	O
or	O
Tropical	O
Spastic	O
Paraparesis	O
(	O
HAM	O
/	O
TSP	O
)	O
.	O

Both	O
retroviruses	O
are	O
endemic	O
in	O
native	O
populations	O
of	O
The	O
Americas	O
,	O
Africa	O
and	O
at	O
-	O
risk	O
populations	O
.	O

No	O
etiologic	O
role	O
has	O
been	O
described	O
for	O
HTLV-2	O
,	O
although	O
it	O
has	O
been	O
associated	O
with	O
HAM	O
/	O
TSP	O
-	O
like	O
neurologic	O
syndromes	O
.	O

From	O
the	O
total	O
,	O
5	O
samples	O
resulted	O
seropositive	O
with	O
a	O
final	O
prevalence	O
of	O
0.00072	O
.	O

Furthermore	O
,	O
in	O
patient	O
samples	O
expression	O
of	O
miR	O
124a	O
is	O
significantly	O
decreased	O
.	O

Our	O
data	O
strongly	O
indicate	O
that	O
CDK6	B
is	O
regulated	O
by	O
microRNA	O
124	O
in	O
medulloblastoma	O
and	O
that	O
miR	O
124	O
modulates	O
medulloblastoma	O
cell	O
growth	O
.	O

We	O
hypothesized	O
that	O
CDK6	B
expression	O
is	O
also	O
regulated	O
by	O
microRNAs	O
in	O
medulloblastoma	O
.	O

Genomic	O
amplification	O
accounts	O
for	O
some	O
,	O
but	O
not	O
all	O
of	O
the	O
CDK6	B
over	O
-	O
expression	O
.	O

Expression	O
of	O
miR	O
124a	O
was	O
significantly	O
decreased	O
in	O
medulloblastoma	O
cells	O
compared	O
to	O
normal	O
adult	O
cerebellum	O
.	O

We	O
identified	O
putative	O
miR	O
sites	O
in	O
the	O
CDK6	B
including	O
microRNA	O
124a	O
,	O
a	O
brain	O
enriched	O
microRNA	O
.	O

Additionally	O
,	O
re	O
-	O
expression	O
of	O
miR	O
124a	O
in	O
medulloblastoma	O
cells	O
decreased	O
expression	O
of	O
CDK6	B
protein	O
.	O

Functional	O
association	O
between	O
miR	O
124a	O
and	O
CDK6	B
in	O
medulloblastoma	O
was	O
established	O
using	O
luciferase	O
assays	O
.	O

Transfection	O
of	O
miR	O
124	O
significantly	O
decreases	O
medulloblastoma	O
cell	O
growth	O
but	O
does	O
not	O
alter	O
apoptosis	O
.	O

Regulation	O
of	O
cyclin	B
dependent	I
kinase	I
6	I
by	O
microRNA	O
124	O
in	O
medulloblastoma	O
.	O

Despite	O
recent	O
advances	O
in	O
treatment	O
medulloblastoma	O
continues	O
to	O
remain	O
a	O
vexing	O
problem	O
.	O

Recently	O
increased	O
expression	O
of	O
cyclin	B
dependent	I
kinase	I
6	I
(	O
CDK6	B
)	O
was	O
identified	O
as	O
an	O
adverse	O
prognostic	O
marker	O
in	O
medulloblastoma	O
.	O

CONCLUSIONS	O
:	O
The	O
study	O
suggests	O
that	O
spatial	O
orientation	O
memory	O
relies	O
on	O
the	O
integrity	O
of	O
the	O
right	O
hippocampus	O
.	O

Nevertheless	O
,	O
further	O
studies	O
are	O
necessary	O
to	O
confirm	O
this	O
hypothesis	O
.	O

The	O
subjects	O
were	O
submitted	O
to	O
a	O
neuropsychologic	O
evaluation	O
through	O
the	O
Route	O
Learning	O
Test	O
and	O
the	O
Childhood	O
Home	O
Test	O
in	O
the	O
preoperative	O
period	O
.	O

The	O
statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Kruskal	O
-	O
Wallis	O
,	O
analysis	O
of	O
variance	O
,	O
œá	O
,	O
and	O
Mann	O
-	O
Whitney	O
U	O
tests	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
in	O
performance	O
in	O
the	O
remote	O
visuospatial	O
memory	O
(	O
as	O
measured	O
by	O
the	O
Childhood	O
Home	O
Test	O
)	O
across	O
the	O
groups	O
(	O
LTLE	O
,	O
RTLE	O
,	O
and	O
control	O
)	O
.	O

Concerning	O
the	O
spatial	O
orientation	O
memory	O
,	O
however	O
,	O
there	O
was	O
a	O
significant	O
difference	O
between	O
the	O
LTLE	O
and	O
controls	O
as	O
compared	O
with	O
the	O
RTLE	O
group	O
(	O
P<0.001	O
)	O
,	O
the	O
latter	O
showing	O
a	O
poorer	O
performance	O
.	O

However	O
,	O
evaluations	O
of	O
the	O
right	O
hippocampal	O
functions	O
have	O
not	O
been	O
consistent	O
.	O

In	O
ablative	O
interventions	O
,	O
neuropsychologic	O
testing	O
of	O
memory	O
is	O
a	O
crucial	O
step	O
.	O

METHODS	O
:	O
A	O
controlled	O
study	O
of	O
patients	O
with	O
left	O
(	O
LTLE	O
)	O
or	O
right	O
(	O
RTLE	O
)	O
TLE	O
.	O

AIM	O
:	O
To	O
assess	O
the	O
hippocampal	O
function	O
in	O
remote	O
orientation	O
and	O
visuospatial	O
memory	O
in	O
patients	O
with	O
refractory	O
temporal	O
epilepsy	O
.	O

INTRODUCTION	O
:	O
In	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
,	O
about	O
30	O
%	O
of	O
the	O
patients	O
do	O
not	O
achieve	O
adequate	O
pharmacologic	O
control	O
of	O
refractory	O
crises	O
,	O
and	O
surgery	O
becomes	O
an	O
alternative	O
.	O

Route	O
Learning	O
Performance	O
:	O
Is	O
it	O
a	O
Hippocampus	O
Function	O
?	O

Thrombolytic	O
therapy	O
involving	O
recombinant	O
tissue	O
plasminogen	O
activator	O
(	O
rtPA	O
)	O
has	O
been	O
shown	O
to	O
be	O
beneficial	O
only	O
when	O
used	O
within	O
4.5	O
hours	O
of	O
onset	O
of	O
acute	O
ischemic	O
stroke	O
.	O

There	O
are	O
two	O
major	O
types	O
of	O
stroke	O
:	O
cerebral	O
ischemia	O
caused	O
by	O
obstruction	O
of	O
blood	O
vessels	O
in	O
the	O
brain	O
and	O
haemorrhagic	O
stroke	O
that	O
is	O
triggered	O
by	O
the	O
disruption	O
of	O
blood	O
vessels	O
.	O

Stroke	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
death	O
and	O
disability	O
worldwide	O
.	O

microRNAs	O
in	O
stroke	O
pathogenesis	O
.	O

Although	O
the	O
biochemistry	O
of	O
stroke	O
and	O
related	O
diseases	O
is	O
quite	O
well	O
understood	O
,	O
the	O
knowledge	O
on	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
diseases	O
is	O
still	O
at	O
its	O
infancy	O
.	O

microRNAs	O
that	O
form	O
a	O
unique	O
class	O
of	O
endogenous	O
riboregulators	O
of	O
gene	O
function	O
,	O
offer	O
tremendous	O
potential	O
in	O
unraveling	O
the	O
mechanisms	O
underlying	O
stroke	O
pathogenesis	O
.	O

rtPA	O
treatment	O
beyond	O
this	O
time	O
window	O
has	O
been	O
found	O
to	O
be	O
unsuitable	O
and	O
usually	O
resulting	O
in	O
haemorrhagic	O
transformation	O
.	O

Stroke	O
is	O
a	O
multifactorial	O
disease	O
that	O
forms	O
a	O
possible	O
end	O
state	O
for	O
majority	O
of	O
patients	O
suffering	O
from	O
diabetes	O
,	O
atherosclerosis	O
and	O
hypertension	O
which	O
are	O
known	O
risk	O
factors	O
.	O

microRNA	O
expression	O
also	O
reflects	O
the	O
response	O
of	O
individuals	O
to	O
drugs	O
and	O
therapy	O
.	O

Several	O
microRNAs	O
and	O
their	O
target	O
genes	O
,	O
known	O
to	O
be	O
involved	O
in	O
endothelial	O
dysfunction	O
,	O
dysregulation	O
of	O
neurovascular	O
integrity	O
,	O
edema	O
formation	O
,	O
pro	O
-	O
apoptosis	O
,	O
inflammation	O
and	O
extra	O
-	O
cellular	O
matrix	O
remodeling	O
contribute	O
to	O
the	O
critical	O
processes	O
in	O
the	O
pathogenesis	O
of	O
stroke	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
also	O
be	O
discussing	O
the	O
role	O
of	O
microRNAs	O
as	O
possible	O
diagnostic	O
and	O
prognostic	O
biomarkers	O
as	O
well	O
as	O
potential	O
therapeutic	O
targets	O
in	O
stroke	O
pathogenesis	O
.	O

Mutations	O
in	O
ABHD12	B
cause	O
the	O
neurodegenerative	O
disease	O
PHARC	O
:	O
An	O
inborn	O
error	O
of	O
endocannabinoid	O
metabolism	O
.	O

Previously	O
,	O
we	O
mapped	O
this	O
Refsum	O
-	O
like	O
disorder	O
to	O
a	O
16	O
Mb	O
region	O
on	O
chromosome	O
20	O
.	O

Polyneuropathy	O
,	O
hearing	O
loss	O
,	O
ataxia	O
,	O
retinitis	O
pigmentosa	O
,	O
and	O
cataract	O
(	O
PHARC	O
)	O
is	O
a	O
neurodegenerative	O
disease	O
marked	O
by	O
early	O
-	O
onset	O
cataract	O
and	O
hearing	O
loss	O
,	O
retinitis	O
pigmentosa	O
,	O
and	O
involvement	O
of	O
both	O
the	O
central	O
and	O
peripheral	O
nervous	O
systems	O
,	O
including	O
demyelinating	O
sensorimotor	O
polyneuropathy	O
and	O
cerebellar	O
ataxia	O
.	O

Our	O
findings	O
show	O
that	O
ABHD12	B
performs	O
essential	O
functions	O
in	O
both	O
the	O
central	O
and	O
peripheral	O
nervous	O
systems	O
and	O
the	O
eye	O
.	O

Any	O
future	O
drug	O
-	O
mediated	O
interference	O
with	O
this	O
enzyme	O
should	O
consider	O
the	O
potential	O
risk	O
of	O
long	O
-	O
term	O
adverse	O
effects	O
.	O

Here	O
we	O
report	O
that	O
mutations	O
in	O
the	O
ABHD12	B
gene	O
cause	O
PHARC	O
disease	O
and	O
we	O
describe	O
the	O
clinical	O
manifestations	O
in	O
a	O
total	O
of	O
19	O
patients	O
from	O
four	O
different	O
countries	O
.	O

The	O
ABHD12	B
enzyme	O
was	O
recently	O
shown	O
to	O
hydrolyze	O
2-arachidonoyl	O
glycerol	O
(	O
2-AG	O
)	O
,	O
the	O
main	O
endocannabinoid	O
lipid	O
transmitter	O
that	O
acts	O
on	O
cannabinoid	O
receptors	O
CB1	B
and	O
CB2	B
.	O

Our	O
data	O
therefore	O
represent	O
an	O
example	O
of	O
an	O
inherited	O
disorder	O
related	O
to	O
endocannabinoid	O
metabolism	O
.	O

The	O
endocannabinoid	O
system	O
is	O
involved	O
in	O
a	O
wide	O
range	O
of	O
physiological	O
processes	O
including	O
neurotransmission	O
,	O
mood	O
,	O
appetite	O
,	O
pain	O
appreciation	O
,	O
addiction	O
behavior	O
,	O
and	O
inflammation	O
,	O
and	O
several	O
potential	O
drugs	O
targeting	O
these	O
pathways	O
are	O
in	O
development	O
for	O
clinical	O
applications	O
.	O

These	O
cellular	O
responses	O
are	O
mediated	O
by	O
augmented	O
expression	O
of	O
the	O
direct	O
targets	O
of	O
miR-10b	O
,	O
including	O
BCL2L11	B
/	O
Bim	B
,	O
TFAP2C	B
/	O
AP-2Œ≥	B
,	O
CDKN1A	B
/	O
p21	B
,	O
and	O
CDKN2A	B
/	O
p16	B
,	O
which	O
normally	O
protect	O
cells	O
from	O
uncontrolled	O
growth	O
.	O

Analysis	O
of	O
The	O
Cancer	O
Genome	O
Atlas	O
expression	O
data	O
set	O
reveals	O
a	O
strong	O
positive	O
correlation	O
between	O
numerous	O
genes	O
sustaining	O
cellular	O
growth	O
and	O
miR-10b	O
levels	O
in	O
human	O
glioblastomas	O
,	O
while	O
proapoptotic	O
genes	O
anticorrelate	O
with	O
the	O
expression	O
of	O
miR-10b	O
.	O

Molecular	O
functions	O
of	O
these	O
miRNAs	O
in	O
gliomagenesis	O
are	O
mainly	O
unknown	O
.	O

We	O
show	O
that	O
inhibition	O
of	O
miR-10b	O
,	O
a	O
miRNA	O
not	O
expressed	O
in	O
human	O
brain	O
and	O
strongly	O
upregulated	O
in	O
both	O
low	O
-	O
grade	O
and	O
high	O
-	O
grade	O
gliomas	O
,	O
reduces	O
glioma	O
cell	O
growth	O
by	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptosis	O
.	O

Human	O
glioma	O
growth	O
is	O
controlled	O
by	O
microRNA-10b	O
.	O

MicroRNA	O
(	O
miRNA	O
)	O
expression	O
profiling	O
studies	O
revealed	O
a	O
number	O
of	O
miRNAs	O
dysregulated	O
in	O
the	O
malignant	O
brain	O
tumor	O
glioblastoma	O
.	O

Altogether	O
,	O
our	O
experiments	O
validate	O
an	O
important	O
role	O
of	O
miR-10b	O
in	O
gliomagenesis	O
,	O
reveal	O
a	O
novel	O
mechanism	O
of	O
miR-10b	O
-	O
mediated	O
regulation	O
,	O
and	O
suggest	O
the	O
possibility	O
of	O
its	O
future	O
use	O
as	O
a	O
therapeutic	O
target	O
in	O
gliomas	O
.	O

Furthermore	O
,	O
survival	O
of	O
glioblastoma	O
patients	O
expressing	O
high	O
levels	O
of	O
miR-10	O
family	O
members	O
is	O
significantly	O
reduced	O
in	O
comparison	O
to	O
patients	O
with	O
low	O
miR-10	O
levels	O
,	O
indicating	O
that	O
miR-10	O
may	O
contribute	O
to	O
glioma	O
growth	O
in	O
vivo	O
.	O

Finally	O
,	O
inhibition	O
of	O
miR-10b	O
in	O
a	O
mouse	O
model	O
of	O
human	O
glioma	O
results	O
in	O
significant	O
reduction	O
of	O
tumor	O
growth	O
.	O

MRI	O
scan	O
showed	O
an	O
area	O
of	O
encephalomalacia	O
in	O
the	O
left	O
temporal	O
lobe	O
,	O
as	O
well	O
as	O
post	O
-	O
surgical	O
changes	O
in	O
the	O
left	O
frontal	O
area	O
.	O

He	O
presented	O
with	O
status	O
epilepticus	O
every	O
two	O
or	O
three	O
months	O
,	O
and	O
required	O
long	O
periods	O
of	O
hospitalization	O
on	O
each	O
occasion	O
for	O
post	O
-	O
ictal	O
confusion	O
and	O
aphasia	O
.	O

He	O
continued	O
to	O
have	O
frequent	O
seizures	O
despite	O
treatment	O
with	O
multiple	O
combinations	O
of	O
antiepileptic	O
medications	O
.	O

EEG	O
telemetry	O
recorded	O
multiple	O
seizures	O
,	O
all	O
with	O
a	O
clear	O
focus	O
in	O
the	O
left	O
temporal	O
area	O
.	O

Scalp	O
EEG	O
showed	O
continuous	O
spikes	O
and	O
polyspikes	O
and	O
persistent	O
slowing	O
in	O
the	O
left	O
temporal	O
area	O
,	O
as	O
well	O
as	O
spikes	O
in	O
the	O
left	O
frontal	O
area	O
.	O

CASE	O
REPORT	O
:	O
We	O
report	O
a	O
case	O
of	O
a	O
75-year	O
-	O
old	O
right	O
-	O
handed	O
man	O
who	O
underwent	O
a	O
left	O
fronto	O
-	O
temporal	O
craniotomy	O
for	O
resection	O
of	O
a	O
suprasellar	O
meningioma	O
in	O
2002	O
.	O

Immediately	O
following	O
hospital	O
discharge	O
,	O
he	O
began	O
to	O
experience	O
complex	O
partial	O
seizures	O
.	O

BACKGROUND	O
:	O
Epilepsy	O
surgery	O
is	O
increasingly	O
well	O
-	O
supported	O
as	O
an	O
effective	O
treatment	O
for	O
patients	O
with	O
intractable	O
epilepsy	O
.	O

It	O
is	O
most	O
often	O
performed	O
on	O
younger	O
patients	O
and	O
the	O
safety	O
and	O
efficacy	O
of	O
epilepsy	O
surgery	O
in	O
elderly	O
patients	O
are	O
not	O
frequently	O
described	O
.	O

Epilepsy	O
surgery	O
in	O
the	O
elderly	O
:	O
an	O
unusual	O
case	O
of	O
a	O
75-year	O
-	O
old	O
man	O
with	O
recurrent	O
status	O
epilepticus	O
.	O

In	O
addition	O
,	O
few	O
cases	O
with	O
such	O
a	O
malignant	O
evolution	O
of	O
temporal	O
lobe	O
epilepsy	O
have	O
been	O
described	O
in	O
this	O
age	O
group	O
.	O

A	O
left	O
anteromesial	O
temporal	O
lobectomy	O
was	O
performed	O
with	O
intraoperative	O
electrocorticography	O
.	O

Neuropsychological	O
testing	O
showed	O
bilateral	O
memory	O
impairment	O
with	O
no	O
significant	O
cognitive	O
decline	O
expected	O
after	O
unilateral	O
temporal	O
lobe	O
resection	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
one	O
of	O
the	O
oldest	O
patients	O
reported	O
in	O
the	O
literature	O
with	O
epilepsy	O
surgery	O
and	O
supports	O
the	O
possibility	O
of	O
epilepsy	O
surgery	O
in	O
elderly	O
patients	O
for	O
particular	O
cases	O
.	O

Since	O
surgery	O
,	O
the	O
patient	O
was	O
not	O
seizure	O
-	O
free	O
(	O
Engel	O
class	O
II	O
-	O
b	O
)	O
,	O
but	O
had	O
no	O
further	O
episodes	O
of	O
status	O
epilepticus	O
in	O
one	O
year	O
and	O
two	O
months	O
of	O
follow	O
-	O
up	O
.	O

Adult	O
-	O
onset	O
autosomal	O
dominant	O
leukodystrophy	O
:	O
linking	O
nuclear	O
envelope	O
to	O
myelin	O
.	O

Aberrant	O
expression	O
of	O
miRNAs	O
can	O
lead	O
to	O
diseases	O
,	O
including	O
cancer	O
.	O

Expression	O
of	O
many	O
miRNAs	O
in	O
the	O
de	O
-	O
differentiated	O
brain	O
tumor	O
cancer	O
stem	O
cells	O
resembles	O
that	O
of	O
neural	O
stem	O
cells	O
.	O

MicroRNAs	O
:	O
regulators	O
of	O
oncogenesis	O
and	O
stemness	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
essential	O
post	O
-	O
transcriptional	O
regulators	O
that	O
determine	O
cell	O
identity	O
and	O
fate	O
.	O

In	O
this	O
issue	O
of	O
BMC	O
Medicine	O
,	O
Silber	O
et	O
al	O
provide	O
evidence	O
of	O
the	O
expression	O
of	O
such	O
miRNAs	O
and	O
their	O
potential	O
to	O
mediate	O
differentiation	O
in	O
both	O
stem	O
cell	O
populations	O
.	O

In	O
this	O
commentary	O
,	O
we	O
discuss	O
the	O
known	O
functions	O
of	O
miRNAs	O
in	O
cancer	O
and	O
stem	O
cells	O
,	O
their	O
therapeutic	O
potential	O
and	O
how	O
the	O
findings	O
of	O
Silber	O
et	O
al	O
provide	O
insight	O
into	O
the	O
role	O
of	O
miR-124	O
/	O
miR-137	O
dysregulation	O
in	O
glioblastomas	O
.	O

The	O
emerging	O
role	O
of	O
epigenetics	O
in	O
stroke	O
:	O
II	O
.	O
RNA	O
regulatory	O
circuitry	O
.	O

These	O
non	O
-	O
protein	O
-	O
coding	O
RNAs	O
(	O
ncRNAs	O
)	O
include	O
subclasses	O
that	O
are	O
well	O
known	O
,	O
such	O
as	O
transfer	O
RNAs	O
and	O
ribosomal	O
RNAs	O
,	O
as	O
well	O
as	O
those	O
that	O
have	O
more	O
recently	O
been	O
characterized	O
,	O
such	O
as	O
microRNAs	O
,	O
small	O
nucleolar	O
RNAs	O
,	O
and	O
long	O
ncRNAs	O
.	O

In	O
this	O
review	O
,	O
we	O
examine	O
the	O
role	O
of	O
these	O
novel	O
ncRNAs	O
in	O
the	O
nervous	O
system	O
and	O
highlight	O
emerging	O
evidence	O
that	O
implicates	O
RNA	O
-	O
based	O
networks	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
stroke	O
.	O

Recent	O
scientific	O
advances	O
have	O
demonstrated	O
the	O
existence	O
of	O
extensive	O
RNA	O
-	O
based	O
regulatory	O
networks	O
involved	O
in	O
orchestrating	O
nearly	O
every	O
cellular	O
process	O
in	O
health	O
and	O
various	O
disease	O
states	O
.	O

This	O
previously	O
hidden	O
layer	O
of	O
functional	O
RNAs	O
is	O
derived	O
largely	O
from	O
non	O
-	O
protein	O
-	O
coding	O
DNA	O
sequences	O
that	O
constitute	O
more	O
than	O
98	O
%	O
of	O
the	O
genome	O
in	O
humans	O
.	O

These	O
novel	O
approaches	O
for	O
neural	O
cell-	O
and	O
tissue	O
-	O
selective	O
reprogramming	O
of	O
epigenetic	O
regulatory	O
mechanisms	O
are	O
likely	O
to	O
promote	O
more	O
effective	O
neuroprotective	O
and	O
neural	O
regenerative	O
responses	O
for	O
safeguarding	O
and	O
even	O
restoring	O
central	O
nervous	O
system	O
function	O
.	O

We	O
also	O
describe	O
RNA	O
editing	O
,	O
a	O
related	O
epigenetic	O
mechanism	O
that	O
is	O
partly	O
responsible	O
for	O
generating	O
the	O
exquisite	O
degrees	O
of	O
environmental	O
responsiveness	O
and	O
molecular	O
diversity	O
that	O
characterize	O
ncRNAs	O
.	O

In	O
addition	O
,	O
we	O
discuss	O
the	O
development	O
of	O
future	O
therapeutic	O
strategies	O
for	O
locus	O
-	O
specific	O
and	O
genome	O
-	O
wide	O
regulation	O
of	O
genes	O
and	O
functional	O
gene	O
networks	O
through	O
the	O
modulation	O
of	O
RNA	O
transcription	O
,	O
posttranscriptional	O
RNA	O
processing	O
(	O
eg	O
,	O
RNA	O
modifications	O
,	O
quality	O
control	O
,	O
intracellular	O
trafficking	O
,	O
and	O
local	O
and	O
long	O
-	O
distance	O
intercellular	O
transport	O
)	O
,	O
and	O
RNA	O
translation	O
.	O

These	O
results	O
indicate	O
that	O
miRNAs	O
are	O
differentially	O
expressed	O
in	O
C.	O
elegans	O
PD	O
models	O
and	O
suggest	O
a	O
role	O
for	O
these	O
molecules	O
in	O
disease	O
pathogenesis	O
.	O

Here	O
,	O
we	O
show	O
that	O
12	O
specific	O
miRNAs	O
are	O
differentially	O
regulated	O
in	O
the	O
animals	O
overexpressing	O
alpha	B
-	I
synuclein	I
,	O
five	O
in	O
cat-1	O
,	O
and	O
three	O
in	O
the	O
pdr-1	O
mutants	O
.	O

The	O
family	O
of	O
miR-64	O
and	O
miR-65	O
are	O
co	O
-	O
underexpressed	O
in	O
the	O
alpha	B
-	I
synuclein	I
transgenic	O
and	O
cat-1	O
strains	O
,	O
and	O
members	O
of	O
let-7	O
family	O
co	O
-	O
underexpressed	O
in	O
the	O
alpha	B
-	I
synuclein	I
and	O
pdr-1	O
strains	O
;	O
mdl-1	B
and	O
ptc-1	B
genes	O
are	O
target	O
candidates	O
for	O
miR-64	O
and	O
miR-65	O
and	O
are	O
overexpressed	O
in	O
alpha	B
-	I
synuclein	I
transgenic	O
as	O
well	O
as	O
miR-64	O
/	O
65	O
(	O
tm3711	O
)	O
knockout	O
animals	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
play	O
an	O
important	O
role	O
in	O
human	O
brain	O
development	O
and	O
maintenance	O
.	O

To	O
search	O
for	O
miRNAs	O
that	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Parkinsons	O
disease	O
(	O
PD	O
)	O
,	O
we	O
utilized	O
miRNA	O
microarrays	O
to	O
identify	O
potential	O
gene	O
expression	O
changes	O
in	O
115	O
annotated	O
miRNAs	O
in	O
PD	O
-	O
associated	O
Caenorhabditis	O
elegans	O
models	O
that	O
either	O
overexpress	O
human	O
A53	B
T	I
alpha	I
-	I
synuclein	I
or	O
have	O
mutations	O
within	O
the	O
vesicular	O
catecholamine	O
transporter	O
(	O
cat-1	O
)	O
or	O
parkin	O
(	O
pdr-1	O
)	O
ortholog	O
.	O

Global	O
microRNA	O
expression	O
profiling	O
of	O
Caenorhabditis	O
elegans	O
Parkinson	O
's	O
disease	O
models	O
.	O

A	O
series	O
of	O
novel	O
and	O
established	O
medulloblastoma	O
defects	O
were	O
detected	O
(	O
MYC	B
amplification	O
(	O
n	O
=	O
4	O
)	O
,	O
17q21.31	O
high	O
-	O
level	O
gain	O
(	O
n	O
=	O
1	O
)	O
;	O
9p21.1-p21.3	O
(	O
n	O
=	O
1	O
)	O
and	O
6q23.1	O
(	O
n	O
=	O
1	O
)	O
homozygous	O
deletion	O
)	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
We	O
performed	O
a	O
SNP	O
-	O
array	O
based	O
genome	O
-	O
wide	O
copy	O
number	O
analysis	O
in	O
medulloblastoma	O
cell	O
lines	O
,	O
to	O
identify	O
regions	O
of	O
genomic	O
amplification	O
and	O
homozygous	O
deletion	O
,	O
which	O
may	O
harbour	O
critical	O
disease	O
genes	O
.	O

Most	O
notably	O
,	O
a	O
novel	O
recurrent	O
region	O
of	O
genomic	O
amplification	O
at	O
8q24.22-q24.23	O
was	O
identified	O
(	O
n	O
=	O
2	O
)	O
,	O
and	O
selected	O
for	O
further	O
investigation	O
.	O

Amplification	O
and	O
overexpression	O
of	O
Hsa	O
-	O
miR-30b	O
,	O
Hsa	O
-	O
miR-30d	O
and	O
KHDRBS3	B
at	O
8q24.22-q24.23	O
in	O
medulloblastoma	O
.	O

The	O
identification	O
of	O
critical	O
genes	O
involved	O
in	O
its	O
pathogenesis	O
will	O
be	O
central	O
to	O
advances	O
in	O
our	O
understanding	O
of	O
its	O
molecular	O
basis	O
,	O
and	O
the	O
development	O
of	O
improved	O
therapeutic	O
approaches	O
.	O

BACKGROUND	O
:	O
Medulloblastoma	O
is	O
the	O
most	O
common	O
malignant	O
brain	O
tumour	O
of	O
childhood	O
.	O

Of	O
these	O
,	O
only	O
expression	O
of	O
hsa	O
-	O
miR-30b	O
,	O
hsa	O
-	O
miR-30d	O
and	O
KHDRBS3	B
correlated	O
with	O
copy	O
number	O
status	O
,	O
and	O
all	O
three	O
of	O
these	O
transcripts	O
also	O
displayed	O
evidence	O
of	O
elevated	O
expression	O
in	O
sub	O
-	O
sets	O
of	O
primary	O
medulloblastomas	O
,	O
measured	O
relative	O
to	O
the	O
normal	O
cerebellum	O
.	O

Additional	O
analysis	O
by	O
interphase	O
fluorescence	O
in	O
situ	O
hybridisation	O
(	O
iFISH	O
)	O
,	O
PCR	O
-	O
based	O
mapping	O
and	O
SNP	O
-	O
array	O
revealed	O
this	O
novel	O
amplification	O
at	O
8q24.22-q24.23	O
is	O
independent	O
of	O
MYC	B
amplification	O
at	O
8q24.21	O
,	O
and	O
is	O
unique	O
to	O
medulloblastoma	O
in	O
over	O
800	O
cancer	O
cell	O
lines	O
assessed	O
from	O
different	O
tumour	O
types	O
,	O
suggesting	O
it	O
contains	O
key	O
genes	O
specifically	O
involved	O
in	O
medulloblastoma	O
development	O
.	O

Detailed	O
mapping	O
identified	O
a	O
3Mb	O
common	O
minimal	O
region	O
of	O
amplification	O
harbouring	O
3	O
coding	O
genes	O
(	O
ZFAT1	B
,	O
LOC286094	O
,	O
KHDRBS3	B
)	O
and	O
two	O
genes	O
encoding	O
micro	O
-	O
RNAs	O
(	O
hsa	O
-	O
miR-30b	O
,	O
hsa	O
-	O
miR-30d	O
)	O
.	O

Our	O
findings	O
suggest	O
critical	O
roles	O
for	O
these	O
genes	O
in	O
medulloblastoma	O
development	O
,	O
and	O
further	O
support	O
the	O
contribution	O
of	O
micro	O
-	O
RNA	O
species	O
to	O
medulloblastoma	O
pathogenesis	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
These	O
data	O
implicate	O
hsa	O
-	O
miR-30b	O
,	O
hsa	O
-	O
miR-30d	O
and	O
KHDRBS3	B
as	O
putative	O
oncogenic	O
target	O
(	O
s	O
)	O
of	O
a	O
novel	O
recurrent	O
medulloblastoma	O
amplicon	O
at	O
8q24.22-q24.23	O
.	O

PURPOSE	O
Medulloblastomas	O
are	O
heterogeneous	O
tumors	O
that	O
collectively	O
represent	O
the	O
most	O
common	O
malignant	O
brain	O
tumor	O
in	O
children	O
.	O

Integrative	O
genomic	O
analysis	O
of	O
medulloblastoma	O
identifies	O
a	O
molecular	O
subgroup	O
that	O
drives	O
poor	O
clinical	O
outcome	O
.	O

We	O
reveal	O
the	O
relative	O
contribution	O
of	O
each	O
subgroup	O
to	O
clinical	O
outcome	O
as	O
a	O
whole	O
and	O
show	O
that	O
a	O
previously	O
unidentified	O
molecular	O
subgroup	O
,	O
characterized	O
genetically	O
by	O
c	O
-	O
MYC	B
copy	O
number	O
gains	O
and	O
transcriptionally	O
by	O
enrichment	O
of	O
photoreceptor	O
pathways	O
and	O
increased	O
miR-183‚àº96‚àº182	O
expression	O
,	O
is	O
associated	O
with	O
significantly	O
lower	O
rates	O
of	O
event	O
-	O
free	O
and	O
overall	O
survivals	O
.	O

Results	O
Identified	O
are	O
six	O
molecular	O
subgroups	O
of	O
medulloblastoma	O
,	O
each	O
with	O
a	O
unique	O
combination	O
of	O
numerical	O
and	O
structural	O
chromosomal	O
aberrations	O
that	O
globally	O
influence	O
mRNA	O
and	O
miRNA	O
expression	O
.	O

CONCLUSION	O
Our	O
results	O
detail	O
the	O
complex	O
genomic	O
heterogeneity	O
of	O
medulloblastomas	O
and	O
identify	O
a	O
previously	O
unrecognized	O
molecular	O
subgroup	O
with	O
poor	O
clinical	O
outcome	O
for	O
which	O
more	O
effective	O
therapeutic	O
strategies	O
should	O
be	O
developed	O
.	O

PATIENTS	O
AND	O
METHODS	O
We	O
profiled	O
the	O
mRNA	O
transcriptome	O
of	O
194	O
medulloblastomas	O
and	O
performed	O
high	O
-	O
density	O
single	O
nucleotide	O
polymorphism	O
array	O
and	O
miRNA	O
analysis	O
on	O
115	O
and	O
98	O
of	O
these	O
,	O
respectively	O
.	O

To	O
understand	O
the	O
molecular	O
characteristics	O
underlying	O
their	O
heterogeneity	O
and	O
to	O
identify	O
whether	O
such	O
characteristics	O
represent	O
risk	O
factors	O
for	O
patients	O
with	O
this	O
disease	O
,	O
we	O
performed	O
an	O
integrated	O
genomic	O
analysis	O
of	O
a	O
large	O
series	O
of	O
primary	O
tumors	O
.	O

We	O
additionally	O
validated	O
our	O
findings	O
in	O
three	O
previously	O
published	O
independent	O
medulloblastoma	O
data	O
sets	O
.	O

Non	O
-	O
negative	O
matrix	O
factorization	O
-	O
based	O
clustering	O
of	O
mRNA	O
expression	O
data	O
was	O
used	O
to	O
identify	O
molecular	O
subgroups	O
of	O
medulloblastoma	O
;	O
DNA	O
copy	O
number	O
,	O
miRNA	O
profiles	O
,	O
and	O
clinical	O
outcomes	O
were	O
analyzed	O
for	O
each	O
.	O

The	O
reason	O
why	O
a	O
mild	O
TBI	O
results	O
in	O
varying	O
clinical	O
symptoms	O
is	O
currently	O
unknown	O
.	O

Based	O
on	O
evidence	O
that	O
microRNA	O
species	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
may	O
reflect	O
molecular	O
alterations	O
in	O
neurodegenerative	O
disorders	O
,	O
it	O
can	O
be	O
hypothesized	O
that	O
at	O
early	O
,	O
preclinical	O
phases	O
of	O
the	O
disease	O
,	O
PBMC	O
may	O
provide	O
an	O
ideal	O
and	O
clinically	O
assessable	O
""""	O
window	O
""""	O
into	O
the	O
brain	O
.	O

Patients	O
who	O
have	O
sustained	O
a	O
mild	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
from	O
both	O
civilian	O
and	O
military	O
populations	O
exhibit	O
clinical	O
symptoms	O
of	O
varying	O
severity	O
with	O
minimal	O
to	O
profound	O
impact	O
on	O
their	O
daily	O
functioning	O
.	O

Although	O
most	O
patients	O
make	O
a	O
full	O
recovery	O
,	O
a	O
subgroup	O
of	O
mild	O
TBI	O
patients	O
develop	O
cognitive	O
,	O
somatic	O
,	O
and	O
neurobehavioral	O
sequelae	O
that	O
generally	O
resolve	O
over	O
3	O
to	O
6	O
months	O
;	O
a	O
smaller	O
subgroup	O
develop	O
persisting	O
symptoms	O
.	O

Personalized	O
medicine	O
in	O
traumatic	O
brain	O
injury	O
.	O

Thus	O
,	O
it	O
is	O
conceivable	O
that	O
changes	O
in	O
the	O
expression	O
profile	O
of	O
clinically	O
accessible	O
biological	O
indices	O
(	O
biomarkers	O
)	O
,	O
such	O
as	O
microRNA	O
in	O
PBMC	O
,	O
may	O
reflect	O
molecular	O
alterations	O
following	O
TBI	O
that	O
contribute	O
to	O
the	O
onset	O
and	O
progression	O
of	O
TBI	O
phenotypes	O
including	O
chronic	O
traumatic	O
encephalopathy	O
.	O

It	O
is	O
possible	O
that	O
the	O
availability	O
of	O
TBI	O
biomarkers	O
may	O
provide	O
potential	O
elements	O
with	O
clinical	O
relevance	O
to	O
prevention	O
,	O
prognosis	O
,	O
and	O
treatment	O
of	O
postconcussive	O
disorders	O
.	O

This	O
opportunistic	O
mycosis	O
infection	O
presented	O
with	O
clinically	O
totally	O
nonspecific	O
signs	O
and	O
symptoms	O
of	O
CNS	O
affection	O
.	O

Therefore	O
,	O
we	O
suspected	O
affection	O
of	O
CNS	O
with	O
SLE	O
.	O

Even	O
though	O
all	O
diagnostic	O
procedures	O
were	O
made	O
on	O
time	O
and	O
that	O
adequate	O
antifungal	O
and	O
supportive	O
agents	O
were	O
applied	O
very	O
early	O
after	O
the	O
infection	O
onset	O
,	O
the	O
outcome	O
was	O
fatal	O
.	O

Because	O
of	O
infective	O
diathesis	O
in	O
patients	O
with	O
SLE	O
,	O
which	O
present	O
with	O
common	O
and	O
opportunistic	O
infections	O
,	O
and	O
due	O
to	O
high	O
mortality	O
rates	O
caused	O
by	O
these	O
infections	O
,	O
we	O
have	O
tried	O
to	O
emphasise	O
the	O
importance	O
of	O
taking	O
adequate	O
specimens	O
early	O
after	O
infection	O
outcome	O
for	O
these	O
rare	O
infective	O
agents	O
like	O
C.	O
neophormans	O
.	O

It	O
was	O
meningitis	O
caused	O
by	O
C.	O
neoformans	O
.	O

Reports	O
from	O
Europe	O
are	O
very	O
rare	O
,	O
and	O
this	O
case	O
is	O
the	O
one	O
of	O
that	O
kind	O
in	O
Croatia	O
.	O

In	O
recent	O
medical	O
literature	O
are	O
dominant	O
cases	O
reported	O
in	O
Asia	O
.	O

Systemic	O
erythematosus	O
lupus	O
(	O
SLE	O
)	O
is	O
a	O
disease	O
with	O
wide	O
range	O
of	O
clinical	O
manifestations	O
,	O
signs	O
and	O
symptoms	O
.	O

[	O
Cryptococcal	O
meningitis	O
as	O
a	O
diagnostic	O
problem	O
in	O
a	O
patient	O
with	O
SLE	O
--	O
case	O
report	O
]	O
.	O

Very	O
important	O
cause	O
of	O
death	O
in	O
patients	O
with	O
SLE	O
is	O
infection	O
.	O

Disease	O
outcome	O
depends	O
mostly	O
on	O
the	O
affection	O
of	O
kidneys	O
and	O
central	O
nervous	O
system	O
by	O
the	O
disease	O
.	O

During	O
one	O
of	O
the	O
disease	O
flares	O
the	O
patient	O
was	O
hospitalized	O
an	O
opportunistic	O
infection	O
developed	O
.	O

As	O
an	O
outcome	O
of	O
the	O
combined	O
effect	O
of	O
disease	O
and	O
immunosuppressive	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
the	O
disease	O
,	O
the	O
patient	O
had	O
increased	O
infective	O
diathesis	O
(	O
repeated	O
infections	O
caused	O
by	O
S.	O
enteritidis	O
--	O
urinary	O
infections	O
and	O
sepsis	O
)	O
.	O

In	O
this	O
case	O
report	O
we	O
have	O
presented	O
a	O
patient	O
with	O
SLE	O
who	O
initially	O
had	O
severe	O
renal	O
affection	O
,	O
but	O
also	O
complications	O
of	O
immunosuppressive	O
therapy	O
that	O
was	O
administered	O
.	O

Infections	O
are	O
very	O
common	O
among	O
these	O
patients	O
due	O
to	O
aggressive	O
immunosuppressive	O
treatment	O
that	O
is	O
needed	O
for	O
the	O
disease	O
inflammatory	O
activity	O
control	O
.	O

Because	O
of	O
lupus	O
nephropathy	O
,	O
in	O
the	O
early	O
phase	O
of	O
the	O
disease	O
we	O
administered	O
aggressive	O
immunosuppressive	O
therapy	O
(	O
combined	O
parenteral	O
therapy	O
of	O
glucocorticoides	O
and	O
cyclophosphamide	O
)	O
.	O

Even	O
though	O
the	O
disease	O
was	O
accidentally	O
diagnosed	O
,	O
it	O
had	O
a	O
severe	O
clinical	O
progress	O
.	O

